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The skin is the largest human organ, has a surface area of approximately 2.0 m2, 
and covers the entire surface of our body.1-3 It serves as the primary barrier against 
pathogens, chemicals, ultraviolet (UV) light, and mechanical injury. Moreover, the skin 
regulates body temperature, water release, contains sensory receptors, and has a 
role in the immune system.4 It is composed of three layers: the epidermis, dermis, 
and subcutis (Fig. 1). The epidermis is divided into four layers, from outside to inside: 
stratum corneum (SC), stratum granulosum, stratum spinosum, and stratum basale. 
Keratinocytes, the main cell type in the epidermis, develop from active stem cells in the 
stratum basale. Keratinocytes produce keratin and differentiate upwards throughout 
the epidermis, losing their nuclei in the stratum granulosum, as they move away from 
nutrients. In the SC, they form a protective overcoat of 15-30 layers of flattened, 
anucleated keratinocytes (corneocytes). The epidermis also contains melanocytes which 
produce melanin to protect against UV light. Merkel cells have mechanoreceptors for 
light touch which interact with cutaneous free nerve endings. Finally, Langerhans cells 
are specialized dendritic cells for antigen presentation and are part of the adaptive 
immune system.
Below the epidermis lies the dermis, a thick layer of connective tissue (collagen and 
elastin) giving the skin strength and elasticity. The dermis also contains free nerve 
endings, blood vessels, and adnexal structures such as hair follicles, hair shafts, sweat 
ducts, and sebaceous glands. The thin apical layer of the dermis, the papillary dermis, 
forms finger-like folds extending into the epidermis named papillae. The thick lower 
layer of the dermis is called the reticular dermis and consists of dense connective 
tissue. The deepest skin layer, the subcutis, is composed of adipose tissue and plays an 
important role in thermoregulation, lipid storage, and mechanical shock absorption.
Figure 1. Layers of the skin. Adapted with permission from Kabashima et al 20185
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Skin barrier function
The main physical/mechanical barrier function of the skin is formed by the SC.3 It is 
being continually regenerated, which is important in wound healing.6,7 The SC prevents 
excessive evaporative water loss, preventing our body from desiccation.7,8 Healthy 
SC contains 10-30% water, important for preserving its elasticity and regulation 
of desquamation, which takes place at the outermost 3-5 layers.9-11 The SC has 
a brick and mortar structure (Fig. 2); the brick is formed by the flattened, keratin-
enriched corneocytes, which are connected by corneodesmosomes.12 Corneocytes 
are embedded in the mortar, a highly hydrophobic matrix of intercellular lipids, 
consisting of ceramides (45-50%), cholesterol (25%), cholesterol esters (20%), and 
free fatty acids (10-15%).6,10,13 This lipid network is secreted by lamellar granules in 
the stratum granulosum.7 The water holding capacity of the SC is mainly formed by 
these intercellular lipids, the position of the corneocytes, and by natural moisturizing 
factor (NMF), a highly hygroscopic degradation product of filaggrin inside corneocytes, 
composed of amino acids, lactic acid, urea, and sugars.10,14-16
Various individual and environmental factors are able to induce skin barrier 
abnormalities, such as filaggrin deficiency, aging, changes in ambient temperature 
and air humidity, and mechanical stressors disrupting the SC such as traumatic injury 
or tapestripping.6,7,9,10 Barrier disruption results in increased transepidermal water 
loss (TEWL) and reduced epidermal hydration, stimulating production and secretion 
of cytokines and keratinocyte proliferation, which in turn may cause inflammation.10,17 
Moisturizers can improve skin barrier function by:
 • Occlusion: providing an exogenous barrier to water loss (although prolonged 
skin occlusion produces profound negative effects on barrier function, including 
changed hydration status, barrier permeability, aberrant epidermal lipids, DNA 
synthesis, changes in microbial flora, and interaction with numerous molecular 
and cellular processes)18
 • Humidification: attracting and retaining water from the dermis
 • Hydration: by stimulating synthesis of endogenous water-binding lipids and 
proteins.6,7,10,19,20
Impaired skin barrier function is seen in chronic inflammatory skin disorders like 
ichthyosis vulgaris,21 atopic dermatitis,22-29 and plaque psoriasis.30-32 Additionally, there 
are speculations about skin barrier disturbances in acne vulgaris33, and there is an 
increasing body of evidence showing barrier impairments in rosacea.34-37
1
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Figure 2. Schematic overview of the skin barrier, formed by the stratum corneum. NMF, natural 
moisturizing factor
SKIN INFLAMMATION AND INFLAMMATORY SKIN DISEASES
Inflammatory skin diseases (ISDs) involve a broad range of diseases in which 
inflammation plays an important role.38 Inflammation is an indispensable factor in 
the complex defence mechanism of the body against potential harmful endogenous or 
exogenous stimuli and is involved in tissue repair after damage. Different types of cells 
in the immune system are involved in skin inflammation. These cells release a variety of 
substances that can lead to the signs associated with inflammation; calor (heat), rubor 
(redness), dolor (pain), and tumor (swelling). Therefore, it is often challenging to unravel 
the exact pathogenesis. In this thesis, rosacea, an ISD with facial localization and 
unclear etiology, serves as a model for the inflamed disease state. Rosacea was chosen 
because it is localized at the face, a highly visible and cosmetically important region for 
which noninvasive evaluation is preferred. Furthermore, quantification of its various 
signs and symptoms is needed. Lastly, it responds effectively to anti-inflammatory 
treatment. These factors are described below in more detail.
Rosacea
Clinical features and classification
Rosacea is characterized by papules, pustules, erythema and/or telangiectasia at 
the centrofacial area (cheek, nose, chin, and forehead).39 The inflammatory and non-
inflammatory signs can occur separately or combined in one patient. Symptoms 
range from very mild to very severe and can cause psychological distress such as 
low self-esteem, social anxiety, and even depression.40 Disease course is variable 
and characterized by exacerbations and remissions. According to the subtype-based 
classification system, which was developed in 2002, there are four rosacea subtypes: 
erythematotelangiectatic, papulopustular, phymatous and ocular.39 These are based 
on defined primary and secondary features in rosacea (Fig. 3). Primary signs are: 
flushing (i.e. transient erythema), persistent erythema, papules and pustules, and 
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telangiectasia. Secondary features are: a burning or stinging sensation, plaques, dry 
appearance, oedema, ocular manifestations, extrafacial localizations, and phymatous 
changes. Presence of one or more primary features is indicative of rosacea. Secondary 
symptoms can occur independently or together with the primary symptoms.
It has been previously noted that subtype-based system had some important 
shortcomings:42-46
 • There is overlap between subtypes, i.e. signs often span more than one 
subtype
 • Rosacea signs can evolve into other subtypes
 • Subtypes do not cover the full range of clinical signs which may confound severity 
assessment
 • It does not recognise certain pathognomonic findings (e.g. phyma).
In 2017, for aforementioned shortcomings, a phenotype-based classification system 
was developed (Table 1) in which one or more diagnostic and/or two or more major 
features are required for the diagnosis of rosacea. Unfortunately, the phenotype-based 
classification has not yet been widely adopted due to implementation difficulties. Most 
studies still apply the subtype-based system.47
Figure 3. Clinical symptoms of rosacea. A, Centrofacial erythema, papules, pustules, and dry 
appearance. B, Erythema and telangiectasia. C, Rhinophyma. D, Ocular rosacea. Reprinted with 
permission from www.huidziekten.nl (A-C), and Schaller et al 201841 (D)
1
Voorbereid document - Jade.indd   11 01-05-2021   10:16
12
Chapter 1
Table 1. Phenotype-based classification system of rosacea.42,48
Diagnostic featuresa Major featuresb Minor features
1. Fixed centrofacial erythema 
+ intermittent intensification
2.  Phymatous changes  





• Lid margin telangiectasia
• Interpalpebral 
conjunctival injection








• Collarette accumulation at 
base of lashes
• Lid margin irregularities
• Evaporative tear 
dysfunction
a These features by themselves are diagnostic of rosacea.
b Two or more features may be considered diagnostic.
Epidemiology
Prevalence reports of rosacea vary from less than 1% to more than 20%, due to 
differences in population, diagnostic criteria, and cultural perceptions of disease.49,50 
Rosacea is mostly diagnosed after the age of 30, and in Caucasians with skin type 1 or 
2.50-52 Frequencies in darker skin types are less reported,53 possibly due to difficulties 
in recognizing erythema.48,54 Gender distribution is reported as equal or female 
predominant, but phymatous rosacea is most common in males.50 Ocular rosacea 
prevalence ranges from 6 to 58%. Rosacea is associated with various systemic diseases 
such as migraine, depression, inflammatory bowel disease, respiratory diseases, 
Parkinson’s disease and hypertension.45,48,55 The cause of these associations is yet 
unknown but it is hypothesized that shared neurogenic, inflammatory, and vascular 
abnormalities may play a role.
Pathogenesis
The aetiology of rosacea is uncertain, but probably multifactorial.35-37,45,48,56-59 Factors 
that may be involved are dysregulation of the innate and adaptive immune system 
(Th1/Th17 cell type inflammation), neurogenic dysregulation, vascular abnormalities, 
micro-organisms such as Demodex mites, skin barrier dysfunction, and genetic factors 
(Fig. 4).
Demodex mites are obligatory parasites of human sebaceous follicles (Fig. 5). These 
follicles are mainly present in the face, especially on the nose, cheeks, forehead and 
chin.60-64 Demodex feed on epidermal cells and sebum. There are two species; Demodex 
folliculorum (length: 0.3 mm), residing grouped in hair follicles, and Demodex brevis 
(length: 0.2 mm), staying solitary in the sebaceous glands. Steadily increasing with 
age, there is up to a 100% colonization rate of Demodex mites in adults.61,65 Since their 
discovery, the pathogenicity of these mites has been debated. Their biological function 
as a component of normal skin microbiome is unknown. Higher mite numbers have 
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been found in rosacea skin compared to healthy controls, correlating with an increase 
in inflammation markers, possibly leading to inflammatory skin changes.49,63,65-71 
Proposed mechanisms are mechanical blockage of hair follicles, foreign body reactions, 
and secretion of waste and bacteria.60,63
Besides from causative factors, various triggers have been described that can 
aggravate rosacea symptoms, such as heat, stress, UV light, spicy food, alcohol, and 
hot beverages.49 They are thought to induce rosacea via dilation of cutaneous vessels, 
after stimulation of transient receptor potential (TRP) channels on sensory neurons 
and keratinocytes (Fig. 4).48
Figure 4. Supposed multifactorial pathogenesis of rosacea. Adapted with permission from Two 
et al 201535
Figure 5. Demodex mite. A, Under a light microscope. B, In a skin biopsy. Reprinted with permission 
from Elston et al 201464
1




Rosacea is treatable but not curable. Explanation about the chronic character of the 
disease and general skin care should be given to all patients. General skin care topics 
that should be discussed are adequate sun protection (factor 30+), trigger avoidance, 
and use of moisturizers and mild cleansers. The available treatment options to reduce 
or clear the various symptoms are presented in Table 2. Treatment decisions should be 
based on presenting features and different treatments can be combined to increase 
efficacy. Papules and pustules respond better to treatment than erythema and 
flushing, which may be persisting. For moderate inflammatory rosacea with papules 
and pustules, ivermectin is the most effective topical treatment option, having dual 
anti-inflammatory and anti-parasitic properties.72 Oral antimicrobial agents (usually 
8-12 weeks) are indicated if response to topical agents is inadequate or in severe 
inflammatory presentation. If severe cases with inflammatory papules and pustules do 
not respond to oral antibiotics, or if these symptoms recur after the discontinuation 
of oral antibiotics, treatment with low-dose oral isotretinoin (usually 12-16 weeks) can 
be considered. Continuation of topical therapy after remission of clinical symptoms 
is recommended to reduce the risk of recurrence. Laser therapy may be beneficial in 
patients with facial erythema or flushing that do not respond to conventional anti-
inflammatory therapy. Phymatous and ocular rosacea require separate treatment. For 
phymatous rosacea, it is desirable to first treat the inflammatory component, before 
switching to physical treatment modalities. For ocular rosacea, immediate referral to 
an ophthalmologist is recommended in case of corneal involvement, acute pain or 
vision loss, or when paediatric ocular rosacea is suspected (which may progress more 
severely).45,48,73-77
Voorbereid document - Jade.indd   14 01-05-2021   10:16
15



































































































































































































































































































































































































































































































































































Voorbereid document - Jade.indd   15 01-05-2021   10:16
16
Chapter 1
Diagnosing rosacea: current limitations
Currently, clinical assessment represents the gold standard to diagnose rosacea.42,44 
Various numerical scales exist to score erythema, telangiectasia, papules, pustules, 
and global impression.42,78,79 These scales are subjective, not validated, require training, 
and are therefore prone to interobserver variability, questioning the meaning of 
reported outcomes. Comparison of individual studies is therefore challenging.80 Also, 
solely visual evaluation cannot reveal ongoing sub-surface skin processes, and the 
human eye is unable to notice subtle changes over time.39,78,79,81-83 Unfortunately, there 
are no rosacea-specific biomarkers, and histopathological findings are nonspecific; 
biopsies are usually only obtained to rule out other diagnoses.35,45,83-85 Moreover, it is 
challenging to select an appropriate biopsy sample site due to the heterogeneity of 
inflammatory areas in rosacea. This can lead to non-specific and descriptive diagnoses. 
Invasive methods such as skin biopsies are also not preferred in rosacea for cosmetic 
reasons, and rosacea skin is usually very sensitive and gets irritated easily. Tissue 
processing takes time, is tedious, operator-dependent and not free from artifacts.86 
Lastly, biopsies can lead to inflammation, scarring, and alteration of examined skin, 
hindering temporal monitoring of the same skin site.
Summarized, current diagnostic assessment in rosacea has important shortcomings, 
being:
 • The clinical spectrum is wide
 • Current clinical scoring scales are subjective
 • Clinical scoring does not provide information about subsurface processes
 • Facial biopsies are invasive and results are non-specific.
To achieve optimal results, rosacea treatment is preferably adjusted to clinical 
symptoms and disease severity.36,87,88 Therefore, standardized, objective, reliable, and 
preferably noninvasive measurement tools in rosacea are needed. With noninvasive 
techniques the same facial skin can be easily monitored over time, without causing 
damage or skin alteration.
NONINVASIVE MEASUREMENT METHODS
A variety of noninvasive diagnostic tools have been developed and investigated in 
dermatological research,12,89-92 divided in imaging and biophysical methods. These 
techniques are also widely used in ISDs such as rosacea, but a comprehensive overview 
is lacking. Therefore, an overview will be presented in this thesis. The studies in this 
thesis focus on visualisation of the epidermis and dermis, and on assessment of skin 
barrier function and erythema. Noninvasive tools that are suitable for these purposes 
are explained in more detail below.
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Reflectance confocal microscopy
Reflectance confocal microscopy (RCM) provides in vivo visualisation of the skin at 
nearly histologic resolution.93 A commonly used commercially available device is the 
VivaScope 1500 (Fig. 6).
Figure 6. Vivascope 1500. A metal ring with an adhesive window is applied to the skin with a drop 
of water in between. The VivaCam is used to obtain a dermatoscopic image. Then, ultrasound 
gel is applied on the window and the objective lens housing is attached to the magnetic metal 
ring. After starting the laser, black and white images appear on the computer screen. Reprinted 
with permission from the thesis of M. Peppelman94
Technical and practical aspects
The RCM uses a low-energy, near-infrared 830 nm laser light source, which penetrates 
into the skin and illuminates a horizontal, focal plane within the tissue.93 Light is back-
scattered from certain tissue structures at the focal point, and enters a detector 
through a pinhole aperture (Fig. 7). Out of focus light from other tissue points are 
blocked from detection.95 The lateral (horizontal) resolution of RCM is 0.5-1 µm and the 
axial (vertical) resolution is 3-5 µm. RCM produces images parallel to the skin surface 
(en face) up to a depth of approximately 250 µm, enabling visualisation of the epidermis, 
papillary dermis and superficial part of the reticular dermis. Contrast is provided by 
refractive index differences between cells and surrounding tissue. Images are viewed 
in greyscale. Melanin and keratin have a high refractive index, appearing bright in RCM. 
The reflectivity of white blood cells, chromatin, collagen, and elastin is lower, appearing 
darker (Fig. 8).93,96-99 Individual layers of normal skin can be distinguished clearly.93,100,101 
However, reflection differences are present depending on anatomical site, skin type, 
and extent of UV-light damage.101-103
1
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Figure 7. Schematic representation of the principle of the reflectance confocal microscope. 
Reprinted with permission from the thesis of M. Peppelman94
A standard RCM image depicts an area of 0.5x0.5 mm2 of the point of interest in the 
skin (confocal image) at 30x magnification. Confocal images can be stitched together 
by horizontal movement of the objective lens into a 2-dimensional mosaic up to 
8x8 mm2 (VivaBlock).104 Moreover, the objective lens can move vertically to capture 
images in depth (VivaStack). In addition, movies can be captured to document dynamic 
processes such as blood flow.
Applications in dermatology
RCM allows comfortable, noninvasive imaging of the skin without causing pain or 
scarring. Skin structure is not altered due to tissue processing or staining, which is 
especially advantageous in facial dermatoses. Moreover, an inflammatory response, 
which may interfere with the diagnosis and study observations, is prevented. RCM 
allows temporal monitoring of the same skin location for assessing therapy efficacy 
and enables visualisation of disease progression.
Initially, RCM was mainly used to diagnose melanocytic lesions and (non-)melanoma 
skin cancer, as melanin and melanosomes are strong contrast sources for RCM 
imaging.105-116 Later, RCM application was expanded to evaluate various ISDs and 
infestations with fungi and parasites.117-120 RCM has been used in psoriasis,121-125, 
acne vulgaris126-129, and also in rosacea, but only to study Demodex mites.130-135 So far, 
inflammatory and vascular parameters have not been studied in rosacea with RCM, 
therefore these will be subject of this thesis.
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Figure 8. RCM images of the skin and illustration of the refractile structures in decreasing bright-
ness. The transversal histological image shows the levels at which the RCM images are obtained. 
The stratum corneum (SC) appears as bright grey, anuclear cells. The stratum granulosum (SG) 
and stratum spinosum (SS) can be recognized by the appearance of dark round nuclei with sur-
rounding bright cytoplasm in a regular honeycombed pattern. At the dermal-epidermal junction 
(DEJ), the dermal papillae are visible; dark round areas surrounded by a rim of bright basal cells. 
The dermis (D) will appear as a bright fibre-like network and dark linear blood vessels. Reprinted 
with permission from the thesis of M. Peppelman94
1




A wide variety of biophysical analysis techniques have been developed to investigate 
and monitor the skin barrier function.136 These techniques are often hand-held 
probes placed in contact with the skin, allowing in vivo measurements. Tools to study 
transepidermal water loss (TEWL), SC hydration and erythema are discussed below.
TEWL devices
TEWL corresponds to the flux in water vapor, also including passive sweat gland 
activity, that moves from inside the body to the external environment by passive 
diffusion across the SC.13 TEWL measurements are taken over a fixed area of SC over 
a fixed period of time, and is expressed as [g/m2/h].136 Skin barrier dysfunction results 
in increased TEWL, and these changes relate well to the degree of impairment.12,137 
Contrary, reduced TEWL is linked to a stronger or recovering skin barrier.138 Monitoring 
of the variability in TEWL is therefore useful to evaluate therapy efficacy. TEWL shows 
significant variation at different anatomical sites due to differences in the nature 
of the intercellular lipids and/or corneocytes, sweat gland activity, occlusion, skin 
temperature, skin thickness, and microvasculature.139-141 Numerous instruments have 
been developed to measure TEWL, with a major application in cosmetic studies to 
evaluate the effect of moisturizers on the skin barrier. Three measurement principles 
are used: open-, unventilated-, and condenser-chamber devices, each with their own 
advantages and limitations (Fig. 9).12,13,142,143
Figure 9. TEWL device principles. A, Open-chamber. A hollow cylinder is placed in contact with 
the skin, and water vapor diffuses through the open chamber. Spatially separated temperature 
and humidity sensors detect the humidity gradient. Limitation: vulnerable to environmental influ-
ences. B, Unventilated-chamber. The upper end of the chamber is closed, resulting in water vapor 
collecting in the chamber. The temperature and relative humidity sensors detect the rate of in-
crease of relative humidity. Limitation: not suitable for continuous measurements. C, Condenser- 
chamber. The upper end of the chamber is closed by a condenser that removes water vapor 
from the chamber. Water vapor density is measured by sensors in the chamber and condenser. 
Advantages: suitable for continuous measurements, less vulnerable to environmental factors. 
Reprinted with permission from Alexander et al 201813
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SC hydration devices
Stratum corneum hydration is measured by analysis of electrical conductance or 
capacitance of the skin surface.142 Electrical transport through keratinized tissue 
involves different types of electrical charge carriers of which the conduction exchange 
of protons along the H-bonded network of water molecules dominates, and is therefore 
highly dependent on water content.144 Conductance-based instruments apply an 
electric current to measure the conductance of the SC in [µS]. Capacitance-based 
instruments apply a small oscillating electric field with low frequency to measure the 
dielectric constant of the skin in arbitrary units [a.u.]. See Fig. 10 for the capacitance 
principle of single and multi-sensor devices.145 Current, conventional corneometers 
are single-sensor, only able to perform one measurement. In this thesis, also a newly 
developed multi-sensor device will be investigated. Corresponding to TEWL, also SC 
hydration shows anatomical site variation.146,147 It is important to note that any polar 
substance or chemical applied to the skin surface may contribute to the electrical 
signal being recorded with the instrument and read as water. As water distribution of 
the skin surface is not completely even, due to the skin relief and variable distribution 
of sweat glands,142 mapping of SC hydration is highly desirable to obtain accurate 
results.
Figure 10. Capacitance-based device principle. The device produces a small oscillating electric 
field with low frequency and measures the dielectric constant of the skin which is placed in con-
tact with the electrode surface. Left: single sensor device has one sensor, resulting in one large 
electrical ‘loop’ through the skin. Limitation: hydration is measured in the stratum corneum and 
the well-hydrated living upper dermis as well. Right: multi-sensor device, recently developed 
and not yet validated. It consists of 76 800 sensors, making multiple, small, electrical loops 
through the skin. Advantage: multiple measurements take place at once and can be averaged or 
can be used to get a hydration image of the stratum corneum, and hydration measurement is 
theoretically restricted to the ‘dry’ stratum corneum only.
1




Skin colour results from absorption and scattering of light by skin chromophores, 
mainly being melanin and haemoglobin.148,149 Two principles for skin colour 
quantification exist; reflectance spectrophotometry and tristimulus colorimetry.136,150 
Reflectance spectrophotometry records information over a full visible spectrum of 
light or focuses on the quantification of reflectance at a few selected light wavelengths 
corresponding to the peak absorption of haemoglobin and melanin. The reflected 
spectrum is detected by photodiodes of the device and translated into colour values 
(‘erythema index’ or ‘melanin index’).148 With tristimulus colorimetry, three wave-
bands that are well separated in the visible spectrum (RGB; red, green and blue) are 
used, corresponding to the three types of colour sensors in the human eye. Using CIE 
(Commission Internationale de l’Eclarage), wavelength and intensity information are 
converted into three numbers, indicating how a colour of an object appears to a human 
observer; L* (brightness), α* (red-green), b* (blue-yellow). The α* value is frequently 
used as a parameter to quantify erythema in clinical studies, as it correlates almost 
linearly with the amount of haemoglobin in the superficial plexus.150 Unfortunately, 
current colour measurement instruments only cover a small facial area, questioning 
representativeness of the entire face. Moreover, they require skin contact, and 
skin colour is easily influenced by skin pressure. These problems may be solved by 
computer-assisted image analysis; this will be used in this thesis.
Current limitations of biophysical devices
Besides from the aforementioned device specific limitations, current biophysical 
devices in general have some other drawbacks. Most devices are expensive, and their 
practice use is limited due to their size, weight, and speed. Generated results can 
be influenced by various internal and external factors such as age, anatomical site, 
blood flow, ambient temperature and humidity, sweating, and sun exposure.7,13,144,149-155 
Moreover, due to the differences in measurement principles it is difficult to compare 
results of different devices.12 Compliance to guidelines is needed to obtain reliable 
and standardized measurements,142,144,149 which requires familiarity with extensive 
and complicated protocols, repeated calibration, and standardized measurement 
conditions. As a result, biophysical analysis techniques have not had a great impact 
in dermatological practice so far. Biophysical tools suitable for clinical practice 
need to be accurate, easy-to-use, rapid, and relatively inexpensive. Ideally, this 
results in their routine application in dermatology clinics for objective monitoring 
of inflammatory dermatoses, and for improvement of personalized treatment and 
therapy compliance.
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AIM AND OUTLINE OF THIS THESIS
Objective and noninvasive measurement methods are needed to evaluate ISDs, 
because current clinical assessment is subjective and biopsies are not preferred in 
cosmetically important regions such as the face. However, these methods are not yet 
embedded in daily practice due to various practical and cost-effectiveness concerns.
The main objective of this thesis was to evaluate the value of novel and conventional 
noninvasive imaging and biophysical tools in healthy and inflamed skin in daily clinical 
practice. Rosacea served as a model for inflamed skin state. This thesis primarily 
focused on two aims:
1. To investigate the value of imaging and biophysical tools in healthy and impaired 
skin barrier function.
2. To investigate the value of imaging and biophysical methods in inflamed skin, with 
emphasis on rosacea.
In chapter 2 we evaluated the value of novel and combined biophysical tools to assess 
normal and impaired skin barrier function. In chapter 2.1, the Epsilon®, a new tool 
measuring SC hydration, was investigated to determine its use in the measurement 
of anatomical site variation of water content in the skin. Chapter 2.2 focused on 
the feasibility of combining multiple existent biophysical/imaging devices to measure 
differences in skin barrier function after cream application. Furthermore, the value of the 
GPSkin®, a new tool to measure TEWL and SC hydration simultaneously, was evaluated 
to quantify an impaired skin barrier function after tapestripping (chapter 2.3).
The purpose of chapter 3 was to investigate the value of novel and conventional 
imaging and biophysical tools in rosacea for application in daily clinical practice. 
Chapter 3.1 provides an extensive overview of available noninvasive objective skin 
measurement techniques for rosacea assessment. Based on this systematic review, we 
examined the value of reflectance confocal microscopy for the monitoring of rosacea 
during treatment with topical ivermectin (chapter 3.2). The value of the GPSkin® 
was tested to monitor the skin barrier function in rosacea patients before and during 
treatment in chapter 2.3. Then, in chapter 3.3, we developed a computer-aided 
image analysis tool to facilitate quantification of facial erythema in rosacea. Next, we 
presented five rosacea patients with worsening of symptoms due to occlusion of the 
skin after use of a CPAP mask (chapter 3.4). In chapter 3.5, we evaluated the efficacy 
of oral β-blockers for rosacea-associated facial flushing and erythema by performing 
a systematic review.
Lastly, the results as described in this thesis were summarized and discussed in 
chapter 4, and future perspectives were provided.
1




1 Yousef H, Sharma S. Anatomy, Skin (Integument), Epidermis. Treasure Island, FL: StatPearls 
Publishing; 2017.
2 Agarwal S, Krishnamurthy K. Histology, Skin. Treasure Island, FL: StatPearls Publishing: 
2019.
3 Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol 
2008;17:1063-72.
4 Fuchs E, Raghavan S. Getting under the skin of epidermal morphogenesis. Nat Rev Genet 
2002;3:199-209.
5 Kabashima K, Honda T, Ginhoux F, et al. The immunological anatomy of the skin. Nature 
Reviews Immunology 2019;19:19-30.
6 Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier 
disorders. Am J Clin Dermatol 2003;4:771-88.
7 Madison KC. Barrier function of the skin: “la raison d’etre” of the epidermis. J Invest 
Dermatol 2003;121:231-41.
8 Elias PM. Skin barrier function. Curr Allergy Asthma Rep 2008;8:299-305.
9 Yosipovitch G, Misery L, Proksch E, et al. Skin Barrier Damage and Itch: Review of 
Mechanisms, Topical Management and Future Directions. Acta Derm Venereol 
2019;99:1201-9.
10 Rawlings AV, Matts PJ. Stratum corneum moisturization at the molecular level: an update 
in relation to the dry skin cycle. J Invest Dermatol 2005;124:1099-110.
11 Parra JL, Paye M. EEMCO guidance for the in vivo assessment of skin surface pH. Skin 
Pharmacol Appl Skin Physiol 2003;16:188-202.
12 Darlenski R, Sassning S, Tsankov N, et al. Non-invasive in vivo methods for investigation 
of the skin barrier physical properties. European Journal of Pharmaceutics and 
Biopharmaceutics 2009;72:295-303.
13 Alexander H, Brown S, Danby S, et al. Research Techniques Made Simple: Transepidermal 
Water Loss Measurement as a Research Tool. J Invest Dermatol 2018;138:2295-300.e1.
14 Sandilands A, Sutherland C, Irvine AD, et al. Filaggrin in the frontline: role in skin barrier 
function and disease. J Cell Sci 2009;122:1285-94.
15 Kezic S, Kammeyer A, Calkoen F, et al. Natural moisturizing factor components in the 
stratum corneum as biomarkers of filaggrin genotype: evaluation of minimally invasive 
methods. Br J Dermatol 2009;161:1098-104.
16 Verdier-Sevrain S, Bonte F. Skin hydration: a review on its molecular mechanisms. J Cosmet 
Dermatol 2007;6:75-82.
17 Hu L, Mauro TM, Dang E, et al. Epidermal Dysfunction Leads to an Age-Associated Increase 
in Levels of Serum Inflammatory Cytokines. J Invest Dermatol 2017;137:1277-85.
18 van den Eijnde W, Heus R, Falcone D, et al. Skin Barrier Impairment due to the Occlusive 
Effect of Firefighter Clothing. Ann Work Expo Health 2020;64:331-337.
19 Samadi A, Ahmad Nasrollahi S, Maghsoudi Ashtiani M, et al. Changes in skin barrier function 
following single and repeated applications of 4 types of moisturizers: A randomized 
controlled trial. J Eur Acad Dermatol Venereol 2020;34:e288-e290.
20 Danby SG, Chalmers J, Brown K, et al. A functional mechanistic study of the effect of 
emollients on the structure and function of the skin barrier. Br J Dermatol 2016;175:1011-9.
21 Perusquia-Ortiz AM, Oji V, Sauerland MC, et al. Complete filaggrin deficiency in ichthyosis 
vulgaris is associated with only moderate changes in epidermal permeability barrier 
function profile. J Eur Acad Dermatol Venereol 2013;27:1552-8.
22 Loden M, Olsson H, Axell T, et al. Friction, capacitance and transepidermal water loss 
(TEWL) in dry atopic and normal skin. Br J Dermatol 1992;126:137-41.
Voorbereid document - Jade.indd   24 01-05-2021   10:16
25
General introduction and thesis outline
23 Gupta J, Grube E, Ericksen MB, et al. Intrinsically defective skin barrier function in children 
with atopic dermatitis correlates with disease severity. J Allergy Clin Immunol 2008;121:725-
30.e2.
24 Berents TL, Lodrup Carlsen KC, Mowinckel P, et al. Transepidermal water loss in infancy 
associated with atopic eczema at 2 years of age: a population-based cohort study. Br J 
Dermatol 2017;177:e35-e7.
25 Kelleher M, Dunn-Galvin A, Hourihane JO, et al. Skin barrier dysfunction measured by 
transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis 
at 1 year. J Allergy Clin Immunol 2015;135:930-5.e1.
26 Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: the skin barrier and beyond. Br J 
Dermatol 2019;180:464-74.
27 Addor FA, Aoki V. Skin barrier in atopic dermatitis. An Bras Dermatol 2010;85:184-94.
28 Elias PM. Primary role of barrier dysfunction in the pathogenesis of atopic dermatitis. Exp 
Dermatol 2018;27:847-51.
29 Seidenari S, Giusti G. Objective assessment of the skin of children affected by atopic 
dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved 
skin. Acta Derm Venereol 1995;75:429-33.
30 Nikam VN, Monteiro RC, Dandakeri S, et al. Transepidermal Water Loss in Psoriasis: A 
Case-control Study. Indian Dermatol Online J 2019;10:267-71.
31 Takahashi H, Tsuji H, Minami-Hori M, et al. Defective barrier function accompanied by 
structural changes of psoriatic stratum corneum. J Dermatol 2014;41:144-8.
32 Motta S, Monti M, Sesana S, et al. Abnormality of water barrier function in psoriasis. Role 
of ceramide fractions. Arch Dermatol 1994;130:452-6.
33 Thiboutot D, Del Rosso JQ. Acne Vulgaris and the Epidermal Barrier: Is Acne Vulgaris 
Associated with Inherent Epidermal Abnormalities that Cause Impairment of Barrier 
Functions? Do Any Topical Acne Therapies Alter the Structural and/or Functional Integrity 
of the Epidermal Barrier? J Clin Aesthet Dermatol 2013;6:18-24.
34 Addor FA. Skin barrier in rosacea. An Bras Dermatol 2016;91:59-63.
35 Two AM, Wu W, Gallo RL, et al. Rosacea: part I. Introduction, categorization, histology, 
pathogenesis, and risk factors. J Am Acad Dermatol 2015;72:749-58; quiz 59-60.
36 Woo YR, Lim JH, Cho DH, et al. Rosacea: Molecular Mechanisms and Management of a 
Chronic Cutaneous Inflammatory Condition. Int J Mol Sci 2016;17.
37 Medgyesi B, Dajnoki Z, Béke G, et al. Rosacea Is Characterized by a Profoundly Diminished 
Skin Barrier. J Invest Dermatol 2020;140:1938-1950.e5.
38 Bolognia J, Schaffer J, Cerroni L. Dermatology. Elsevier, 2017.
39 Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the 
National Rosacea Society Expert Committee on the classification and staging of rosacea. 
J Am Acad Dermatol 2004;50:907-12.
40 Heisig M, Reich A. Psychosocial aspects of rosacea with a focus on anxiety and depression. 
Clin Cosmet Investig Dermatol 2018;11:103-7.
41 Schaller M, Pietschke K. Successful therapy of ocular rosacea with topical ivermectin. Br 
J Dermatol 2018;179:520-1.
42 Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of 
rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad 
Dermatol 2018;78:148-55.
43 Tan J, Berg M, Gallo RL, et al. Applying the phenotype approach for rosacea to practice 
and research. Br J Dermatol 2018;179:741-6.
44 Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment 
of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J 
Dermatol 2017;176:431-8.
1
Voorbereid document - Jade.indd   25 01-05-2021   10:16
26
Chapter 1
45 van Zuuren EJ. Rosacea. New England Journal of Medicine 2017;377:1754-64.
46 Thyssen JP. Subtyping, phenotyping or endotyping rosacea: how can we improve disease 
understanding and patient care? Br J Dermatol 2018;179:551-2.
47 Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, 
classification and management: update from the global ROSacea COnsensus 2019 panel. 
Br J Dermatol 2020;182:1269-1276.
48 Marson JW, Baldwin HE. Rosacea: a wholistic review and update from pathogenesis to 
diagnosis and therapy. Int J Dermatol 2020;59:e175-e182.
49 Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013;69:S27-35.
50 Gether L, Overgaard LK, Egeberg A, et al. Incidence and prevalence of rosacea: a systematic 
review and meta-analysis. Br J Dermatol 2018;179:282-9.
51 Rainer BM, Kang S, Chien AL. Rosacea: Epidemiology, pathogenesis, and treatment. 
Dermatoendocrinol 2017;9:e1361574.
52 Spoendlin J, Voegel JJ, Jick SS, et al. A study on the epidemiology of rosacea in the U.K. Br 
J Dermatol 2012;167:598-605.
53 Abram K, Silm H, Maaroos HI, et al. Risk factors associated with rosacea. J Eur Acad 
Dermatol Venereol 2010;24:565-71.
54 Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of 
rosacea, highlighting skin of color: Review and clinical practice experience. J Am Acad 
Dermatol 2019;80:1722-9.e7.
55 Rainer BM, Fischer AH, Luz Felipe da Silva D, et al. Rosacea is associated with chronic 
systemic diseases in a skin severity–dependent manner: Results of a case-control study. 
Journal of the American Academy of Dermatology 2015;73:604-8.
56 Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical 
presentation and new therapeutics. Exp Dermatol 2017;26:659-67.
57 Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype 
classification. J Am Acad Dermatol 2004;51:327-41; quiz 42-4.
58 Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of 
recent findings. J Am Acad Dermatol 2013;69:S15-26.
59 Ahn CS, Huang WW. Rosacea Pathogenesis. Dermatol Clin 2018;36:81-6.
60 Lacey N, Ni Raghallaigh S, Powell FC. Demodex mites--commensals, parasites or mutualistic 
organisms? Dermatology 2011;222:128-30.
61 Elston DM. Demodex mites: facts and controversies. Clin Dermatol 2010;28:502-4.
62 Lacey N, Russell-Hallinan A, Powell FC. Study of Demodex mites: Challenges and Solutions. 
J Eur Acad Dermatol Venereol 2016;30:764-75.
63 Jarmuda S, O’Reilly N, Zaba R, et al. Potential role of Demodex mites and bacteria in the 
induction of rosacea. J Med Microbiol 2012;61:1504-10.
64 Elston CA, Elston DM. Demodex mites. Clin Dermatol 2014;32:739-43.
65 Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case-control study using 
standardized skin-surface biopsy. Br J Dermatol 1993;128:650-9.
66 Zhao YE, Wu LP, Peng Y, et al. Retrospective analysis of the association between Demodex 
infestation and rosacea. Arch Dermatol 2010;146:896-902.
67 Chang YS, Huang YC. Role of Demodex mite infestation in rosacea: A systematic review 
and meta-analysis. J Am Acad Dermatol 2017;77:441-7.e6.
68 Lacey N, Russell-Hallinan A, Zouboulis CC, et al. Demodex mites modulate sebocyte immune 
reaction: possible role in the pathogenesis of rosacea. Br J Dermatol 2018;179:420-30.
69 Casas C, Paul C, Lahfa M, et al. Quantification of Demodex folliculorum by PCR in rosacea 
and its relationship to skin innate immune activation. Exp Dermatol 2012;21:906-10.
70 Forton FM, De Maertelaer V. Two Consecutive Standardized Skin Surface Biopsies: An 
Improved Sampling Method to Evaluate Demodex Density as a Diagnostic Tool for Rosacea 
and Demodicosis. Acta Derm Venereol 2017;97:242-8.
71 Lacey N, Delaney S, Kavanagh K, et al. Mite-related bacterial antigens stimulate 
inflammatory cells in rosacea. Br J Dermatol 2007;157:474-81.
Voorbereid document - Jade.indd   26 01-05-2021   10:16
27
General introduction and thesis outline
72 Del Rosso JQ. Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea. J Clin 
Aesthet Dermatol 2017;10:39-42.
73 van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype 
approach: an updated systematic review including GRADE assessments. Br J Dermatol 
2019;181:65-79.
74 van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for rosacea. Cochrane Database 
Syst Rev 2015;Cd003262.
75 Rosamilia LL. Rosacea treatment schema: an update. Cutis 2017;100:11-3.
76 Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations 
from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol 2017;176:465-71.
77 NVDV. Richtlijn rosacea, 2019. https://nvdv.nl/patienten/richtlijnen-en-onderzoek/
richtlijnen/richtlijn-rosacea.
78 Gessert CE, Bamford JT. Measuring the severity of rosacea: a review. Int J Dermatol 
2003;42:444-8.
79 Hopkinson D, Moradi Tuchayi S, Alinia H, et al. Assessment of rosacea severity: A review 
of evaluation methods used in clinical trials. J Am Acad Dermatol 2015;73:138-43.e4.
80 Tan J, Liu H, Leyden JJ, et al. Reliability of Clinician Erythema Assessment grading scale. 
Journal of the American Academy of Dermatology 2014;71:760-3.
81 Bamford JT, Gessert CE, Renier CM. Measurement of the severity of rosacea. Journal of 
the American Academy of Dermatology 2004;51:697-703.
82 Bamford JT. Interobserver variation in the assessment of rosacea. Arch Dermatol 
1998;134:508.
83 Tan J, Steinhoff M, Berg M, et al. Shortcomings in rosacea diagnosis and classification. Br 
J Dermatol 2017;176:197-9.
84 Cribier B. Rosacea under the microscope: characteristic histological findings. J Eur Acad 
Dermatol Venereol 2013;27:1336-43.
85 Lee WJ, Jung JM, Lee YJ, et al. Histopathological Analysis of 226 Patients With Rosacea 
According to Rosacea Subtype and Severity. Am J Dermatopathol 2016;38:347-52.
86 Taxy JB. Frozen section and the surgical pathologist: a point of view. Arch Pathol Lab Med 
2009;133:1135-8.
87 Scheinfeld N, Berk T. A review of the diagnosis and treatment of rosacea. Postgrad Med 
2010;122:139-43.
88 Two AM, Wu W, Gallo RL, et al. Rosacea: part II. Topical and systemic therapies in the 
treatment of rosacea. J Am Acad Dermatol 2015;72:761-70; quiz 71-2.
89 Aspres N, Egerton IB, Lim AC, et al. Imaging the skin. Australas J Dermatol 2003;44:19-27.
90 Dasgeb B, Kainerstorfer J, Mehregan D, et al. An introduction to primary skin imaging. Int 
J Dermatol 2013;52:1319-30.
91 Rallan D, Harland CC. Skin imaging: is it clinically useful? Clin Exp Dermatol 2004;29:453-9.
92 Mehta HH, Nikam VV, Jaiswal CR, et al. A cross-sectional study of variations in the 
biophysical parameters of skin among healthy volunteers. Indian J Dermatol Venereol 
Leprol 2018;84:521.
93 Levine A, Markowitz O. Introduction to reflectance confocal microscopy and its use in 
clinical practice. JAAD Case Rep 2018;4:1014-23.
94 Peppelman M. In vivo reflectance confocal microscopy: Innovations in skin imaging. 
Radboud University Medical Center, 2015.
95 Gonzalez S, Swindells K, Rajadhyaksha M, et al. Changing paradigms in dermatology: 
confocal microscopy in clinical and surgical dermatology. Clin Dermatol 2003;21:359-69.
96 Shahriari N, Grant-Kels JM, Rabinovitz H, et al. In vivo reflectance confocal microscopy 
image interpretation for the dermatopathologist. J Cutan Pathol 2018;45:187-97.
97 Rajadhyaksha M, Grossman M, Esterowitz D, et al. In vivo confocal scanning laser microscopy 
of human skin: melanin provides strong contrast. J Invest Dermatol 1995;104:946-52.
1
Voorbereid document - Jade.indd   27 01-05-2021   10:16
28
Chapter 1
98 Rajadhyaksha M, Gonzalez S, Zavislan JM, et al. In vivo confocal scanning laser microscopy 
of human skin II: advances in instrumentation and comparison with histology. J Invest 
Dermatol 1999;113:293-303.
99 Calzavara-Pinton P, Longo C, Venturini M, et al. Reflectance confocal microscopy for in vivo 
skin imaging. Photochem Photobiol 2008;84:1421-30.
100 Ardigo M, Longo C, Gonzalez S. Multicentre study on inflammatory skin diseases from 
The International Confocal Working Group: specific confocal microscopy features and an 
algorithmic method of diagnosis. Br J Dermatol 2016;175:364-74.
101 Puig S. Reflectance Confocal Microscopy for Skin Diseases. Berlin/Hedelberg, Germany: 
Springer. 2012.
102 Huzaira M, Rius F, Rajadhyaksha M, et al. Topographic variations in normal skin, as viewed 
by in vivo reflectance confocal microscopy. J Invest Dermatol 2001;116:846-52.
103 Robertson K, Rees JL. Variation in epidermal morphology in human skin at different body 
sites as measured by reflectance confocal microscopy. Acta Derm Venereol 2010;90:368-73.
104 Rajadhyaksha M, Marghoob A, Rossi A, et al. Reflectance confocal microscopy of skin in 
vivo: From bench to bedside. Lasers Surg Med 2017;49:7-19.
105 Ahlgrimm-Siess V, Laimer M, Rabinovitz HS, et al. Confocal Microscopy in Skin Cancer. Curr 
Dermatol Rep 2018;7:105-18.
106 Edwards SJ, Osei-Assibey G, Patalay R, et al. Diagnostic accuracy of reflectance confocal 
microscopy using VivaScope for detecting and monitoring skin lesions: a systematic review. 
Clin Exp Dermatol 2017;42:266-75.
107 Guitera P, Pellacani G, Longo C, et al. In vivo reflectance confocal microscopy enhances 
secondary evaluation of melanocytic lesions. J Invest Dermatol 2009;129:131-8.
108 Pellacani G, Cesinaro AM, Seidenari S. Reflectance-mode confocal microscopy for the in 
vivo characterization of pagetoid melanocytosis in melanomas and nevi. J Invest Dermatol 
2005;125:532-7.
109 Pellacani G, Cesinaro AM, Seidenari S. Reflectance-mode confocal microscopy of pigmented 
skin lesions--improvement in melanoma diagnostic specificity. J Am Acad Dermatol 
2005;53:979-85.
110 Lupu M, Popa IM, Voiculescu VM, et al. A Systematic Review and Meta-Analysis of the 
Accuracy of in VivoReflectance Confocal Microscopy for the Diagnosis of Primary Basal 
Cell Carcinoma. J Clin Med 2019;8.
111 Xiong YD, Ma S, Li X, et al. A meta-analysis of reflectance confocal microscopy for the 
diagnosis of malignant skin tumours. J Eur Acad Dermatol Venereol 2016;30:1295-302.
112 Nori S, Rius-Diaz F, Cuevas J, et al. Sensitivity and specificity of reflectance-mode confocal 
microscopy for in vivo diagnosis of basal cell carcinoma: a multicenter study. J Am Acad 
Dermatol 2004;51:923-30.
113 Agero AL, Busam KJ, Benvenuto-Andrade C, et al. Reflectance confocal microscopy of 
pigmented basal cell carcinoma. J Am Acad Dermatol 2006;54:638-43.
114 Gonzalez S, Tannous Z. Real-time, in vivo confocal reflectance microscopy of basal cell 
carcinoma. J Am Acad Dermatol 2002;47:869-74.
115 Segura S, Puig S, Carrera C, et al. Development of a two-step method for the diagnosis of 
melanoma by reflectance confocal microscopy. J Am Acad Dermatol 2009;61:216-29.
116 Guitera P, Menzies SW, Longo C, et al. In vivo confocal microscopy for diagnosis of 
melanoma and basal cell carcinoma using a two-step method: analysis of 710 consecutive 
clinically equivocal cases. J Invest Dermatol 2012;132:2386-94.
117 Hoogedoorn L, Peppelman M, van de Kerkhof PC, et al. The value of in vivo reflectance 
confocal microscopy in the diagnosis and monitoring of inflammatory and infectious skin 
diseases: a systematic review. Br J Dermatol 2015;172:1222-48.
118 Ardigo M, Agozzino M, Franceschini C, et al. Reflectance Confocal Microscopy Algorithms 
for Inflammatory and Hair Diseases. Dermatol Clin 2016;34:487-96.
119 Agozzino M, Gonzalez S, Ardigo M. Reflectance Confocal Microscopy for Inflammatory Skin 
Diseases. Actas Dermosifiliogr 2016;107:631-9.
Voorbereid document - Jade.indd   28 01-05-2021   10:16
29
General introduction and thesis outline
120 Cinotti E, Perrot JL, Labeille B, et al. Reflectance confocal microscopy for cutaneous 
infections and infestations. J Eur Acad Dermatol Venereol 2016;30:754-63.
121 Batani A, Branisteanu DE, Ilie MA, et al. Assessment of dermal papillary and microvascular 
parameters in psoriasis vulgaris using in vivo reflectance confocal microscopy. Exp Ther 
Med 2018;15:1241-6.
122 Hoogedoorn L, Wolberink EA, van de Kerkhof PC, et al. Noninvasive differentiation between 
stable and unstable chronic plaque psoriasis using in vivo reflectance confocal microscopy. 
J Am Acad Dermatol 2015;73:870-2.
123 Wolberink EA, van Erp PE, Teussink MM, et al. Cellular features of psoriatic skin: imaging 
and quantification using in vivo reflectance confocal microscopy. Cytometry B Clin Cytom 
2011;80:141-9.
124 Wolberink EA, van Erp PE, de Boer-van Huizen RT, et al. Reflectance confocal microscopy: 
an effective tool for monitoring ultraviolet B phototherapy in psoriasis. Br J Dermatol 
2012;167:396-403.
125 Ardigo M, Cota C, Berardesca E, et al. Concordance between in vivo reflectance confocal 
microscopy and histology in the evaluation of plaque psoriasis. J Eur Acad Dermatol 
Venereol 2009;23:660-7.
126 Fuchs CSK, Andersen AJB, Ardigo M, et al. Acne vulgaris severity graded by in vivo 
reflectance confocal microscopy and optical coherence tomography. Lasers Surg Med 
2019;51:104-13.
127 Manfredini M, Greco M, Farnetani F, et al. In vivo monitoring of topical therapy for acne 
with reflectance confocal microscopy. Skin Res Technol 2017;23:36-40.
128 Manfredini M, Mazzaglia G, Ciardo S, et al. Acne: in vivo morphologic study of lesions 
and surrounding skin by means of reflectance confocal microscopy. J Eur Acad Dermatol 
Venereol 2015;29:933-9.
129 Rossi E, Mandel VD, Paganelli A, et al. Plasma exeresis for active acne vulgaris: Clinical and 
in vivo microscopic documentation of treatment efficacy by means of reflectance confocal 
microscopy. Skin Res Technol 2018;24:522-4.
130 Harmelin Y, Delaunay P, Erfan N, et al. Interest of confocal laser scanning microscopy for 
the diagnosis and treatment monitoring of demodicosis. J Eur Acad Dermatol Venereol 
2014;28:255-7.
131 Turgut Erdemir A, Gurel MS, Koku Aksu AE, et al. Reflectance confocal microscopy vs. 
standardized skin surface biopsy for measuring the density of Demodex mites. Skin Res 
Technol 2014;20:435-9.
132 Sattler EC, Hoffmann VS, Ruzicka T, et al. Reflectance confocal microscopy for monitoring 
the density of Demodex mites in patients with rosacea before and after treatment. Br J 
Dermatol 2015;173:69-75.
133 Ruini C, Sattler E, Hartmann D, et al. Monitoring structural changes in Demodex mites 
under topical Ivermectin in rosacea by means of reflectance confocal microscopy: a case 
series. J Eur Acad Dermatol Venereol 2017;31:e299-e301.
134 Turgut Erdemir A, Gurel MS, Koku Aksu AE, et al. Demodex mites in acne rosacea: 
reflectance confocal microscopic study. Australas J Dermatol 2017;58:e26-e30.
135 Falay Gur T, Erdemir AV, Gurel MS, et al. The investigation of the relationships of demodex 
density with inflammatory response and oxidative stress in rosacea. Arch Dermatol Res 
2018;310:759-67.
136 van Erp PEJ, Peppelman M, Falcone D. Noninvasive analysis and minimally invasive in vivo 
experimental challenges of the skin barrier. Exp Dermatol 2018;27:867-75.
137 Rogiers V. EEMCO guidance for the assessment of transepidermal water loss in cosmetic 
sciences. Skin Pharmacol Appl Skin Physiol 2001;14:117-28.
138 Damien F, Boncheva M. The Extent of Orthorhombic Lipid Phases in the Stratum 
Corneum Determines the Barrier Efficiency of Human Skin In Vivo. Journal of Investigative 
Dermatology 2010;130:611-4.
1
Voorbereid document - Jade.indd   29 01-05-2021   10:16
30
Chapter 1
139 Kottner J, Lichterfeld A, Blume-Peytavi U. Transepidermal water loss in young and aged 
healthy humans: a systematic review and meta-analysis. Archives of Dermatological 
Research 2013;305:315-23.
140 Lampe MA, Burlingame AL, Whitney J, et al. Human stratum corneum lipids: characterization 
and regional variations. J Lipid Res 1983;24:120-30.
141 Tagami H. Location-related differences in structure and function of the stratum corneum 
with special emphasis on those of the facial skin. Int J Cosmet Sci 2008;30:413-34.
142 Berardesca E, Loden M, Serup J, et al. The revised EEMCO guidance for the in vivo 
measurement of water in the skin. Skin Res Technol 2018;24:351-8.
143 Farahmand S, Tien L, Hui X, et al. Measuring transepidermal water loss: a comparative in 
vivo study of condenser-chamber, unventilated-chamber and open-chamber systems. 
Skin Res Technol 2009;15:392-8.
144 Berardesca E. EEMCO guidance for the assessment of stratum corneum hydration: 
electrical methods. Skin Res Technol 1997;3:126-32.
145 Imhof B. Stratum corneum hydration measurement using capacitance contact imaging. 
[Poster]. 2017.
146 Mayrovitz HN, Bernal M, Brlit F, et al. Biophysical measures of skin tissue water: variations 
within and among anatomical sites and correlations between measures. Skin Res Technol 
2013;19:47-54.
147 Manuskiatti W, Schwindt DA, Maibach HI. Influence of age, anatomic site and race on skin 
roughness and scaliness. Dermatology 1998;196:401-7.
148 Stamatas GN, Zmudzka BZ, Kollias N, et al. Non-invasive measurements of skin 
pigmentation in situ. Pigment Cell Res 2004;17:618-26.
149 Fullerton A, Fischer T, Lahti A, et al. Guidelines for measurement of skin colour and 
erythema. A report from the Standardization Group of the European Society of Contact 
Dermatitis. Contact Dermatitis 1996;35:1-10.
150 Takiwaki H. Measurement of skin color: practical application and theoretical considerations. 
J Med Invest 1998;44:121-6.
151 Marrakchi S, Maibach HI. Biophysical parameters of skin: map of human face, regional, 
and age-related differences. Contact Dermatitis 2007;57:28-34.
152 Voegeli R, Rawlings AV, Seroul P, et al. A novel continuous colour mapping approach for 
visualization of facial skin hydration and transepidermal water loss for four ethnic groups. 
Int J Cosmet Sci 2015;37:595-605.
153 Nam GW, Baek JH, Koh JS, et al. The seasonal variation in skin hydration, sebum, scaliness, 
brightness and elasticity in Korean females. Skin Res Technol 2015;21:1-8.
154 Akdeniz M, Gabriel S, Lichterfeld-Kottner A, et al. Transepidermal water loss in healthy 
adults: a systematic review and meta-analysis update. Br J Dermatol 2018;179:1049-55.
155 Pinnagoda J, Tupker RA, Agner T, et al. Guidelines for transepidermal water loss (TEWL) 
measurement. A report from the Standardization Group of the European Society of 
Contact Dermatitis. Contact Dermatitis 1990;22:164-78.
Voorbereid document - Jade.indd   30 01-05-2021   10:16
31
General introduction and thesis outline
1
Voorbereid document - Jade.indd   31 01-05-2021   10:16
Voorbereid document - Jade.indd   32 01-05-2021   10:16
Voorbereid document - Jade.indd   33 01-05-2021   10:16
Voorbereid document - Jade.indd   34 01-05-2021   10:16
CHAPTER 2.1
Anatomical site variation of water content in







*authors contributed equally to this work
Skin Research and Technology 2019;25:333-338





This pilot study aimed to investigate the anatomical site variation of water content of 
the stratum corneum (SC) on the body by measuring skin capacitance with the Epsilon, 
a new generation corneometer with multiple sensors. Secondly, values of the Epsilon 
were compared to values measured by conventional single sensor corneometers.
Methods
The hydration status of SC was measured in 15 healthy Caucasian volunteers with the 
Epsilon at five body sites (cheek, lower forearm, mid-calf, lower back and abdomen). 
Transepidermal water loss (TEWL) was measured with the Aquaflux to get more insight 
into the condition of the skin barrier. A literature search was performed to compare 
Epsilon values with conventional corneometers.
Results
The tested anatomical locations showed significant differences in water content (P < 
0.001) with large inter-individual variations; highest values were found in the cheek 
(11.64ε) and lowest values in the mid-calf (4.43ε). No correlation between water content 
and TEWL was found. In general, Epsilon values were lower compared to values of 
conventional corneometers, with a similar trend.
Conclusion
This pilot study showed significant variations in water content at different skin 
locations measured by the Epsilon. Moreover, the Epsilon measured consistent lower 
values compared to single sensor corneometers. Further validation of the device is 
recommended.
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INTRODUCTION
The stratum corneum (SC) plays an important role in skin surface management by 
protecting the human body against microorganisms and guaranteeing skin barrier 
function by regulation of moisture grade and temperature.1-3 SC imbalance can 
lead to various inflammatory skin diseases, for instance constitutional eczema. The 
structure and barrier function of the SC can be studied noninvasively with different 
measurement tools; water content and transepidermal water loss (TEWL) are two 
commonly evaluated skin variables.4 A corneometer measures the water content 
by measuring electrical capacitance of the skin surface. Until today, single sensor 
corneometers are used, showing significant differences in water content between 
various skin locations.5-7 Recently, the Epsilon, a multi-sensor corneometer with 
76800 sensors at one probe was introduced.8 Due to this increase in sensors, multiple 
measurements take place at once. In addition, options for analysis are integrated in 
this device and water content-based images can be obtained.
To the best of our knowledge, this is the first study to investigate the anatomical 
site variation of water content in human skin with the Epsilon. Also, measured water 
content values of the Epsilon were compared to values measured by conventional 
single sensor corneometers by performing a literature search.
MATERIALS AND METHODS
Participants
Fifteen healthy Caucasian volunteers (nine women and six men; median age 26 
years; range 21-62 years) participated in this explorative study. Informed consent 
was obtained. The study was approved by the local medical ethics committee and 
conducted according to the principles of the Declaration of Helsinki. Exclusion 
criteria were as follows: age < 18 years, signs of skin diseases or open wounds at 
the measurement sites, use of immunosuppressive medication, diagnosed with 
inflammatory dermatoses. Participants were asked not to use cream or body lotion 
at the day of measurements.
Technical device specifications
Water content of the SC was measured with the Epsilon (Epsilon E100, Biox, UK). 
This corneometer measures calibrated dielectric permittivity (dielectric constant, ε) 
through the SC and consists of a probe of 76 800 sensors with a sensing area of 12.8 
x 15 mm, depth resolution of 20 µm and spacial resolution of 50 µm.8,9 The hardware 
and the probe of the Epsilon are shown in Fig. 1A-D. Due to the multiple sensors, skin 
surface hydration can be mapped, taking skin relief and variable distribution of sweat 
glands into account (Fig. 1E,F). This allows measurement of more average values and 
2
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exclusion of regions with poor physical contact between sensor and skin.10 Moreover, 
the Epsilon is the only corneometer with a linearized and calibrated response, allowing 
consistent quantitative image evaluation.9 In this study, the standardised Burst mode 
option was used with a 5 seconds delay after first skin contact (to rule out initial 
variations in occlusion), a frame interval of 1-second, and a total measurement frame 
of 30 seconds.
To investigate the overall SC barrier function, TEWL was measured with the Aquaflux 
(Aquaflux AF200, Biox, UK). The closed measurement chamber of the Aquaflux contains 
sensors for relative humidity and temperature.8,11 After calibration, measurements 
were performed with standard settings and a maximum measurement time of 80 
seconds. The mean TEWL value was based on ten measure points, within a humidity 
degree of maximum 50%.
Figure 1. The Epsilon is a novel instrument for measuring near-surface dielectric permittivity 
(ε) and contact imaging of the skin. Its proprietary electronics and signal processing algorithms 
map the sensor’s nonlinear signals onto a calibrated scale for measuring properties such as 
stratum corneum hydration. A, The Epsilon instrument on the parking stand. B, A measurement 
performed on the inner arm. C, Close-up of the Epsilon measurement head with the metal bezel. 
D, The sensor surface embedded in an epoxy frame. E, Typical contact image of the inner forearm 
skin. F, A contact image of the skin in the face with visible sweat gland activity.
Study procedures
In each participant, water content and TEWL were investigated at five anatomical 
locations; cheek, first 1/3 of the flexor surface of the lower forearm, mid-calf, lower 
back and abdomen (Fig. 2). For water content, one Burst mode measurement per body 
site was performed; for TEWL, the average of three measurements per body site was 
obtained. Standardized environmental circumstances were created; room temperature 
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was kept constant at 20°C and exposed skin was air-acclimatized for at least 5 minutes 
prior to measurements.
Figure 2. Measurement locations of water content and transepidermal water loss (TEWL).
Statistics
Burst mode results from the Epsilon from all body sites were used to create regression 
functions and y-axis intersections were calculated. Statistical analysis was done 
with SPSS Statistics 22 (IBM Corporation, Armonk, New York). A Kruskal-Wallis test 
with Dunn-Bonferroni post hoc method was performed to demonstrate possible 
differences between the water content among the body sites. A relationship between 
water content and TEWL was investigated using Pearson correlation analysis. Tests 
were performed at 0.05 significance level.
Comparison with conventional corneometers
To compare the Epsilon results with conventional corneometer values, a PubMed 
search was performed. Study inclusion criteria were as follows: in vivo setting, healthy/
normal human skin, non-experimental setting OR use of a baseline control area in case 
of an intervention with topical therapies. Studied body sites preferably corresponded 
to the body sites chosen in this pilot study.
2




Anatomical variation in water content
The water content differed significantly between the five body sites (P < 0.001). As 
Fig. 3 shows, the cheek had the highest water content (median 11.64ε), followed by 
the forearm (9.35ε), abdomen (7.45ε), lower back (7.07ε) and mid-calf (4.43ε). Post hoc 
analysis revealed that the water content of the mid-calf was significantly lower than the 
water content of the cheek (P < 0.001) and the forearm (P < 0.001). Additionally, a large 
interindividual variation in water content among the various skin locations was seen. 
There was no significant correlation between water content (measured by Epsilon) and 
TEWL (r = 0.194, n = 75, P = 0.095).
Figure 3. Water content at five body sites measured with the Epsilon. The values are expressed 
as median with interquartile range and range (minimum-maximum).
Comparison with conventional corneometers
Table 1 shows literature-based reference values of the water content with single sensor 
corneometers. In general, single sensor corneometers showed higher water content 
values than the Epsilon. In line with the Epsilon, also conventional corneometers 
measured lower values of the calf compared to the cheek and forearm.
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This pilot study is the first to measure water content of the SC in different body sites 
with the Epsilon. Our findings showed significant differences among the body sites, 
in correspondence with previous studies that also showed this trend.5-7,14,26 Many 
factors could influence these regional differences, for example, variations in presence 
of sebaceous glands and lipids, natural moisturizing factor (NMF), size of corneocytes, 
exogenous compounds on skin surface and occlusion.4,14,27 Also SC thickness variation 
could play a role; the smallest SC cell number is found in genital skin, followed by 
the face, neck, scalp, trunk, extremities and palmoplantar region.4,27,28 Moreover, skin 
surface hydration gradually increases in deeper layers of the SC, reaching a certain 
high level in the fully hydrated epidermis.12,25 It is therefore more likely to measure 
water content in deeper and more hydrated layers of skin with thinner SC (e.g., cheek), 
resulting in higher values.
Another important finding was that water content values of the Epsilon were lower 
compared to values of conventional corneometers. First, it is important to bear in mind 
that Epsilon measurement units are displayed using a calibrated dielectric permittivity 
scale (ε) rather than an arbitrary scale (a.u.) as used in conventional corneometers. 
As both instrument types use the same capacitance measurement principle, they 
should correlate well; this was already shown by one-to-one testing of both devices 
on the volar forearm of healthy volunteers.29 With the multisensory character of the 
Epsilon, the sensing depth will probably be more superficial compared to conventional 
corneometers, which make one big electrical loop through the skin. This increases the 
chance that Epsilon measurements are confined to the relatively “dry” SC only. Another 
advantage of the Epsilon is the Burst mode setting, correcting for time-dependent skin 
occlusion differences, while conventional corneometers perform single time point 
measurements. Thirdly, due to the “skin mapping” character of the Epsilon, the number 
of values in one measurement can be averaged. All of the above could potentially lead 
to more accurate water content values.
The large interindividual variation of water content among the different skin 
locations could be influenced by individual parameters, for example, age, gender and 
lifestyle.4,5,26,30 This was not studied in more detail because of the explorative character 
of this pilot.
Interestingly, no correlation was found between water content and TEWL. One would 
expect that TEWL increases in a disrupted skin barrier, resulting in lower water content, 
and vice versa. However, also previous studies showed no or only weak correlations 
between these two measurements.24,31 As mentioned earlier, other factors besides 
from TEWL and water content seem to be responsible for alterations of skin barrier 
function.
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Despite the relatively small number of volunteers, these pilot results are promising. 
Larger populations of healthy volunteers and patients should be investigated for 
further validation of the Epsilon. This could elucidate the potential of this device 
for diagnosis and/or therapeutic monitoring of subjects having skin diseases with 
decreased barrier function, for example, inflammatory dermatoses. It would also be 
interesting to study possible interactions between water content and other noninvasive 
skin barrier measurements (e.g., NMF and sebum levels24,25) and the possible impact 
of inter-seasonal fluctuation on skin condition.
In conclusion, we found significant regional differences in water content in human skin 
measured by the Epsilon. Moreover, the Epsilon measures lower water content values 
compared to conventional single sensor corneometers and these values show an equal 
trend in differences of water content among different body sites. It is recommended 
to investigate these findings in a larger population for further validation of the Epsilon 
and to determine if this device can be implemented into the clinical setting.
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The epidermal barrier function is disrupted in various inflammatory skin diseases. 
Accurate methods to measure skin barrier function are needed to assess the effect of 
therapeutic agents. Therefore, we developed a noninvasive multiparametric approach 
to measure four different parameters regarding the skin barrier. In the current pilot 
study, we evaluate this method in 14 healthy volunteers. We assessed erythema, 
transepidermal water loss (TEWL), water content, and epidermal thickness at both 
cheeks before and 30 minutes after application of Lanette and Vaseline-Lanette cream. 
For this, we used spectrophotometry, the Aquaflux device, the Epsilon device, and 
reflection confocal microscopy, respectively. Stratum corneum (SC) thickness was 
significantly increased after application of both creams (P < 0.05), and this increase 
was larger after Lanette cream compared to after Vaseline-Lanette cream (P = 0.035). 
Erythema, TEWL and water content did not significantly change after cream application. 
Our multiparametric approach is promising and offers a feasible and practical way to 
quickly obtain multifaceted information about skin barrier function. Further exploration 
of this approach after prolonged use of cream and in conditions of disrupted skin 
barrier are recommended areas for future research.
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INTRODUCTION
The skin barrier acts as a first-order shield to protect the human body against micro-
organisms, ultraviolet (UV) light, and mechanical injury, and also helps regulate 
temperature and water flux.1,2 It is predominantly formed by the outermost layer of 
human epithelial cells, the stratum corneum (SC). 3 The skin barrier function is disrupted 
in inflammatory skin diseases like rosacea and atopic dermatitis.4-10 An impaired skin 
barrier is characterized by increased transepidermal water loss (TEWL) and reduced 
epidermal hydration, and predisposes one to cutaneous inflammation.2 Conversely, 
skin moisturizers can improve the skin barrier and help prevent inflammation.2,9,11-14 
However, not all moisturizers are beneficial to the skin barrier, and, for unknown 
reasons, some topical ointments may exacerbate symptoms in inflammatory skin 
disease.15,16
The skin barrier function is most often assessed using methods that quantify water 
content and TEWL. Unfortunately, these are single-device methods that measure only 
one or a few parameters, while a multiparametric approach is preferred to better 
assess subtle features of skin damage and restoration in the very complex environment 
of the skin. In order to better understand the mechanisms of skin therapeutic agents, 
accurate, objective, and reliable methods to measure skin barrier function are needed. 
Besides water content and TEWL, other skin parameters may influence skin barrier 
function, such as natural moisturizing factor (NMF), SC thickness, dermal vasodilatation 
(erythema), intracellular lipids, and pH.2,4,15 A wide array of noninvasive biophysical and 
imaging methods is available to assess most of these parameters.17 In the current pilot 
study, we demonstrate the feasibility of combining a quartet of biophysical/imaging 
devices to measure the following four skin parameters noninvasively; erythema, TEWL, 
water content, and epidermal thickness. These four skin parameters were selected 
for their ability to be measured in the face and their practical use. To the best of our 
knowledge, this combination of parameters has never been studied before in skin 




Fourteen healthy Caucasian volunteers (12 women and two men; mean age, 24 
years; range, 21-26 years) with skin types I to III were included in the study after 
providing written informed consent. The study was approved by the local medical 
ethics committee and conducted according to the principles of the Declaration of 
Helsinki. Measurements were performed in October 2018 at the department of 
Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands. The 
2
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following exclusion criteria were adopted: age < 18 years, signs of skin disease at 
measurement sites, known hypersensitivity reaction to Vaseline-Lanette cream, use of 
immunosuppressive medication, or a diagnosis of inflammatory skin disease. Subjects 
did not use cream, body lotion, make-up, or perfume at the day of measurements and 
refrained from physical exercise within three hours before measurements.
Products
We applied two widely used vehicles that are able to penetrate the skin within 30 
minutes: Lanette cream and Vaseline-Lanette cream (Table 1).
Table 1. Ingredients of investigational products.
Product Ingredients (in order of percentage of cream content)
Lanette cream I FNA Purified water, decyloleate, cetostearyl alcohol, B emulsifying, 
sorbitol solution, sorbic acid
Vaseline-Lanette cream FNA Cetostearyl alcohol, B emulsifying, cetiol V, sorbic acid, sorbitol 
solution, white petrolatum (vaseline), purified water
FNA, Formularium der Nederlandse Apothekers
Study procedures and technical device specifications
Measurements of the four skin barrier parameters (erythema, TEWL, water content, 
and SC and epidermal thickness) were performed on both cheeks. First, measurement 
locations were demarcated with a surgical pen (Fig. 1). Table 2 shows a detailed 
overview of the measurement principles of the four devices used to measure the 
skin barrier parameters. Facial skin was acclimatized to the ambient air for at least 
10 minutes before the start of the measurements, and room temperature and air 
humidity were kept constant at 20-23°C and 38-55%, respectively. Volunteers were laid 
down in supine position during acclimatization period and measurements to prevent 
possible orthostatic interactions.
Figure 1. Measurement locations for erythema, transepidermal water loss, water content and 
skin thickness per cheek.
Voorbereid document - Jade.indd   52 01-05-2021   10:16
53



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Voorbereid document - Jade.indd   54 01-05-2021   10:16
55
Noninvasive skin barrier assessment: multiparametric approach
Firstly, erythema was measured with a spectrophotometer (CM-2600d, Konica 
Minolta, Ramsey, NJ, USA). Using the principle of diffuse reflectance spectroscopy, 
light absorption from primary chromophores in the skin (melanin, oxyhemoglobin, 
and deoxy-hemoglobin) was measured.19 Before each measuring session, calibration 
to a standard white plate provided with the meter was performed. After pressing the 
calibrate button, three calibration measurements were automatically taken. Next, 
three measurements on each cheek were taken; the device was lifted and gently 
reapplied between each recording. The average of the three consecutive erythema 
measurements was automatically calculated by the device. The measuring head was 
kept steady and perpendicular to the skin surface with very light pressure against 
the skin during measurements to prevent minor venous congestion. More detailed 
information about measurement requirements can be found in Fullerton et al.18
Next, TEWL was measured with the Aquaflux (AF200, Biox, London, UK). After 
calibration, three measurements per cheek were performed with standard settings 
and a maximum measurement time of 180 seconds. The average of the three 
measurements per cheek side was calculated. Also, the Aquaflux device was kept 
steady and perpendicular to the skin surface with very light skin pressure during 
measurements.
Thirdly, water content was determined by performing one measurement per cheek 
with the Epsilon (E100, Biox, London, UK), a new-generation corneometer. Compared 
to conventional single sensor corneometers, the Epsilon contains 76 800 sensors; thus, 
multiple measurements take place at once.25 Moreover, analysis software is integrated 
in the device, and water-content-based images can be obtained. The Burst mode option 
was used with a 5-seconds measurement delay after first skin contact to rule out initial 
variation in skin occlusion. A frame interval of 1 second and a total measurement 
window of 30 seconds was selected. To keep contact with the skin surface, moderate 
pressure was applied.
Lastly, the reflectance confocal microscope (RCM; Vivascope 1500, Mavig, Munich, 
Germany) was used to determine skin thickness. For each cheek, one dermoscopic 
image (VivaCam) was obtained and used as map. Next, five vertical mappings 
(VivaStacks) were performed at the center and at the four outer corners of the image 
(Fig. 2). Series of images of 0.5 x 0.5 mm were obtained, starting from the skin surface 
up to a depth of 100 µm with interval steps of 3 µm. With a standardized protocol (Fig. 
S1, Supplementary Materials) all VivaStack images were evaluated by one researcher 
to determine thickness of the SC and the viable epidermis (without SC).
2
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Figure 2. Dermoscopic image of the cheek made by using the reflectance confocal microscope. 
The red dots show the exact locations were the VivaStacks were performed.
After baseline measurements, the Lanette cream was applied to the right cheek, and 
the Vaseline-Lanette cream to the left cheek (Fig. 1). One finger-tip unit (FTU) of cream 
was used per cheek side, according to the finger-tip method.28 One FTU corresponds 
to 0.5 g. After 30 minutes, the creams were completely absorbed into the skin, and all 
skin parameters (erythema, TEWL, water content, epidermal thickness) were repeated 
as described above.
Analysis
Burst mode values from the Epsilon measurements were used to create regression 
functions, and intersections with the y-axis were calculated. Statistical analysis was 
performed with SPSS (SPSS statistics 25, IBM Corporation, USA). Possible baseline 
differences of the skin barrier parameters between the right and left cheek were 
explored with the Wilcoxon signed-rank test. The Wilcoxon signed-rank test was also 
used to demonstrate significant differences between skin barrier parameters before 
and after application of both creams. A relationship between the skin parameters and 
environmental factors was investigated using Spearman’s correlation. P-values below 
0.05 were considered significant.
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RESULTS
Compared to baseline, the thickness of the SC increased significantly after application 
of both creams (P < 0.05, Table 3 and Fig. 3). The absolute difference of the SC thickness 
before and after application was significantly larger for Lanette cream compared 
to Vaseline-Lanette cream (P = 0.035). Fig. 4 shows no morphological changes of 
corneocytes in the SC after cream application with RCM. Erythema, TEWL, water 
content and thickness of the viable epidermis did not significantly change after 
application of Lanette cream and Vaseline-Lanette cream. Additionally, relatively 
large interindividual variations among skin parameters were seen. Values of all 
skin parameters at baseline compared to 30 minutes after cream application per 
subject are displayed in Fig. S2 and Table S1 (Supplementary Materials). No significant 
differences in median baseline values of erythema, TEWL, water content and thickness 
of the SC and the viable epidermis were found between the right and left cheek among 
subjects (P > 0.05 for all values).
There were no significant relationships between the four skin parameters. Additionally, 
no biologically relevant correlations between the skin parameters and environmental 
factors were found (data now shown).
Table 3. Skin parameters measured at baseline and at 30 min after cream application.
Skin parameter Lanette Vaseline-Lanette
Baseline 30 minutes 
after cream 
application



















































a Median (range). b P < 0.05 (baseline vs. 30 minutes after cream application).
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Figure 3. Thickness of stratum corneum (A) and viable epidermis (B) measured by the re-
flectance confocal microscope at baseline and 30 minutes after cream application. Values are 
expressed as medians with interquartile ranges and ranges (minimum–maximum).
Figure 4. Representative reflectance confocal microscopy images of the stratum corneum at 
baseline (A) and 30 minutes after cream application (B).
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DISCUSSION
This is the first study that combines the noninvasive measurements of erythema, 
TEWL, water content, and epidermal thickness to assess the effects of indifferent 
creams on the healthy skin barrier. Cream application did not affect erythema, TEWL 
and water content 30 minutes after application on the cheeks, but did lead to increased 
SC thickness. The four modalities used in this study (spectrophotometer, Aquaflux, 
Epsilon, RCM) can monitor the same facial skin location over time without discomfort, 
damage or alteration. All devices are portable and easy to use, and measurements are 
painless and rapid (15 minutes total).
To measure TEWL, we used the Aquaflux, a condenser closed-chamber system. Earlier 
research showed that this chamber system is the most sensitive TEWL system, allowing 
continuous measurements, and is the least vulnerable to environmental influences.21,29 
However, some drawbacks have to be taken into account. The device glides easily onto 
skin during measurements; manual fixation is recommended, which we did. Start-
up time including calibration takes relatively long (15 minutes); thus, this should be 
prepared before measurements. Additionally, repeated measurements on exactly the 
same location are challenging due to the small probe. This might have resulted in small 
intraindividual variations, because TEWL values can vary between facial areas.30-32
Water content was measured with the Epsilon, a state-of-the-art corneometer using 
multi-sensor skin mapping technology with correction for skin occlusive effects.23,25 
The sensing depth of the Epsilon is restricted to the less hydrated SC, in contrast to 
earlier model conventional corneometers that measure the deeper, more hydrated 
epidermis;32,33 this potentially leads to more accurate water content values. The Epsilon 
showed significant variations in water content at different anatomical skin locations;25 
however, the size of the probe head (approx. 4 x 3 cm) restricts measurements to 
non-recessed body parts.
Lastly, epidermal thickness was assessed using RCM. The images with cellular resolution 
allow very detailed measurements of the epidermal layer.27 Earlier work showed very 
good correspondence of RCM and histology for epidermal thickness measurements.34 
Limitations for use in daily practice are the high device cost and limited imaging depth, 
as imaging resolution decreases substantially below 150 µm (superficial dermis). In 
addition, measuring facial skin may be challenging. The transition from epidermis to 
dermis differs from other anatomical locations; in facial skin, interpapillary processes 
do not or barely exist due to sun exposure, and the dermal-epidermal junction is low 
refractive in skin types I/II because of limited melanin content in the basal layer.35,36 
So, knowledge about skin morphology is recommended for evaluation of the images. 
Of all imaging tools, RCM is superior in noninvasive skin thickness measurements. 
Possible alternatives are high-frequency ultrasound, near-infrared spectroscopy, 
2
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optical coherence tomography, or Raman spectroscopy; however, these devices have 
lower resolution and are also expensive.17,37-39 Moreover, they may not all be suitable 
for facial imaging due to their size (e.g., Raman spectroscopy)
It is already known that application of moisturizers increases SC thickness, probably 
due to absorption of water (indicating increased water-binding capacity), corneocyte 
swelling or reorganization in the lipid bilayer.15,40,41 Surprisingly, we did not measure 
increased water content after cream application. Moreover, the RCM images showed 
no morphological changes of corneocytes in the SC after cream application. This 
suggests that increased SC thickness in our study may not be due to increased 
hydration or corneocyte swelling, but rather due to cream components other than 
water.23 Alternatively, it could be that we did not find increased SC water content 
because water may have diffused into deeper layers of the epidermis in the 30 minutes 
after cream application, or it could be that repeated use of moisturizers is needed to 
significantly increase epidermal water content.14,15,40,42-44
Given the explorative design, our study consisted of a small number of young 
volunteers and female predominance. It would be interesting to investigate our method 
with prolonged use of topical creams in a larger population, at various facial locations 
and to include an untreated reference area. Moreover, measurements in subjects after 
controlled skin barrier perturbation (e.g., tapestripping21) or in patients with disturbed 
skin barrier function could provide more insight into the effect of cream application. 
It would also be interesting to expand our method with the other skin-barrier-related 
parameters (sebum, pH).
In conclusion, we combined the noninvasive measurements of erythema, TEWL, water 
content and epidermal thickness to assess the effect of different creams on the healthy 
facial skin barrier. Cream application did not affect erythema, TEWL and water content, 
but did lead to increased SC thickness. Our multiparametric approach is promising 
and offers a feasible and practical way to quickly obtain multifaceted information 
about skin barrier function. Further exploration of this approach after prolonged use 
of cream and in conditions of disrupted skin barriers are recommended areas for 
future research.
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SUPPLEMENTARY MATERIALS
Figure S1. Protocol used for VivaStack evaluation to determine thickness of the stratum corne-
um (SC) and epidermis with reflectance confocal microscopy (adapted from Ardigo et al26), with 
examples to distinguish the boundaries between the different skin layers. The central part of 
the images was used to determine the transition of the different skin layers, to rule out variation 
in depth (skin layers) within the images. A, Image acquisition should start above the beginning 
of the SC; the plastic window is seen as a bright round circle. B, Beginning of SC, the first image 
with bright, highly reflective anuclear cells is visible. C, The last image with completely bright SC is 
considered as the end of the SC/begin of viable epidermis. D1, Part of the viable epidermis with 
nucleated cells (honeycombed pattern) at centre of the image. D2, Close-up of honeycombed 
pattern as described in D1. E, First appearance of the papillary dermis at the centre of the image 
is considered as the end of the epidermis. F, Disappearance of the honeycombed pattern at the 
centre of the image is also considered as the end of the epidermis.
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Value of GPSkin for the measurement of skin
barrier impairment and for monitoring of
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Stratum corneum hydration (SCH) and transepidermal water loss (TEWL) provide useful 
information about skin barrier function. This study aimed to determine the value of 
GPSkin Pro, a new handheld device determining both SCH and TEWL, to measure skin 
barrier impairment and to monitor barrier function in rosacea in daily practice.
Materials and Methods
Two pilots were performed. Pilot 1: in 27 healthy participants, GPSkin SCH and TEWL 
were compared to Aquaflux and Epsilon values at the forearm before and after skin 
barrier perturbation via tapestripping. Moreover, GPSkin values were measured at both 
cheeks without intervention. Pilot 2: in 16 rosacea patients, GPSkin measurements were 
performed at the forearm, and at both cheeks before and during anti-inflammatory 
treatment. They were compared to clinical symptoms and to GPSkin values from pilot 1.
Results
Pilot 1: after merging data from before and after tapestripping, a strong correlation 
was observed between GPSkin TEWL and Aquaflux (Rs = 0.9256), and GPSkin SCH 
and Epsilon (Rs = 0.8798). Pilot 2: SCH was significantly lower at the cheeks of rosacea 
patients compared to controls, with a normalizing trend during successful treatment. 
TEWL was comparable among patients and controls and did not change during 
treatment at all locations.
Conclusion
The GPSkin determines TEWL and SCH accurately in healthy and impaired skin 
barrier state and can monitor skin barrier function in rosacea during treatment. The 
GPSkin device is much more practical compared to previous skin barrier tools when 
used in clinical practice. Its further validation in other inflammatory skin diseases is 
recommended.
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INTRODUCTION
Measurement of stratum corneum hydration (SCH) and transepidermal water loss 
(TEWL) provide important information about the function of the skin barrier.1-3 
Impaired skin barrier function due to stratum corneum (SC) abnormalities is a hallmark 
of chronic inflammatory skin diseases, such as atopic dermatitis, psoriasis, and possibly 
also rosacea.3-5 SCH and TEWL are also promising markers to distinguish healthy from 
inflamed skin and to monitor treatment.6-8
A variety of skin barrier device methodologies is available to measure SCH and TEWL.3,9-11 
Unfortunately, these conventional devices have various disadvantages; they are 
expensive, bulky, not wireless, require repeated calibration, and intra- and inter-
instrument variation is large, making comparison of study outcomes challenging.3 For 
all these reasons, assessment of skin barrier function is currently limited to research 
facilities with the available financial and logistic resources.
Recently, a new, noninvasive handheld device measuring SCH and TEWL simultaneously 
was introduced; the GPSkin. It is low-cost, lightweight, pocked-sized, rapid, wireless, 
and data are directly transmitted to a smartphone application via Bluetooth. Earlier 
studies showed that the GPSkin provides precise and reliable SCH and TEWL values 
when compared to conventional devices in healthy skin.12-14 Moreover, it is able to 
show skin barrier differences after application of topical agents.14 However, to our 
knowledge its validity in case of a damaged skin barrier and its ability to monitor skin 
barrier function in patients with inflamed skin is not examined yet. As papules and 
pustules in rosacea often improve during anti-inflammatory treatment,15 we will use 
this facial dermatosis as a model to monitor inflamed skin state.
The aim of this study was to determine the value of GPSkin to measure accurate 
SCH and TEWL values after barrier function impairment, by comparing these values 
with conventional devices. Moreover, the value of the GPSkin to monitor skin barrier 
function in daily practice in rosacea patients during anti-inflammatory treatment was 
determined. To do so, GPSkin values were compared to clinical scores.
MATERIALS AND METHODS
This explorative pilot study, approved by the local medical ethics committee, consisted 
of two sub-pilots (Fig. 1). In pilot 1, SCH and TEWL were determined with the GPSkin 
Pro (GPOWER Inc, Seoul, South Korea) at the volar forearm in healthy volunteers before 
and directly after skin barrier perturbation. As a validation for GPSkin values, parallel 
measurements with conventional devices were conducted; SCH with the Epsilon (E100, 
Biox, London, UK), and TEWL with the Aquaflux (AF200, Biox, London, UK). In pilot 2, 
2
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GPSkin values were measured at both cheeks in rosacea patients before and during 
treatment. These values were linked to GPSkin values of healthy controls from pilot 1, 
and to their clinical symptoms.
Figure 1. Overview of the study design, consisting of two sub-pilots. Pilot 1, healthy volunteers. 
GPSkin, Epsilon and Aquaflux measurements were performed at the right volar forearm before 
and directly after tapestripping. Moreover, GPSkin measurements were performed one at the 
left and right cheek without intervention. Pilot 2, rosacea patients. GPSkin values and clinical 
scores were determined at the left and right cheek before and minimal 1 month after start of 
new topical and/or oral anti-inflammatory rosacea treatment. Additionally, GPSkin values were 
determined at both time points at the right volar forearm without intervention.
Devices
GPSkin
The GPSkin measures SCH and TEWL simultaneously by placing its probe onto the skin 
for 5-10 seconds. For SCH, two electronic sensors at the edge of the probe measure 
SC capacitance (i.e. dielectric constant). For TEWL, the probe opening (11 x 14 mm) 
contains a pseudo-closed chamber system with temperature and humidity sensors; 
this system is similar to a closed chamber system, but provides chamber ventilation 
to decrease its humidity and pressure. All measurement results are directly sent by 
Bluetooth to a smartphone application for data access.12,13,16 The device weights 40 g 
and is wireless.
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Epsilon
Stratum corneum hydration can be measured with the Epsilon, a new generation 
corneometer, calculating the electrical capacitance of the SC by placing the probe 
of the device (1.3 x 1.5 cm) onto the skin for 30 seconds. Compared to conventional 
single sensor corneometers, the Epsilon contains 76 800 sensors, arranged in a 256 x 
300 array with a spacial resolution of 50 µm and a sensing depth of 20 µm. Moreover, 
analysis software is integrated into the device, and linear water-content-based images 
can be obtained. This allows mapping of SCH and exclusion of regions with poor 
physical contact between sensor and skin.17-19 The device is transported in a 2 kg case 
and measurements require connection to a laptop.
Aquaflux
This device measures TEWL by placing its probe onto the skin for a maximum of 
180 seconds. The probe opening (7 x 7 mm) holds a closed chamber equipped 
with a condenser (-7.65 °C). The condenser acts as a sink for incoming water vapor, 
crystallizing incoming moisture into ice. Water vapor flux due to diffusion is calculated 
using the humidity sensor with inbuilt calibration. No recovery time is necessary 
before starting the next measurement, as the chamber microclimate is controlled, 
independently of ambient humidity.10,18,20-22 The device in total weights 1020 g and 
requires connection to a laptop.
Pilot 1 Healthy skin
Participants
For pilot 1, healthy Caucasian volunteers were included. Informed consent was 
obtained from each participant. Measurements were performed in August 2019 
at the department of Dermatology, Radboud University Medical Center, Nijmegen, 
the Netherlands. Exclusion criteria were: age < 18 years, diagnosis of inflammatory/
acneiform skin diseases, signs of inflammatory/acneiform skin diseases at the 
measurement sites, and use of immunosuppressive medication. Subjects did not use 
cream, body lotion or foundation on the day of measurements and refrained from 
physical activity and showering within 3 hours before the measurements.
Study procedures
The measurements took place at the right volar forearm, because this location is 
easy to access, mainly refrained from ultraviolet-light damage, hair, and sebaceous 
glands, and often used as a standard anatomical site for skin barrier studies.3,22-24 All 
procedures were performed by one investigator ( JGML). A circular area of approx. 3 x 
3 cm was demarked with a pen at this location. The demarked skin was acclimatized to 
ambient air (room temperature: 22-26°C; air humidity: 40-65%) for at least 10 minutes 
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before start of measurements. Volunteers were placed in upright, sitting position 
during all study procedures.
First, SCH and TEWL were measured with the GPSkin once at the air-exposed forearm. 
Then, SCH was determined by performing one measurement with the Epsilon. The 
Snapshot mode was used with a 5 seconds delay after first skin contact, and the 
average of three frames was calculated automatically. For both devices, moderate 
pressure was applied to keep contact with the skin surface. Thirdly, TEWL was 
measured with the Aquaflux. After calibration of this device, two measurements 
were performed with standard settings and a maximum measurement time of 180 
seconds. The average of the two measurements was calculated. The Aquaflux was 
kept steady and perpendicular to the skin surface with very light skin pressure during 
measurements.
Next, the skin barrier of the demarked forearm location was disturbed using 
tapestripping, a noninvasive, painless, widely applied procedure to analyse SC barrier 
function without interfering with deeper, living epidermal keratinocytes.9,25-29 Repetitive 
adhesive tapes were applicated to the skin for 10 seconds with a standardized pressure 
pen (150 g/cm2; D’Squame, Monaderm, Monaco) and sequentially removed until the 
skin became partly to homogeneously refulgent, corresponding to partial to almost 
complete removal of the SC; 13-33 tapes per volunteer were needed. In this way, a 
wide range of SCH and TEWL values was obtained.
Directly after the tapestripping procedure, GPSkin, Epsilon, and Aquaflux measure-
ments were repeated at the demarked location as described above. Lastly, one GPSkin 
measurement per cheek site was performed in each volunteer for later comparison 
to rosacea patients in pilot 2 (Fig. 1).
Pilot 2 Rosacea
Participants
Patients with a clinical diagnosis of facial rosacea were included in pilot 2 after 
signing informed consent. They were recruited between July and December 2019 
at the department of Dermatology, Radboud University Medical Center, Nijmegen, 
the Netherlands. Patients needed to start with new topical or oral anti-inflammatory 
rosacea treatment according to clinical daily practice via their physician.15 Excluded 
were patients aged < 18 years, using immunosuppressive medication, or having other 
facial dermatological conditions or underlying diseases able to interfere with rosacea 
diagnosis or assessment.
Voorbereid document - Jade.indd   72 01-05-2021   10:16
73
GPSkin value in impaired skin barrier and rosacea
Study procedures
Forearm and facial skin were acclimatized to ambient air for at least 10 minutes before 
the start of measurements. Then, one GPSkin measurement per cheek site and at 
the right volar forearm was performed. Additionally, facial clinical assessment was 
performed including lesion count, investigator’s global assessment (IGA), papules and 
pustules scale, erythema scale, and telangiectasia scale (Table S1, Supplementary 
Materials). Directly after these measurements, anti-inflammatory rosacea treatment 
was started; topical ivermectin (n = 13), topical metronidazole (n = 1), doxycycline 
(n = 1), or topical ivermectin combined with doxycycline (n = 1). Minimally one month 
later (median follow-up time: 63 days; range: 35-94 days), GPSkin measurements and 
clinical assessment at both cheeks and the right forearm were repeated.
Statistical analysis
Due to the nonparametric character of data from pilot 1, Spearman correlation 
analysis (Rs) was used to calculate the relationship between GPSkin values and results 
obtained from the Aquaflux and Epsilon. Next, a simple linear regression analysis (R2) 
was performed to test for a possible linear relationship between the measurements 
from the GPSkin and conventional devices. For both analyses, values from before and 
after tapestripping were merged. For pilot 2, differences between baseline GPSkin 
values of rosacea patients and healthy controls were analysed using the Mann-Whitney 
U test. A Friedman test with Dunn-Bonferroni post hoc method was performed to 
demonstrate possible differences between GPSkin results among the three body sites. 
GPSkin and lesion count differences of rosacea patients at baseline and during therapy 
were explored with the Wilcoxon signed rank test. For all statistical tests, P-values 
<0.05 were considered significant. Statistical analysis was performed using GraphPad 
Prism 5.03 (GraphPad Software, San Diego, CA, USA) and SPSS (SPSS statistics 25, IBM 
Corporation, USA).
RESULTS
Pilot 1 Healthy skin
Twenty-seven volunteers (18 females and 9 males; median age 37 years, range 23-67 
years; skin type I-III) participated in pilot 1. Correlation of GPSkin TEWL and SCH with 
Aquaflux and Epsilon was very strong (Rs > 0.80; Fig. 2), and also highly linearly related 
(R2 > 0.80). Interestingly, the range of Epsilon values was large with GPSkin values ≥ 
60. Before tapestripping, median TEWL was 5.1 g/m2/h (range: 0.4-19.6) for GPSkin 
and 12.2 g/m2/h (range: 8.1-17.6) for the Aquaflux. Median SCH was 21 arbitrary units 
(a.u.; range: 9-38) for the GPSkin and 9.6 a.u. (range: 5.3-16.1) for the Epsilon. After 
tapestripping, median TEWL was 42.7 (range: 19.6-80.0) for the GPSkin and 70.8 (range: 
25.1-88.3) for the Aquaflux. Median SCH was 73 (range: 27-74) for the GPSkin and 45.7 
(range: 10.6-63.5) for the Epsilon.
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Figure 2. Linear regression with R2-values and 95% confidence intervals (dotted lines) for GPSkin 
vs. conventional devices. Spearman correlation coefficient (Rs) is also displayed. GPSkin was 
tested against the Aquaflux to measure TEWL (A), and the Epsilon to measure hydration (B).
Pilot 2 Rosacea
Comparison to healthy controls
Sixteen rosacea patients (11 females and five males; median age 51 years, range 21-84 
years) participated in pilot 2. No significant differences were found in TEWL GPSkin 
readings between rosacea patients and controls (Fig. 3A). Post hoc analysis revealed 
that TEWL at the forearm was significantly lower compared to the left and right cheek, 
both in rosacea patients as well as controls (P < 0.05). SCH was significantly lower in 
rosacea patients compared to controls at the left and right cheek (Table 1, Fig. 3B). 
SCH values showed no significant anatomical differences.
Figure 3. GPSkin results at the left cheek, right cheek, and volar forearm of rosacea patients at 
baseline and healthy controls. A, TEWL, transepidermal water loss. B, SCH, stratum corneum 
hydration. The boxes indicate the median value with 75th percentile and range. * 0.01 ≥ P < 0.05, 
** 0.001 ≥ P < 0.01, *** P < 0.001
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All 16 rosacea patients attended the follow-up visit. The GPSkin follow-up data from 
the volar forearm of one patient were excluded, because TEWL and SCH were very 
low (4 g/m2/h and 1 a.u. respectively), probably due to a low battery. Median number 
of facial inflammatory lesions significantly decreased from 19 (range 0-45) at baseline 
to 3 (range 0-21; P = 0.001) during treatment. Improvement in IGA and erythema was 
noticed; telangiectasias remained unaffected (Fig. 4). Compared to baseline, TEWL at 
both cheeks and the forearm did not change at follow-up (Table 2, Fig. 5). Although not 
statistically significant, a clear trend towards increased SCH at the left and right cheek 
was seen during treatment; this increase in SCH was not seen at the forearm. Fig. 6 
showed that SCH and TEWL were significantly and negatively correlated (Rs = -0.3970, 
P = 0.024). No correlations were found between GPSkin values and clinical scores (R2 
all < 0.25; data not shown).
Figure 4. Clinical scores of all rosacea patients (n =  16) at baseline and during treatment 
(= follow-up). A-C, IGA scale, erythema scale, and telangiectasia scale. IGA, investigator’s global 
assessment.
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Figure 5. GPSkin results at the left cheek, right cheek, and volar forearm of rosacea patients at 
baseline and during follow-up. A, TEWL, transepidermal water loss. B, SCH, stratum corneum 
hydration. The boxes indicate the median value with 75th percentile and range.
Figure 6. Weak inverse correlation found between stratum corneum hydration and transepi-
dermal water loss in rosacea patients (baseline and follow-up data combined), measured with 
the GPSkin.
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DISCUSSION
We showed that the GPSkin is able to provide reliable and accurate TEWL and SCH 
values compared to conventional devices, also after skin barrier perturbation. 
Moreover, we found that SCH, measured with the GPSkin, was significantly lower in 
rosacea patients compared to controls, with a recovering trend towards normal values 
after successful rosacea-treatment. TEWL values in rosacea patients were comparable 
to healthy controls and did not change during treatment.
The GPSkin offers interesting advantages for application in clinical practice compared 
to conventional skin barrier devices. First, it measures TEWL and SCH simultaneously, 
preventing precise replacements of probes on the same skin site.14 Second, data about 
skin temperature and humidity are displayed. Third, it is extremely portable, affordable, 
allows rapid and simple measuring, and has a long battery life (months, depending on 
use frequency), resulting in much higher ease of use compared to the non-wireless, 
heavier-weighted Epsilon and Aquaflux. Forth, data results are immediately visible 
at the smartphone screen, allowing immediate feedback to the patient. Based on 
our experiences within this study, this is very beneficial for improvement of therapy 
compliance.
In pilot 1, the correlation of TEWL and SCH measured by the GPSkin and conventional 
tools was very high, both before and after tapestripping. The Aquaflux has a 
sophisticated chamber system to measure changes in TEWL after tapestripping,10,20 
and the Epsilon provides precise SCH values due to its multi-sensor character.17 This 
implicates that the GPSkin is able to provide very accurate skin barrier values as well. 
Aquaflux TEWL values were consistently higher compared to GPSkin with equal ranges, 
both before and after tapestripping. This can be explained by calibration differences 
between both devices.12 Theoretically, unventilated closed chamber systems such as 
GPSkin could result in divergent values after prolonged measuring due to water vapor 
accumulation,3,10 but this was not observed in this study. Regarding SCH, GPSkin values 
were higher than Epsilon values. As the Epsilon has multiple sensors, the sensing depth 
is more superficial compared to conventional devices (which have only one sensor), 
confining measurement to the ‘dry’ SC only before tapestripping.17 After tapestripping, 
SCH measured by the Epsilon showed larger diversity than those measured by the 
GPSkin (Fig. 2). This may be caused by tapestripping heterogeneity; this technique 
often results in skin areas with high damage surrounded by relatively undamaged 
SC.10 Due to the relatively large probe surface and multi-sensory character of the 
Epsilon, all these areas were integrated into the measurement, while GPSkin values 
were determined based on only one sensor with a smaller probe. Moreover, if the SC 
is mostly removed, capacitance measurements primarily reflects the hydration state 
of the ‘wet’ stratum granulosum rather than the SC;23,29 especially the Epsilon device 
seems less reliable in this situation.
2
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The number of tape strips removed varied between the healthy volunteers; we tried 
to induce a partial to almost complete skin barrier removal, in order to obtain a wide 
range of SCH and TEWL values. A stronger SC cohesion results in less mass removal, 
requiring more strips to be applicated for the same barrier disruption effect.9 Tape 
stripping procedure may be influenced by contact time, anatomical location, and 
applied pressure.30 Therefore, a standardized protocol is needed, which we used.
Current literature is inconclusive regarding potential SCH and TEWL differences 
in rosacea skin compared to healthy skin, probably due to a large heterogeneity 
in studied rosacea subtypes, measurement locations, and biophysical devices.31 
We hypothesize that rosacea skin displays decreased SCH due to skin dryness, a 
frequently mentioned symptom in this skin disease. Application of topical treatment, 
such as ivermectin, reduces skin dryness and thereby increases SCH. SCH and TEWL 
were negatively correlated in the rosacea group, implying that an increase in skin 
hydration could slow down the TEWL.14 Decreased TEWL after treatment was however 
not observed in this study. Possibly, skin barrier recovery measured by TEWL takes 
longer than the immediate moisturizing effect, especially in nonprotected areas such 
as the face.14,32,33
Both in rosacea patients and in controls, TEWL of the forearm was lower than the 
cheeks. This is in line with previous work; anatomical differences in TEWL may be 
caused by intrinsic differences in eccrine sweat gland and sebaceous follicle activity, 
skin temperature, blood flow, SC thickness, lipid content, and corneocyte size and 
turnover time.33-36 Most likely, also external physical effects in the face may cause 
differences in TEWL values. No chiral skin barrier differences seem to occur between 
the left and right forearm.36,37 However, regional differences for both TEWL as well as 
SCH exist within short distances of the face, requiring measurements at exactly the 
same place during follow-up.33,36-38 This makes rosacea a challenging model for skin 
inflammation.
In pilot 2, we deliberately chose not to use a climate room during measurements, as 
this prevents translation of our results into the daily, clinical setting. We accepted 
normal fluctuations in weather, season, and daytime. Despite this, TEWL values were 
constant at baseline and at follow-up, implying that external factors did not have 
a large impact on the results at both time points. This is a very interesting finding, 
making application in daily practice certainly feasible. However, it remains important 
to interpret skin barrier results in the light of potential influencing external factors 
such as temperature, humidity, occlusion, ultraviolet-light, anatomical location, cream 
use, physical activity, and sweating.5,35,39,40 Considering the inter-individual variations 
in SCH and TEWL, a baseline value should always be registered in each patient, and 
lesional skin should be compared with non-lesional skin.9
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CONCLUSION
The GPSkin allows accurate, simple, and rapid determination of TEWL and SCH, both 
in normal as well as in impaired skin barrier. Moreover, the GPSkin is able to measure 
improvement in skin barrier parameters in inflamed skin during successful treatment 
and could therefore possibly contribute to objectification of treatment effectiveness. 
Based on our results, influence of external factors on GPSkin values seems to be 
limited. Further validation of the GPSkin in other inflammatory skin diseases with 
impaired skin barrier, such as atopic dermatitis and psoriasis, is preferred. Ultimately, 
the GPSkin would replace the conventional, expensive, and relatively complex skin 
barrier tools, both in research and clinical setting. This paves the way for objective, 
home-based skin barrier monitoring for patients with a variety of inflammatory skin 
diseases, further improving patient-centred care and therapy compliance.
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Table S1. Clinical scores.
1. Lesion count






Papule: circumscribed solid elevation < 1 cm
Pustule: circumscribed elevation with white exsudates < 1 cm
Nodule: circumscribed solid elevation > 1 cm
2. Investigators Global Assessment (IGA) scale (0-1 = success, 2-4 = failure)
Score Grade Clinical description
0 Clear No inflammatory lesions present, no erythema.
1 Almost clear Very few small papules/pustules, very mild erythema present.
2 Mild Few small papules/pustules, mild erythema.
3 Moderate Several small or large papules/pustules, moderate erythema.
4 Severe Numerous small and/or large pustules, severe erythema.
3. Papules and pustules scale
Score Grade Clinical description
0 Clear Clear skin with no inflammatory (pustules) or noninflammatory (papules) 
lesions
1 Almost clear Rare noninflammatory lesions with no more than one small inflammatory 
lesion
2 Mild Some noninflammatory lesions with no more than a few inflammatory 
lesions (papules/pustules only, no nodular lesions)
3 Moderate Up to many noninflammatory lesions and may have some inflammatory 
lesions, but no more than one small nodular lesion
4 Severe Up to many noninflammatory and inflammatory lesions, but no more than 
a few nodular lesions
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4. Erythema scale
Score Grade Description of background erythema
0 Clear No redness present. Background erythema is consistent with non-involved 
areas.
1 Almost clear Slight and localized background erythema in involved areas of the face, 
usually limited to the malar prominence of the cheeks. Gives the impression 
of a healthy glow to the cheeks.
2 Mild Slight to mild background erythema NOT limited just to the cheeks, but 
extends to the lateral cheeks, chin, or forehead.
3 Moderate Definite background redness, easily recognized, and extending to lateral 
cheeks, chin, or forehead.
4 Severe Severe background erythema over the entire face.
5. Telangiectasia scale
Score Grade Description of telangiectasia: fine superficial blood vessels that are 
visible near the surface of the skin
0 None No telangiectasia present on the face.
1 Mild Some to a few telangiectasias are present on the face.
2 Moderate Many telangiectasias, easily recognized, and extending to lateral cheeks, chin, 
or forehead.
3 Severe Many to numerous telangiectasias over the entire face that blends in or matches 
with the erythema caused by inflammatory lesions. Few matted and dense 
cluster of vessels present.
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Noninvasive objective skin measurement
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Rosacea assessment and therapy monitoring can be challenging to standardize, as 
most clinical evaluation systems are prone to interobserver variability and not always 
validated. Therefore, objective, reliable and preferably noninvasive measurement tools 
are needed.
Objectives
To give insight into available noninvasive imaging techniques and biophysical methods 
in rosacea by performing a systematic review.
Methods
PubMed, Embase, Cochrane and Web of Science databases were searched until 1 
September 2018 in accordance with PRISMA guidelines, to identify studies providing 
original data about objective noninvasive imaging and/or biophysical skin measurement 
techniques for diagnosis, assessing severity or therapy monitoring of adult patients 
with cutaneous facial rosacea. Risk of bias of included articles was assessed with 
the Cochrane Risk of Bias tool, Quality in Prognosis Studies tool, and the Newcastle–
Ottawa Scale.
Results
A total of 78 studies were included, describing 14 imaging and biophysical methods. 
Widespread information about (sub)surface cutaneous morphology and functionality 
was obtained. Methodological study quality was relatively low and interstudy outcome 
variability was large. Several tools show promising value in research settings: 
for treatment follow-up Demodex mites are countable with reflectance confocal 
microscopy, spectrometry can quantify erythema, and rosacea severity could be 
objectified with skin hydration- and transepidermal water loss measurements.
Conclusions
This systematic review describes the spectrum of noninvasive imaging and biophysical 
methods in rosacea assessment, giving multifaceted information about structure and 
properties of rosacea skin, especially useful for research purposes. Larger studies 
with good methodological quality are needed to create validated protocols for further 
implementation into research.
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INTRODUCTION
Rosacea is a chronic inflammatory skin disease of uncertain pathophysiology; many 
factors may play a role in disease development.1-9 Initially, four rosacea subtypes were 
described: erythematotelangiectatic, papulopustular, phymatous and ocular. Recently, 
the classification system was changed from subtype-based to phenotype-based to 
increase diagnostic and presentation accuracy, but as many trials predate the updated 
phenotype approach, the subtype-based system still dominates rosacea literature.8,10-12 
To achieve optimal results, rosacea treatment is preferably adjusted to clinical 
symptoms and disease severity.3,13,14 However, the variety of clinical manifestations 
among individual patients and presence of various classification systems make 
standardization and quantification of rosacea measurements challenging.11,15 Currently, 
clinical features represent the gold standard to establish the diagnosis.8,11 Various 
numerical scales exist to assess erythema, telangiectasia, papules, pustules and global 
rosacea score for research purposes.16,17 These scales are subjective and often not 
validated, decreasing confidence in the validity of reported outcomes.7,16-19 Moreover, 
visual evaluation alone cannot appreciate processes unfolding below the skin surface. 
Histopathological findings are nonspecific,1 but experienced dermatopathologists 
are generally able to diagnose rosacea based on characteristic histological and 
immunohistochemical features,20 which can overlap among subtypes.1,15 Recently, a 
study showed that high Demodex densities (measured by two consecutive standardized 
skin surface biopsies (SSSBs)) were associated with papulopustular rosacea;21 however, 
this sampling method can cause slight ephemeral irritation and the test has yet to be 
confirmed by other independent studies and for other clinical features of rosacea.
Due to these complexities standardized, validated, objective, reliable and preferably 
noninvasive measurement tools are needed. The advantage of noninvasive over 
invasive techniques is the ability to monitor the same facial skin location over time 
without causing irritation, damage or alteration, including inflammatory responses, 
which may interfere with diagnosis and evaluation. A variety of noninvasive objective 
skin measurements exist.22-25 These techniques are widely used in rosacea, but a 
comprehensive overview is lacking. This systematic review elucidates the spectrum of 
available noninvasive objective skin measurement techniques for rosacea. The current 
literature was reviewed for the following purposes:
1. To provide an overview of available noninvasive objective skin measurement 
techniques for assessing diagnosis, severity and therapy monitoring of rosacea;
2. To assess displayed skin features of these tools, including technique advantages 
and limitations;
3. To provide recommendations for future use of these tools in an investigational 
setting.
3




The study protocol was registered in PROSPERO (registration number: CRD42018108401).26 
A systematic literature search following PRISMA guidelines was performed in four 
electronic databases:27 PubMed, Embase, Cochrane Library and Web of Science. The 
search was based on studies using objective noninvasive imaging and/or biophysical 
skin measurement techniques for diagnosis, assessing severity or therapy follow-up 
of rosacea. Skin measurement tools were extracted from literature and by exploring 
their PubMed MeSH-terms.4,22-25,28 We defined ‘noninvasive’ as every method that 
theoretically cannot lead to skin irritation, bleeding or scarring; this excluded biopsies, 
epilation of eyelashes/hairs, use of tape or glue onto the skin, collection of skin 
scrapings or excretions from sebaceous follicles. Only studies involving adult patients 
with cutaneous facial rosacea were included (Table S1, Supplementary Materials).
All databases were searched to include published studies from date of inception 
until 1 September 2018. Full details on the search strategy are available in Table S2 
(Supplementary Materials). Titles and abstracts were screened for relevance by two 
independent reviewers ( JGML and FMCV). Next, full texts were critically assessed for 
eligibility by the same independent reviewers. Missing full texts were requested via 
e-mail from study authors and Radboud University Medical Library. In both phases, any 
differences regarding inclusion between the reviewers were resolved by discussion. 
Excluded were papers involving patients aged < 18 years; ocular, extrafacial and drug-
induced rosacea; therapeutic techniques; subjective measurements; in vitro and animal 
studies; studies in languages other than English, German or Dutch; meta-analysis, 
(systematic) reviews and abstracts of congresses or with unavailable full texts. The 
reference lists of all included articles were checked for relevant articles not identified 
by the initial search.
Extracted study characteristics included study design, number of participants, rosacea 
type, assessed skin parameters, measurement locations, method type/aim/findings, 
and use of reference test. A narrative synthesis was conducted for imaging techniques 
and biophysical methods separately. Risk of bias was assessed by two reviewers ( JGML 
and FMCV), with disagreements resolved by discussion. The Cochrane Risk of Bias tool 
was used for assessment of risk of bias in randomized controlled trials (RCTs), with 
studies graded as having low, high, or unclear risk of bias.29 For case–control studies, 
the Newcastle–Ottawa Scale was used.30 For prognostic cohort studies without a 
control group (including case reports and case series), the Quality in Prognosis Studies 
(QUIPS) tool was used.31 For the QUIPS, overall risk of bias for each of the studies was 
judged as: (1) low, if there was a low risk of bias in all key domains; (2) unclear, if there 
was an unclear risk of bias for one or more key domains; and (3) high, if there was a 
high risk of bias for one or more key domains.32
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RESULTS
A total of 3690 articles were identified (Fig. 1). After removal of duplicates, 2140 articles 
were assessed for screening. This resulted in inclusion of 260 abstracts, eligible for 
full-text screening. Finally, 78 articles were included for this systematic review: 36 
articles concerned skin imaging techniques and 79 articles were about noninvasive 
biophysical measurements. Several studies were included in multiple categories, 
because more than one method was used (Table S3, Supplementary Materials). Most 
of the included studies in this review were cohort studies (n = 31) and case–control 
studies (n = 24), followed by RCTs (n = 14), case reports (n = 8) and case series (n = 1). 
Below and in the table which is available online (link: https://onlinelibrary.wiley.com/
doi/abs/10.1111/bjd.18151), all imaging techniques and biophysical skin measurement 
methods included in this review are presented. Advantages and limitations of each 
technique are presented in Table 1 (end of chapter).
Figure 1. Flow chart: article selection process.
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Six studies described use of reflectance confocal microscopy (RCM, also called confocal 
laser scanning microscopy) in diagnostics and therapy monitoring of rosacea.33-38 
Imaging items of interest were Demodex mites, inhabiting human facial sebaceous 
follicles.39
Demodex manifested as roundish/elongated cone-shaped grey structures, surrounded 
by a bright ring.33-36 All case–control studies showed significantly higher Demodex 
numbers in patients compared with controls.33-35,38 There was evidence that patients 
with papulopustular rosacea (PPR) had significantly higher mite numbers than those 
with erythematotelangiectatic rosacea (ETR),35 and that RCM measures higher Demodex 
densities compared with only one SSSB (when two consecutive SSSBs were not 
taken).34 Moreover, a significant reduction in Demodex mites after topical treatment was 
seen, correlating with clinical improvement.36,37 Treatment also resulted in qualitative 
changes of residual mite appearance.37 In contrast, Harmelin et al. reported Demodex 
disappearance in six of eight treated patients, while complete clinical resolution (not 
further specified) was established in only three from the six patients with Demodex 
disappearance; the other three showed clinical improvement, but did not resolve 
completely.33 No correlation between clinical severity and mite density was found 
by Falay Gur et al.38 It was not possible to distinguish mite species, viability or life 
stages.35,36,38
Dermoscopy
In total, eight studies used dermoscopy40-47 (of which two studies used polarized 
light40,41), and one article used video dermoscopy for diagnostic and monitoring 
purposes.48 ETR was the most studied rosacea subtype.42,43,46-48
Lallas et al. showed a 100% presence of vascular polygons in patients with ETR.42,43 
Vascular polygons were also seen in granulomatous rosacea,45 together with a rosette 
sign.41 Unfortunately, rosette signs are nonspecific optical effects of polarized light 
interacting with keratin-filled adnexal openings, observable in a wide range of skin 
neoplasms.41,49 Two studies showed a reduction of background erythema after laser 
treatment.44,46 Vascular changes were described in three studies: decrease of vascular 
network,47 vessel density44 and capillary diameter.48 However, Lallas et al. showed 
that polygonal vessels only disappeared in four of 12 patients after treatment with 
topical metronidazole, while clinical improvement (not further specified) was seen in 
eight patients;43 Micali et al. noticed persistence of telangiectasias after brimonidine 
application while clinical improvement was substantial.46 Segal et al. noticed Demodex 
tails and follicular openings, and reticular dilated vessels in patients with microscopically 
proven demodicosis using skin scrapings.40
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Capillaroscopy
Two case–control studies involving capillaroscopy were performed in patients with 
rosacea.50,51 Fonseca et al. examined the nail-fold capillary beds in eight patients with 
rosacea and controls with a stereomicroscope.51 No specific capillaroscopic patterns 
in rosacea were found. Rosina et al. performed videocapillaroscopy on the cheek and 
nail folds in patients with ETR, seborrheic dermatitis and healthy controls.50 In the nail 
folds, this study too did not show any differences between all three mentioned cohorts. 
On the cheek, patients with ETR had significantly larger polygons, more prominent 
telangiectasia, larger mean vessel diameter and neoangiogenesis. Moreover, they 
showed a reddish background due to subpapillary vessel dilation.
Optical coherence tomography
Two studies used optical coherence tomography (OCT) in rosacea for Demodex 
quantification and therapy monitoring.52,53 Earlier research used OCT to visualize 
dermal vessels in normal skin.54-56
In Maier et al., OCT showed Demodex mites in 20 patients with rosacea – Demodex 
folliculitis and Demodex-aggravated dermatitis perioralis (Table 1).52 Demodex was visible 
in all patients as bright, round, grouped dots in the superficial part of dark hair follicles, 
while skin scraping tests were mite-positive in only 15 patients. Mite number was 
significantly higher in patients than in controls (positive predictive value 67%, sensitivity 
100%, specificity 65%). The case report of Urban et al. demonstrated decreased dermal 
hyporeflectivity of patients with ETR after treatment with brimonidine, suggesting a 
decrease in dermal oedema.53 No significant changes in vessel diameter were seen.
Computer-aided imaging analysis
Fifteen articles used computer-aided imaging analysis in rosacea diagnosis, severity 
assessment and therapy monitoring, mainly in ETR.46,48,57-69 To measure erythema, five 
studies used the VISIA® Complexion Analysis system (Canfield Scientific, Parsippany, 
NJ, U.S.A.),46,62,63,68,69 a commercially available high-resolution facial imaging system with 
quantitative imaging-analysis software (RBX®; Canfield Scientific), which separates red 
skin-colour components.70 In all studies, reduction of concentrated facial dark-red areas 
after treatment (brimonidine, laser, photodynamic therapy) was seen, corresponding to 
a reduction in erythema. The remaining 10 articles incorporated a variety of spectral 
imaging methods (L*a*b* colour space,60,61,67 red–blue difference index,61 erythema 
dose,61 red–green–blue imaging,57,59,66 emission of visible and infrared light48) to quantify 
erythema,57,58,60,61,64-67 telangiectasias57 and skin haemoglobin distribution.48,59
Other techniques
Sonographic imaging and infrared photography are two additional imaging techniques 
used in rosacea cases.71,72 Detailed information is summarized in Table 1.
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Skin hydration was assessed in 16 studies by corneometry, mainly for therapy 
monitoring.62,66,68,73-85 A corneometer measures electrical capacitance of skin surface, 
providing insight into stratum corneum barrier function,28 motivated by earlier studies 
implying decreased barrier function in patients with rosacea.1,3
In general, a wide range of skin capacitance values was reported (16.5–381.6 a.u.). Case–
control studies demonstrated that skin hydration in patients with ETR and PPR was 
significantly lower than in controls.81,82,84,85 Moreover, Kim et al. found significantly lower 
values in facial areas with increased erythema (measured with a skin colour imaging 
system) compared with areas having normal skin colour, and in severe compared 
with mild/moderate rosacea.66 Significant skin hydration increases were seen after 
successful treatment (moisturizers, topical metronidazole, oral tetracyclines).75,77-80,82,83 
In two RCTs where patients with ETR and PPR used creams containing silymarin or 
glycine/chitosan, the placebo groups using vehicle creams without these ingredients 
also had significantly higher skin hydration after treatment.78,79 Others noticed no 
significant changes in skin hydration, while rosacea severity decreased after treatment 
(various topical agents, photodynamic therapy).62,68,73,74,76
Transepidermal water loss
Transepidermal water loss (TEWL) was assessed in 16 studies.66,73-77,80,81,83-90 TEWL 
is widely accepted as a reference parameter to investigate epidermal permeability 
barrier function.91 Seven studies used open measurement chambers,75,77,80,83,86-88 two 
studies unventilated closed measurement chambers,66,90 and in seven studies the 
measurement principle was not specified.73,74,76,81,84,85,89
In general, a wide range of TEWL values was reported (11.5–35.8 g/m2/h). Patients 
showed higher TEWL values compared with controls.66,84-86,89 However, some studies 
showed no differences at the nasolabial fold,81 lateral chin,86 forehead85 and nose.85 
Kim et al. found significantly higher values in severe compared with mild/moderate 
rosacea.66 Significant decreases after treatment with various topical creams were 
observed and were associated with reduced rosacea severity.75,80,83,87,88,90 Others 
showed no TEWL differences after treatment with topical agents, while rosacea severity 
score decreased.73,74,76,77
Sebum
Eleven studies were interested in quantifying sebum in rosacea.38,68,82,84,85,92-97 Seven 
studies used a Sebumeter®,38,68,82,84,85,96,97 five studies used other methods (photometric 
quantification of cigarette paper,95 gravimetric absorption92,93 and chromatography92,94). 
It is important to note that a 1:1 correlation between Sebumeter score and amount of 
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skin oily material is not present.98 Moreover, reference values for normal facial sebum 
levels are scarce.99
Most studies found normal sebum levels and skin surface lipid composition in patients 
compared with controls,38,82,93,94,97 and no correlation with disease severity93,94 or 
rosacea subtype existed.68 Two case–control studies found lower than normal skin 
surface lipids in patients with PPR,84,95 and another higher oil levels in patients with 
nasal rosacea.85 A fourth study showed significant differences in lipid composition on 
the back of patients (Table 1).92 Two studies noticed no change in sebum levels after 
treatment (topical photodynamic therapy, oral tetracyclines);68,82 two did (other sebum 
composition, decrease of sebum levels).92,96
pH
Skin pH was measured with pH-meters in three studies.82,83,85 Results were inconclusive: 
one case–control study found significantly higher centrofacial pH values in patients 
with PPR vs. controls,82 while the other did not.85 No changes in pH were found in 
patients with PPR after use of oral minocycline,82 while the RCT did show significant 
decreases after application of tranexamic acid solution compared with vehicle 
treatment.83 However, also for facial pH, reference values are scarcely available.99-102
Erythema
Twenty-two studies assessed monitoring of facial skin ery thema by 
spectrometry.48,64,68,78-80,82,83,90,96,103-114 Three spectrometric methods were 
applied;28 reflectance spectrophotometry,3,64,68,78-80,82,96,104,106-108,110,111,113 tristimulus 
colorimetry83,90,103,109,112 and diffuse reflectance spectroscopy.105,114 One study used an 
optical densitometer.48 In all studies, erythema values decreased after treatment, 
corresponding to clinical improvement. However, erythema index and L*a*b* colour 
space values varied enormously (16.3–1002.77 and 6.9–20.2 a.u., respectively). Method 
of colour calibration was often not described.
Skin blood flow
In eight studies, cutaneous blood flow was established by laser Doppler velocimetry. 
Overall, no significant differences in facial blood flow between patients and controls 
were seen, nor after flushing-trigger tasks.89,115-117 Only Sibenge et al. found higher 
blood flow in facial flushing-affected areas in patients compared with controls.118 
Interestingly, flux was greater in patients with severe rosacea than with mild 
rosacea115,116 and values at PPR-affected skin were significantly higher than unaffected 
skin.117 Moreover, a decrease of flux was noticed after treatment with Intense Pulsed 
Light and acupuncture, in line with clinical improvements.57,119 However, Wilkin et al. 
found no statistical differences in patients after nadolol treatment.120
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Skin temperature was measured in three studies.117,121,122 This was performed with an 
infrared thermometer,117 infrared video camera,122 and iron–constantan thermocouple 
junctions.121 No significant differences between ETR- or PPR-affected areas and 
nonaffected areas or controls were found.117 Significant skin temperature rises were 
seen immediately after laser treatment122 and alcohol ingestion.121
Risk of bias
Sample size of most studies was small (and multiple case series/reports). Most RCTs 
were unblinded or single-blinded (Fig. S1, Supplementary Materials). Moreover, the 
method of random sequence generation and allocation concealment was often not 
described. For case–control studies, selection of controls, ascertainment of exposure, 
and nonresponse rate were often not described (Table S2, Supplementary Materials). 
For cohort studies, the domain ‘Study Confounding’ carried the highest risk of bias (Fig. 
S2, Supplementary Materials) due to insufficient description of potential confounders 
(e.g. comedication). Approximately 50% of studies did not describe or insufficiently 
described study population characteristics (domain ‘Study Population’) and reasons 
for/potential impact of subjects lost to follow-up (domain ‘Study Attrition’).
DISCUSSION
Noninvasive, objective methods are needed for reliable assessment and therapy 
monitoring in rosacea. We included a large number of publications describing (sub)
surface morphology and functionality of rosacea skin. This is especially useful for 
research purposes (e.g. follow-up of new treatments), but can possibly also contribute 
to elucidation of its multifactorial pathogenesis.
Unfortunately, the quality of included studies was relatively low and interstudy outcome 
variability was large; various rosacea subtypes, measurement locations, treatments 
and biophysical devices were used. A description of measurement sites (involved or 
uninvolved skin) was not always given. Method standardization and validation was 
often lacking. Additionally, most methods can only measure one or a few parameters 
in the very complex environment of rosacea symptoms. Subsequently, the gained 
information may not be conclusive with a single modality; more than one instrument 
may be useful to obtain a more complete picture.
Imaging equipment can have high purchase costs and require extensive protocols and 
trained personnel to obtain accurate and reproducible results. Penetration depth and 
resolution is limited (RCM, OCT and ultrasonography). Vessel irregularities are difficult 
to quantify (dermoscopy and capillaroscopy), as there is no standard to measure 
capillary shape.50,123 Demodex could potentially be confused with other similar structures 
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(e.g. trichostasis, follicular hyperkeratosis) by dermoscopy; RCM does not impose 
this limitation, as the mites are easily recognizable with this imaging technique.
Biophysical parameters are strongly influenced by intrinsic and extrinsic factors like 
age, sex, race, circadian rhythm, season, exercise, and acclimatization period;22,95,99,100,124-
131 therefore data collection is inherently difficult to standardize. For TEWL, open 
measurement chambers are more vulnerable to environmental influences than are 
closed chambers;129,132 condenser closed chambers seem to be the most sensitive 
TEWL system,132 but this device type was not used in rosacea. For pH, all three 
studies used pH900 meters, possibly overestimating true pH due to a small electrode 
area and short stabilization period of only 3 seconds.130 For erythema, skin light 
absorption by components other than haemoglobin (melanin, bilirubin) may influence 
outcomes64,105,114 and application of variable skin pressure can change haemoglobin 
level and skin colour.67,82 For laser Doppler, absolute values are meaningless without 
measuring sympathetic flux changes and blood vessel density, which is impossible 
with noninvasive techniques.89,115 Control for these factors was often not described 
or accounted for in the reviewed articles, and comparisons with normal skin were 
scarce. Additionally, biophysical tools are probe-related; they only cover a small facial 
area, questioning representativeness of the entire face. Placing the device on the 
same area of interest in follow-up visits is therefore challenging.64,76,113 Computer-
aided image analysis does not impose these problems as whole face erythema is 
mapped. Moreover, redness values are obtained without performing skin contact. 
On the contrary, their analysis methods were often experimental based, and neither 
standardized nor validated; therefore results were difficult to interpret.
Due to the strict exclusion criteria we applied in this review, all techniques that could 
possibly lead to skin irritation were excluded, as well as near-noninvasive tools like 
SSSBs and tapes. The SSSB (with two consecutive SSSBs) is a standardized, reproducible, 
cheap and simple sampling method to measure Demodex density as accurately as 
RCM.21,133 Sebutape® (Clinical and Derm, Dallas, TX, U.S.A.) enables assessment of the 
seborrheic activity of skin pores.134 Another limitation is that language of published 
studies was restricted to English, German and Dutch for practical linguistic reasons, 
which may have resulted in language bias.
Despite the above-mentioned limitations, several tools show promising additional 
value, especially in research settings; for treatment follow-up, Demodex mites can be 
easily counted by RCM, erythema can be monitored with spectrometry, and rosacea 
severity can be objectified with additional skin-hydration and TEWL measurements. 
Evidence-based and validated protocols are needed for long-term application of these 
tools. We recommend using standardized study environments and comparison of 
lesional with nonlesional skin. Furthermore, studies with larger samples sizes are 
needed.
3
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In conclusion, this systematic review provides an overview of the available noninvasive 
imaging and biophysical tools for diagnosis, severity assessment and therapy 
monitoring of rosacea. A selection of these tools is promising and provide valuable 
additional information about the structure and properties of rosacea skin in a manner 
well beyond that achievable through naked-eye examination; however, firstly adequate 
and validated protocols are needed for further implementation of these tools in 
research.
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SUPPLEMENTARY MATERIALS
Table S1. Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
 • Cutaneous facial rosacea (including granulo-
mateous and neurogenic rosacea, rosacea 
fulminans, rosacea conglobata, rhinophyma, 
otophyma, gnatophyma, metophyma, morbus 
Morbihan)
 • Noninvasive objective imaging/biophysical tools 
for measuring of severity/follow-up (methods 
that cannot cause skin irritation, bleeding or 
scarring; includes applying absorbent paper)
 • Adults (≥ 18 years)
 • Randomized controlled trials, non-randomized 
controlled trials, cohort studies, case series, case 
reports
 • Ocular, extrafacial and drug-induced 
rosacea
 • Invasive diagnostic tools (biopsies, 
superficial skin surface biopsies, epilation 
of eyelashes/hairs, use of skin tape/glue, 
collection of skin scrapings or excretions 
from sebaceous follicles)
 • Therapeutic tools (e.g. laser therapy for 
relieve of fibrotic tissue in rhinophyma)
 • Subjective measurements (e.g. estimation 
of erythema and inflammation based on 
clinical photographs)
 • Children (< 18 years)
 • In vitro and animal studies
 • Languages other than English, German or 
Dutch
 • Meta-analysis systematic reviews and 
reviews (no primary source)
 • Full-text not available
 • Abstracts of congresses
 • Duplicates
3
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Table S2. Search strategy.
Pubmed EMBASE Cochrane Library Web of Science
No limitations No limitations No limitations No limitations
(“Rosacea”[Mesh] OR rosacea[tiab] OR 
Rhinophyma[tiab]) AND ((“Diagnostic 
Imaging”[Mesh] OR “Spectrum 
Analysis”[Mesh] OR “Laser-Doppler 
Flowmetry”[Mesh] OR assessment 
tool[tiab] OR Dermoscop*[tiab] 
OR Dermatoscop*[tiab] 
OR Photograph* [tiab] OR 
Microscop*[tiab] OR tomograph*[tiab] 
OR Laser Doppler*[tiab] OR 
Fluorescence*[tiab] OR imaging[tiab] 
OR Measurement*[tiab] OR 
Monitor*[tiab] OR ((Characteristic*[tiab] 
OR characterisation[tiab] OR 
characterization[tiab]) AND skin[tiab]) 
OR Diagnos*[tiab] OR VISIA[tiab] OR 
mexameter[tiab] OR video*[tiab] OR 
videos[tiab] OR spectroscop*[tiab] 
OR spectrophotometr*[tiab] OR 
Sonograph*[tiab] OR Ultrasound*[tiab] 
OR Ultrasonograph*[tiab] OR 
Videocapillaroscop*[tiab] OR 
Capillaroscop*[tiab] OR Microscopic 
Angioscop*[tiab]) OR (“Galvanic Skin 
Response”[Mesh] OR “Water Loss, 
Insensible”[Mesh] OR “Sebum”[Mesh] 
OR “Hydrogen-Ion Concentration”[Mesh] 
OR Water content[tiab] OR water 
loss[tiab] OR TEWL[tiab] OR stratum 
corneum[tiab] OR skin surface[tiab] OR 
moisture[tiab] OR corneomet*[tiab] 
OR Permittivity[tiab] OR 
Permeability[tiab] OR Capacitance[tiab] 
OR Bioimpedance[tiab] OR 
Conductance[tiab] OR Aquaflux[tiab] 
OR Biox[tiab] OR epsilon[tiab] OR 
barrier[tiab] OR Sebum[tiab] OR fatty 
acid*[tiab] OR pH [tiab]))
(rosacea/ OR rosacea.ti,ab,kw. 
OR Rhinophyma.ti,ab,kw.) 
AND ((exp diagnostic imaging/ 
OR exp spectroscopy/ OR 




ti,ab,kw. OR Photograph* 
.ti,ab,kw. OR Microscop*.
ti,ab,kw. OR tomograph*.
ti,ab,kw. OR Laser Doppler*.
ti,ab,kw. OR Fluorescence*.
ti,ab,kw. OR imaging.ti,ab,kw. 
OR Measurement*.ti,ab,kw. 




AND skin.ti,ab,kw.) OR 
Diagnos*.ti,ab,kw. OR VISIA.
ti,ab,kw. OR mexameter.
ti,ab,kw. OR video*.ti,ab,kw. 
OR videos.ti,ab,kw. OR 
spectroscop*.ti,ab,kw. OR 
spectrophotometr*.ti,ab,kw. 






ti,ab,kw.) OR (electrodermal 
response/ OR skin water loss/ 
OR sebum/ OR pH/ OR skin 
conductance/ or skin lipid/ 
or skin permeability/ or skin 
potential/ OR Water content.
ti,ab,kw. OR water loss.ti,ab,kw. 
OR TEWL.ti,ab,kw. OR stratum 








ti,ab,kw. OR Aquaflux.ti,ab,kw. 
OR Biox.ti,ab,kw. OR epsilon.
ti,ab,kw. OR barrier.ti,ab,kw. 
OR Sebum.ti,ab,kw. OR 
fatty acid*.ti,ab,kw. OR pH 
.ti,ab,kw.))
Rosacea (MeSH) (rosacea OR Rhinophyma) 
AND ((“laser doppler” 




OR Microscop* OR 
tomograph* OR 
Laser Doppler* OR 
Fluorescence* OR imaging 
OR Measurement* 
OR Monitor* OR 
((Characteristic* OR 
characterisation OR 
characterization) AND skin) 
OR Diagnos* OR VISIA OR 
mexameter OR video* OR 
videos OR spectroscop* 
OR spectrophotometr* 




OR Capillaroscop* OR 
“Microscopic Angioscop*”) 
OR (“skin lipid” or “skin 
potential” OR “Water 
content” OR “water loss” 
OR TEWL OR “stratum 
corneum” OR “skin 
surface” OR moisture OR 
corneomet* OR Permittivity 
OR Permeability 
OR Capacitance OR 
Bioimpedance OR 
Conductance OR Aquaflux 
OR Biox OR epsilon OR 
barrier OR Sebum OR “fatty 









29-2 to 1-9-2018: 
47 hits
29-2 to 1-9-2018: 
66 hits
29-2 to 1-9-2018: 
6 hits










Voorbereid document - Jade.indd   104 01-05-2021   10:16
105
Noninvasive objective methods in rosacea
Table S3. Overview of categories of included studies.
















* Some studies were included in multiple categories, because they evaluated more than one imaging/
biophysical tool.
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Figure S1A. Review author’s judgement about each risk of bias item for each included RCT (n = 14) 
with Cochrane Risk of Bias tool.
Figure S1B. Review author’s judgement about each risk of bias item presented as percentages across 
all included RCTs (n = 14) with Cochrane Risk of Bias tool.
3
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Figure S2A. Review author’s judgement about each risk of bias item for each included cohort 
study and case report/series (n = 40) with Quality in Prognosis Studies tool.
Figure S2B. Review author’s judgement about each risk of bias item presented as percentages 
across all included cohort studies and case reports/series (n = 40) with Quality in Prognosis 
Studies tool.
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Value of reflectance confocal microscopy for








Journal of Dermatological Treatment 2020;19:1-9





Reflectance confocal microscopy (RCM) enables noninvasive Demodex mite detection 
in rosacea. Objective scoring of rosacea severity is currently lacking.
Objectives
To determine the value of RCM for monitoring Demodex, inflammation and vascular 
parameters in rosacea during treatment.
Methods
In 20 rosacea patients, clinical and RCM examination were performed before, during, 
and 12 weeks after a 16-week treatment course with topical ivermectin. Using RCM, 
number of mites and inflammatory cells, epidermal thickness, and vascular density and 
diameter were measured. RCM features were correlated with clinical assessment.
Results
Treatment resulted in clinical reduction of inflammatory lesions. Mites were detected 
in 80% of patients at baseline, 30% at week 16, and 63% at week 28. The number of 
mites reduced significantly during treatment, but no changes in inflammatory cells, 
epidermal thickness or vascular parameters were observed. Correlation between 
number of inflammatory lesions and mites was low. None of the RCM variables were 
significant predictors for clinical success.
Conclusions
RCM enables anti-inflammatory effect monitoring of topical ivermectin by determining 
mite presence. Quantifying exact mite number, and inflammatory and vascular 
characteristics is challenging due to device limitations. In its current form, RCM seems 
of limited value for noninvasive follow-up of rosacea in clinical practice.
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INTRODUCTION
Reflectance confocal microscopy (RCM) is a noninvasive imaging technique for in vivo 
visualization of the superficial skin layers with a resolution comparable to conventional 
histology.1,2 Unlike invasive tools such as skin biopsies, RCM enables temporal 
monitoring of the skin without causing irritation, damage or alteration. Historically, 
RCM has been mainly used for the diagnosis of (non-)melanoma skin cancer,3-6 but it 
also has promising potential in the evaluation of inflammatory skin diseases.7 Some 
knowledge has already been gained with the detection and quantification of Demodex 
mites in rosacea.8-13
Rosacea is a chronic inflammatory skin disorder of uncertain etiology, characterized 
by among others papules, pustules, erythema, telangiectasia, and flushing.14-16 
Demodex mites have been implicated in rosacea etiology,14,17-19 and studies show that 
the Demodex population is markedly increased in patients with rosacea compared to 
healthy controls.20-25 With RCM, mites are visible as roundish or cone-shaped, bright 
structures inside hair follicles.8,9,26,27 Moreover, structural changes in Demodex mites 
have been observed after ivermectin treatment using RCM.28 However, no RCM studies 
have yet assessed inflammatory and vascular parameters in rosacea.29,30
Due to the variety in clinical features among individual rosacea patients and the 
presence of multiple subjective, often not validated, classification systems, there 
is a need for methods quantifying rosacea severity in an objective manner.31-35 It is 
hypothesized that clinical effects of rosacea treatment can be quantified and ideally also 
be predicted using RCM monitoring. Topical ivermectin, an antiparasitic preparation 
that has dual anti-inflammatory and acaricidal effects, has been widely studied as a 
safe, easy to use, and effective treatment to reduce papules and pustules in rosacea.36 
This makes ivermectin a suitable intervention to monitor rosacea treatment effects.
The aim of this study was to determine the value of RCM to monitor Demodex 
mites, inflammation and vascular parameters in rosacea patients during treatment 
with topical ivermectin. To do so, RCM features were correlated to clinical scores, 




This study was approved by the ethics committee. Patients were recruited between 
January 2018 and April 2019 at the department of Dermatology, Radboud University 
Medical Center, Nijmegen, the Netherlands. Eligible participants were ≥ 18 years 
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old, and had a clinical diagnosis of moderate to severe facial rosacea (investigator’s 
global assessment [IGA] ≥ 3, > 15 papules or pustules, and/or erythema scale ≥ 3 plus 
telangiectasia scale ≥ 2). Patients currently using ivermectin cream, having other facial 
dermatological conditions or underlying diseases requiring use of topical or systemic 
therapies interfering with rosacea diagnosis or assessment, or the inability to adhere to 
the washout period for these interfering therapies (Table S1, Supplementary Materials) 
were excluded. Participants were instructed to avoid known rosacea aggravating 
environmental factors and foods, and to abstain from sunbathing or using tanning 
beds throughout the study.
Clinical and RCM procedures
Written consent was obtained from all participants. After an acclimatization period 
of at least 15 minutes, facial clinical scores were assessed including IGA scale, IGA 
success scale (0 or 1), papules and pustules scale, erythema scale, telangiectasia 
scale, and inflammatory lesion count (Table S2, Supplementary Materials). Next, 
participants’ cheek with the highest clinical scores (left cheek: n = 13; right cheek: n = 7) 
was examined using RCM. The cheek was chosen because highest Demodex densities 
have been found here, and the RCM ring can be attached firmly on the relatively flat 
surface.37,38 After examination, participants were instructed to apply topical ivermectin 
1% once daily in the evening for 16 consecutive weeks. Clinical and RCM examination 
were performed at five time points: week 0 (baseline), 6, 12, 16 (during treatment), 
and week 28 (follow-up). The same cheek was examined with RCM during consecutive 
visits. Therapy compliance was monitored using patient diaries and by weighing the 
used ivermectin tubes at week 6, 12, and 16. All examinations were performed in the 
same room by the same clinician ( JGML), and room temperature was kept constant 
between 19 and 24°C.
RCM device and image analysis
RCM analysis was performed using a Vivascope 1500® confocal microscope (Mavig, 
Munich, Germany).39 Four surface-parallel horizontal areas of 8 x 8 mm were scanned 
with the Vivablock function at the level of the stratum corneum/granulosum, stratum 
spinosum, dermo-epidermal junction (DEJ), and the superficial dermis. Next, four 
vertical mappings (Vivastacks) of 0.5 x 0.5 mm were obtained, starting from the skin 
surface up to a depth of 150 µm with interval steps of 3 µm. Then, three movies of 
0.5 x 0.5 mm of approximately 5 seconds each were made in the superficial dermis to 
visualize dermal blood flow. Analysis of RCM images was performed by one investigator 
( JGML). Using all Vivablocks, Vivastacks and movies, the number of Demodex mites, 
inflammatory cells, degree of spongiosis, epidermal thickness, and vascular diameter 
and density were calculated.
Voorbereid document - Jade.indd   120 01-05-2021   10:17
121
RCM in rosacea during topical ivermectin treatment
Calculating Demodex mites
After selecting one 8 x 8 mm Vivablock at z = 20-80 µm (i.e. stratum granulosum/
spinosum; mite quantification is best performed at this level8,11), mites were noted 
as present or absent. Then, the number of mites, hair follicles, infested follicles, and 
number of mites per individual follicle were counted; a separate category doubt was 
added if the follicle content was not well defined. Mean number of mites per follicle 
and mean number of mites per infested follicle were calculated.
Calculating inflammatory cells and spongiosis
The number of inflammatory cells, visible as round-to-polygonal bright cells,40 was 
counted in one 8 x 8 mm Vivablock at the level of the DEJ. A group of > 40 inflammatory 
cells was defined as one inflammatory nest. Dendritic cells were noted as present or 
absent.
To determine degree of spongiosis, three single images in a Vivablock with a clear 
honeycombed pattern from the stratum granulosum were selected. In these images, 
number of keratinocytes in a square with known surface area without hair follicles 
were counted manually using ImageJ® freeware,41 and extrapolated into number of 
keratinocytes/mm2. Lower values mean more intercellular edema, indicating increased 
spongiosis. The mean score of the three images was calculated.
Calculating epidermal thickness
Thickness of the stratum corneum (SC) and the viable epidermis, without SC, were 
determined (in µm) from the four Vivastacks with a standardized protocol as described 
in our earlier work.39 The mean thickness of the SC and the viable epidermis of the 
four Vivastacks were calculated.
Scoring vascularity
Vascular diameter and density were determined separately from the three movies of 
the superficial dermis, and classified using a five-point scale: 1 (normal, i.e. similar to 
healthy facial skin), 2 (mildly increased), 3 (moderately increased), 4 (severely increased), 
5 (very severely increased). Example movies of each score can be requested from the 
author. The mean score of three movies for both parameters were calculated.
Statistical analysis
Descriptive statistics were used to explore baseline characteristics and categorical 
data. Differences in the same continuous variable between various time points 
were evaluated with Wilcoxon signed-rank tests for matched pairs. No correction 
for multiple comparisons was applied, because of the exploratory character of this 
study. Correlating clinical scores and RCM variables using measurements in the same 
patients at various time points can lead to biased estimates if the clustering within 
patients is ignored. Therefore, to get an overall estimate of correlation between 
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number of inflammatory lesions and number of mites, a meta-analysis was constructed 
to aggregate the Spearman correlations (R) at the five consecutive time points. 
Additionally, possible interactions between RCM features and achieving IGA 0 or 1 
(=clinical success) were measured in term of an odds ratio in the 95% confidence 
interval by using mixed model logistic regression analysis. Statistical analysis was 
performed using GraphPad Prism 5.03 (GraphPad Software, Inc., San Diego, CA, USA) 
and R 3.6.0 (Foundation for Statistical Computing, Vienna, Austria). For all tests, P < 




Twenty-one patients were included in this study. One patient was excluded because of 
starting tetracycline during the study. Therefore, data from 20 participants were used 
for statistical analysis. In one patient, the week 28 visit was not performed due to the 
patients’ inability to travel to the hospital within the study visit window (two weeks). 
The RCM data of the week 12 visit of one patient were unexpectedly not saved at the 
computer and were therefore missing.
Demographic and baseline characteristics are displayed in Table 1. Most patients had 
IGA 3 (80%), erythema 3 (65%), and telangiectasia 2 or 3 (80%) scores. Median facial 
inflammatory lesion count at baseline was 36.5 (range 0-144). All patients applied 
ivermectin daily and according to prescription; mean daily quantity applied was 0.36 g.
Eleven patients reported one or more dermatologically related adverse event (AE); 
stinging/burning (n = 7), increased facial erythema (n = 4), itching (n = 3), and facial 
skin dryness (n = 1). All AEs occurred during the 16-week treatment period and were 
mild and self-limiting.
Clinical assessment
Fig. 1 presents the clinical scores at the five time points, and representative clinical 
pictures are shown in Fig. 2. Treatment resulted in clinical success (IGA 0 or 1) in 45% 
and 47% of patients at week 16 and at week 28, respectively. Median number of facial 
inflammatory lesions significantly decreased from baseline to week 12 (8.5, range 0-39; 
P < 0.001) and week 16 (2.0, range 0-44; P < 0.001), with no further changes at week 
28 compared to week 16 (3.0, range 0.0-30; P = 0.19). Some improvement in erythema 
scores was noticed, while telangiectasias remained mainly unaffected.
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Table 1. Demographic and baseline clinical characteristics.
Characteristics Rosacea patients (n = 20)
Age, years









 3 = Moderate




 1 = Almost clear
 2 = Mild
 3 = Moderate
 4 = Severe
Telangiectasia scale
 1 = None
 2 = Mild
 3 = Moderate


















Mites were detected in 80% of participants at baseline, 30% at week 12 and 16, and 
63% at week 28 (Table 2 and Fig. 3). Median number of mites significantly decreased 
from baseline (13, range 0.0-203) to week 12 (0.0, range 0.0-10; P < 0.001) and week 16 
(0.0, range 0.0-14; P < 0.001), and remained low at week 28 (1.0, range 0.0-21; P = 0.51 
compared to week 16). Median number of follicles were comparable before, during, 
and after treatment. The median number of infested follicles and mites per follicle and 
mites per infested follicle were all significantly decreased after 16 weeks of treatment 
(P < 0.001, Table 2), while only number of mites per infested follicle increased slightly at 
follow-up compared to week 16. Most follicles contained zero mites. The percentage of 
follicles with unclear content (doubt) was higher than follicles with clearly visible mites, 
which is visualized in Fig. 4A-B.
3
Voorbereid document - Jade.indd   123 01-05-2021   10:17
124
Chapter 3.2
Figure 1. Clinical scores of all patients during 16 weeks of treatment with topical ivermectin and 
at week 28 (follow-up). A-E, IGA scale, IGA success scale (IGA 0 or 1), papules and pustules scale, 
erythema scale, and telangiectasia scale. F, Number of facial inflammatory lesions, expressed 
as median with range. IGA, investigator’s global assessment
Figure 2. Rosacea in a 56-year old man, A, At baseline, B, At week 16 of treatment with topical 
ivermectin 1% once daily, and C, 12 weeks post-treatment. Notice the disappearance of papules 
and pustules at the forehead and prominent erythema at the cheeks, while telangiectasias 
and residual erythema at both cheeks are persisting. The green dots serve as a tool to assess 
clinical erythema.
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Figure 3. Demodex mites during 16 weeks of treatment with topical ivermectin and at week 28 
(follow-up), measured with RCM. A, Mite presence per 8 x 8 mm, expressed as present or absent. 
B, Number of mites per 8 x 8 mm, expressed as median with range.
Figure 4. Confocal images of the cheek (0.5 x 0.5 mm). A, Follicle at the level of the stratum 
granulosum containing seven Demodex mites, clearly visible as bright, round contours. B, Follicle 
at the level of the stratum granulosum with unclear content due to vague, white-roundish 
structures, included in mite category doubt. C, Multiple bright, round to oval or fusiform cells 
with dendritic processes at the level of the dermo-epidermal junction, possibly melanocytes or 
Langerhans cells. D, Multiple bright, round cells at the level of the dermo-epidermal junction, 
possibly inflammatory cells.
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Inflammation, epidermal thickness and vascularity
Median number of inflammatory cells, inflammatory nests, and thickness of the SC 
and viable epidermis did not change significantly at week 16 or at follow-up compared 
to baseline (Table 3). Dendritic-like cells were seen before, during and after treatment 
in all patients (Fig. 4C). Interestingly, median number of keratinocytes/mm2 slightly 
decreased from baseline to week 16 (P = 0.004) and week 28 (P = 0.031), implying an 
increase in spongiosis. As shown in Fig. 5, vascular diameter decreased only slightly 
after topical ivermectin application, while vascular density barely changed.
Figure 5. A, Vascular diameter, and B, Vascular density scores during 16 weeks of treatment 
with topical ivermectin and at week 28 (follow-up), determined with RCM.
Correlating clinical scores with RCM parameters
As the correlation estimates in the meta-analysis were homogeneous over time, 
standard averaging with inversed variance weighting was used in this method. A low 
correlation existed between number of inflammatory lesions and number of mites 
(R = 0.28, 95% CI 0.08-0.48). Mixed model logistic regression revealed that none of 
the RCM variables were significant predictors for clinical success. Despite this, mite 
presence was the most promising parameter (Table 4).
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Table 4. Mixed model logistic regression models determining RCM features associated with clinical 
success (IGA 0/1).
IGA score 0 or 1 P-value
Mite presence, present/absent 2.10 (0.82-6.07) .14

























Vascular diameter, scale 1-5





Values are given as odds ratios (95% confidence intervals). IGA, investigator’s global assessment.
* Large OR + 95% CI due to low median value and highly skewed distribution of this variable (also see 
Table 2).
DISCUSSION
This study confirmed the well-known efficacy of topical ivermectin to reduce 
inflammatory lesions in rosacea.36 To the best of our knowledge, this is the first 
study combining a broad spectrum of RCM and clinical variables to monitor rosacea 
during treatment. Using RCM, we were able to monitor the anti-inflammatory effect 
of topical ivermectin by determination of Demodex mite presence, number of infested 
follicles and number of mites per follicle. However, quantifying exact mite number, 
inflammatory parameters and vascular characteristics was challenging due to various 
device limitations.
To guarantee adequate evaluation of rosacea severity, clinical assessment was 
performed using multiple scales, based on the newly developed phenotype-based 
classification system for rosacea.31,36,42 Topical ivermectin treatment reduced the 
number of facial inflammatory lesions and erythema, with the greatest reduction at 
week 16. We found no changes in telangiectasias, corresponding to previous results,36 
supporting the hypothesis that telangiectasias are non-inflammatory features. A 
significant decrease in mite number was measured with RCM, with lowest counts after 
12 weeks of treatment, preceding clinical outcomes; these findings suggest that topical 
ivermectin treatment should be continued for at least 12 weeks. Ivermectin blocks 
signal transduction in the neuromuscular system of Demodex mites, causing paralysis 
and death.28,43 Our results support the notion that a reduction of Demodex may be 
causative for the observed decrease in inflammation. Various mechanisms for immune 
system triggering by Demodex have been proposed, such as hair follicle blockage, 
3
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foreign-body reactions, and secretion of bacteria and waste.11,44-46 On the other hand, 
Demodex was absent in 20% of rosacea patients at baseline while they responded well 
to ivermectin treatment, and correlation between number of inflammatory lesions 
and mites was low. This suggests that the pathogenesis of rosacea cannot be entirely 
explained by Demodex, and mites could be one of multiple factors inducing follicular 
inflammation.
Compared to earlier RCM studies calculating Demodex density in rosacea,8,9,11-13,47 
we measured low mite numbers, while follicle amounts were very similar.8,11 These 
differences could be explained by the fact that we excluded follicles with unclear 
content from the mite count (Fig. 4B). These follicles could contain sebum, sludge, 
hair shafts, or (disintegrating) mites.28,48 Additionally, counting exact mite number 
was challenging; mites’ contours were often vaguely debordered.49,50 Thirdly, despite 
the used washout periods (Table S1, Supplementary Materials), we cannot exclude 
an influence of previous rosacea treatments applied such as topical metronidazole; 
however, metronidazole does not directly kill Demodex mites.11,51 RCM has some other 
limitations for mite analysis. First, Demodex folliculorum is detectable, but not Demodex 
brevis which lives beneath the RCM maximum visualization depth, namely near the 
sebaceous glands.45,50 Second, mite distribution within the follicular canal varies, giving 
false-negative results when counting mites at only one level.52 Lastly, RCM does not 
enable evaluation of mite viability or life stage.23,49,53,54
In histological sections, the inflammatory infiltrate in rosacea can be observed in both 
superficial as well as deeper skin layers.29,30 In the current study, the DEJ was used as 
a representative level to score inflammation, because deeper layers impair detailed 
vision due to reduced image resolution and co-presence of bright collagen bundles.2 
No changes in inflammatory cell number at the DEJ were measured, which may be due 
to the difficulty of differentiating inflammatory cells from pigmented keratinocytes 
and melanocytes, which all are visible as polygonal, bright structures (Fig. 4C,D).2,55 
Furthermore, RCM cannot differentiate within leukocyte type.29,30
Both vasodilation and increased vascular density are thought to be involved in the 
pathophysiology of facial erythema in rosacea.56 We expected to measure a decrease 
in vasodilation in multiple participants, as this feature is most linked to inflammation, 
but we did not. Capillary diameter can be easily measured with RCM in vessels inside 
dermal papillae,57-60 but as papillae are hardly visible in facial skin,55 this method is not 
suitable in rosacea. Therefore, we tried quantifying vascular density and diameter using 
MATLAB by calculating differences in blood vessel movement between two consecutive 
movie frames. Unfortunately, these differences were not only caused by blood flux, 
but also by movement of the vessel surroundings, namely the patient and the RCM 
device. Consequently, we used Likert scales to grade vascular density and diameter, 
which are unfortunately still subjective.
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Our study has several strengths. All examinations were performed in the same 
room by the same researcher, reducing light- and interobserver variability. Missing 
values were minimal due to high visit and therapy compliance. Both genders were 
equally represented, and age range was large, providing decent generalizability of 
our findings.
The advantage of RCM is its noninvasiveness without causing discomfort or damage, 
providing the ability to monitor the same facial location over time.27 Limitations of our 
study are due to RCM limitations. Imaging of convex areas is challenging, impeding 
the generation of a perfectly horizontal Vivablock necessary for analysis in one skin 
level; image analysis takes time and requires an experienced investigator; RCM images 
are two-dimensional and in black-and-white only; and the apparatus is bulky, not 
wireless, and requires start-up of approximately 10 minutes. Taking these factors into 
account, the RCM in its current form seems unsuitable for quick monitoring of rosacea 
patients in daily clinical practice. On the other hand, in research setting, RCM provides 
valuable additional information about mite presence that could otherwise not have 
been obtained in a noninvasive way.
In summary, we showed that RCM can be used for monitoring of Demodex presence 
in rosacea patients during successful anti-inflammatory treatment with topical 
ivermectin. Quantifying exact mite number and inflammatory and vascular parameters 
is challenging due to various device limitations. In its current form, RCM seems of 
limited value for noninvasive follow-up of rosacea treatment in daily clinical practice. 
However, as imaging techniques become more compact, intelligent (i.e. enabling 
automatic counting), and affordable, RCM’s future widespread application in research 
and possibly also clinical practice for rosacea monitoring can be expected.
3




Table S1. Washout periods for previous topical and/or systemic treatments.
Treatment Washout period
Topical Antibiotics 2 weeks
Antimicrobial soaps 2 weeks
Corticosteroids 2 weeks
Rosacea treatments (azelaic acid, metronidazole, brimonidine) 2 weeks
Other anti-inflammatory treatments 2 weeks
Retinoids 4 weeks
Systemic Antibiotics 4 weeks
Corticosteroids 4 weeks
Retinoids 12 weeks
Table S2. Clinical scores.
1. Lesion count






Papule: circumscribed solid elevation < 1 cm
Pustule: circumscribed elevation with white exsudates < 1 cm
Nodule: circumscribed solid elevation > 1 cm
2. Investigators Global Assessment (IGA) scale (0-1=success, 2-4=failure)
Score Grade Clinical description
0 Clear No inflammatory lesions present, no erythema.
1 Almost clear Very few small papules/pustules, very mild erythema present.
2 Mild Few small papules/pustules, mild erythema.
3 Moderate Several small or large papules/pustules, moderate erythema.
4 Severe Numerous small and/or large pustules, severe erythema.
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3. Papules and pustules scale
Score Grade Clinical description
0 Clear Clear skin with no inflammatory (pustules) or noninflammatory (papules) 
lesions
1 Almost clear Rare noninflammatory lesions with no more than one small inflammatory 
lesion
2 Mild Some noninflammatory lesions with no more than a few inflammatory 
lesions (papules/pustules only, no nodular lesions)
3 Moderate Up to many noninflammatory lesions and may have some inflammatory 
lesions, but no more than one small nodular lesion
4 Severe Up to many noninflammatory and inflammatory lesions, but no more than a 
few nodular lesions
4. Erythema scale
Score Grade Description of background erythema
0 Clear No redness present. Background erythema is consistent with non-
involved areas.
1 Almost clear Slight and localized background erythema in involved areas of the 
face, usually limited to the malar prominence of the cheeks. Gives 
the impression of a healthy glow to the cheeks.
2 Mild Slight to mild background erythema NOT limited just to the cheeks, 
but extends to the lateral cheeks, chin, or forehead.
3 Moderate Definite background redness, easily recognized, and extending to 
lateral cheeks, chin, or forehead.
4 Severe Severe background erythema over the entire face.
5. Telangiectasia scale
Score Grade Description of telangiectasia: fine superficial blood vessels that are 
visible near the surface of the skin
0 None No telangiectasia present on the face.
1 Mild Some to a few telangiectasias are present on the face.
2 Moderate Many telangiectasias, easily recognized, and extending to lateral cheeks, chin, 
or forehead.
3 Severe Many to numerous telangiectasias over the entire face that blends in or matches 
with the erythema caused by inflammatory lesions. Few matted and dense 
cluster of vessels present.
3
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Evaluation of a simple image-based tool to 
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Facial erythema is a common symptom in rosacea. To overcome subjectivity in scoring 
erythema severity, objective redness quantification is desirable. This study evaluated 
an image-based erythema quantification tool to monitor facial erythema in rosacea 
patients during treatment and compared these values to clinical scores.
Materials and Methods
Twenty-one rosacea patients were treated with topical ivermectin for 16 weeks. 
Clinical erythema scores and clinical photographs were taken at week 0, 6, 16, and 
28. Using ImageJ, RGB images were split into red, green and blue channels to measure 
the green/red ratio of lesional skin compared to a green sticker. With CIELAB colour 
space, a* (indicating colour from green to red) of a lesional and non-lesional facial site 
was measured, calculating ∆a*. Interobserver concordance and correlation between 
quantitative and clinical erythema values were determined.
Results
Treatment resulted in reduction of clinical erythema scores. No significant changes 
in red/green ratios were measured. Lesional a* and ∆a* significantly decreased from 
baseline to week 16 and 28 (P < 0.05). A weak correlation existed between clinical 
scores and lesional a* (Rs = 0.37), and between clinical scores and ∆a* (Rs = 0.30), 
with a clear trend towards higher a* and ∆a* for higher clinical scores. Interobserver 
correlation was high (R2 = 0.82).
Conclusion
ImageJ is a simple, rapid, objective, and reproducible tool to monitor erythema in 
rosacea patients during treatment. The photographs allow retrospective analysis, 
evaluation of large and small lesions, and discrimination of subtle redness differences. 
We recommend using lesional a* to monitor erythema of inflammatory dermatoses 
in clinical practice.
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INTRODUCTION
Rosacea is a common inflammatory skin disease, often accompanied by facial 
erythema.1 Erythema is visible due to increased haemoglobin in the papillary dermis, 
caused by inflammation, vasodilation and vasculature changes.2 To achieve optimal 
results, rosacea treatment is preferably adjusted to clinical symptoms and disease 
severity. Unfortunately, evaluation of facial erythema by visual assessment lacks 
objectivity and precision, and is prone to inter- and intra-observer variability.3-6
To overcome subjectivity, an objective, noninvasive technique for the measurement 
of skin colour is desirable. Various noninvasive techniques have already been used 
to quantify redness in rosacea, e.g. spectrophotometry and computer-aided image 
analysis (CAIA).7 Nevertheless, they have some limitations. With spectrometry, 
erythema is measured in only one point, questioning representativeness of the entire 
face. Moreover, spectrophotometers require skin contact, changing skin colour due 
to skin pressure application.8-10 For CAIA, analysis protocols often included multi-
step, complex, time-consuming approaches with expensive and extensive software, 
or protocols are poorly described, not validated nor standardized,2,11-19 and therefore 
difficult to reproduce or use in clinical practice. Additionally, VISIA, a commercially 
available system with quantitative facial imaging analysis software, does not enable 
point/segmented erythema analysis, imposing difficulties in areas with diffuse 
erythema.2 Lastly, two different colour space methods have been applied in previous 
studies, namely RGB and CIELAB. RGB represents object “appearance”, but does not 
correct for brightness; CIELAB indicates colour perception, and has the advantage 
of correcting for variations in brightness.10,20 Due to these various limitations for 
erythema quantification in rosacea, a reliable, rapid, non-contact, and simple erythema 
quantification tool is needed.
The aim of this study was to test an easy-to-use, image-based software tool to 
quantify and monitor facial erythema in rosacea patients during treatment with topical 
ivermectin. Additionally, quantified erythema values were correlated to clinical scores 
and interrater concordance was determined.
MATERIAL AND METHODS
Study participants
Twenty-one patients (9 males, 12 females; skin type I-III; median age 49 years; range 
24-81 years) participated in this study. They were recruited between January 2018 
and April 2019 at the Department of Dermatology, Radboudumc, Nijmegen, the 
Netherlands. Subjects were included if they had moderate-to-severe rosacea, defined 
as an Investigator’s Global Assessment (IGA) score of 3 or 4. Patients currently using 
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ivermectin cream or having other facial dermatological conditions able to interfere with 
rosacea diagnosis or assessment were excluded. They were instructed to avoid known 
offending environmental factors and foods triggering rosacea, and not to sunbathe or 
to use a tanning bed throughout the study.
Treatment, procedures and photography setup
Treatment consisted of topical ivermectin 1% once daily during 16 consecutive weeks. 
Ivermectin is a potent and easy-to-use anti-inflammatory/acaricidal agent for rosacea 
with little side effects, making this a suitable intervention to monitor erythema.21 
Clinical erythema was graded using an erythema scale from 0 to 4 (Table 1) at week 
0, 6, 16, and 28 (follow-up). During these visits, high-resolution facial photographs 
were acquired in JPG-format with a commercially available single-lens reflex digital 
camera (Nikon), equipped with a complementary metal-oxide semiconductor (CMOS) 
sensor and an AF S Micro Nikkor 105 mm 2.8 objective. All photos were taken under 
the same light conditions in a photo studio, with a green circular sticker (0.5 inch 
diameter) attached at the cheek. The camera was manually hold perpendicular to the 
skin and the sticker, at a distance sufficient to image both the erythematous areas 
as well as the sticker. Two Broncolor monolights were used to maintain absolute light 
consistency with respect to exposure and colour. The following settings were used 
to take photographs: manual focus and mode (M), with aperture and shutting speed 
adjusted to match optimal exposure; ISO 200; image quality “JEPfine S”, corresponding 
to images with a low (1:4) compression ratio; and colour space sRGB.
Table 1. Clinical erythema severity assessment.
Score Grade Description of erythema
0 Clear No redness present. Erythema is consistent with non-involved areas.
1 Almost clear Slight and localized erythema in involved areas of the face, usually limited 
to the malar prominence of the cheeks. Gives the impression of a healthy 
glow to the cheeks.
2 Mild Slight to mild erythema NOT limited just to the cheeks, but extends to the 
lateral cheeks, chin, or forehead.
3 Moderate Definite background redness, easily recognized, and extending to lateral 
cheeks, chin, or forehead.
4 Severe Severe erythema over the entire face.
Erythema quantification
Photographs were analysed with ImageJ® freeware (http://imagej.nih.gov/ij). First, the 
RGB colour split function was used to divide the original RGB photographs into their 
constituent red, green and blue channels. The mean green intensity of the green sticker 
was measured. Next, a region of interest (ROI) with the most intense visible facial 
erythema (i.e. lesional skin) was selected; this was the cheek (n = 19), the forehead 
(n = 1) or the chin (n = 1). The mean red intensity of this ROI was measured. Then, 
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the mean intensity of the sticker and the ROI were used to calculate the red/green 
(R/G) ratio as a standardized measure for skin redness. Secondly, the RGB image was 
converted to CIE L*a*b* colour space. L* indicates light intensity from 0 (black) to 100 
(white), while a* indicates colour from green (-60) to red (+60), and b* indicates colour 
from blue (-60) to yellow (+60).9,22 The mean a* value of the stored ROI was measured, 
and compared to a representative non-lesional site (neck), serving as a control site for 
background erythema; ∆a* was calculated (a* of lesional skin minus a* of non-lesional 
skin). Incidental regions of specular reflection were avoided when selecting areas for 
analysis. A step-by-step guideline for the entire procedure is found in Table 2. Analyses 
of week 0 and 28 were performed by two independent researchers ( JGML and PEJE) 
to determine interobserver variation; week 6 and 16 analyses were performed by one 
researcher ( JGML).
Statistical analysis
Differences in R/G ratio, a* and ∆a* between the various time points were evaluated 
with Wilcoxon singed-rank tests. No correlation for multiple comparisons were applied, 
because of the exploratory character of this study. Differences in a* between lesional 
and non-lesional skin per visit and for both researchers, were explored using Mann-
Whitney U tests. To test for a possible relationship between clinical and quantified 
erythema results, Spearman rank correlation (Rs) was used. Lastly, linear regression 
analysis was applied to determine interobserver variation. Statistical analysis was 
performed using Instant Clue Software.23 For all tests, P < 0.05 was considered 
statistically significant. Missing values were excluded from the analyses.
3
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Table 2. Step-by-step protocol for erythema quantification using ImageJ, used in this study.
Original JPG image
1. Drag original JPG photograph into ImageJ (Photo 1).
Split image into the three RGB channels (red, green, blue): Image → Color → Split Channels.
Close blue image, you do not need this one.
RGB green image
2. In green image (Photo 2):
Zoom in on green sticker at the cheek.
Draw a circle inside the green sticker with ‘Freehand selections’.
Analyse → Measure: record mean green value for green sticker.
Close green image.
RGB red image
3. In the red image (Photo 3):
Choose region of interest of lesional skin. Outline ROI with ‘Freehand selections’. Make sure 
to avoid any skin colour inconsistency due to pen lines, hair, tattoos, jewellery etc. inside ROI.
Analyse → Measure: record mean red value.
Save ROI: Analyse → Tools → ROI manager. Click Add [t] → More → Save.
Close red image.
CIELAB a* image
4. In original image (Photo 1):
Split image into CIELAB colour space: Image → Color → RGB to CIELAB.
Scroll to second image (a*, Photo 4).
Drag saved ROI into ImageJ; ROI is placed into the a* image.
Analyse → Measure: record mean a* of lesional skin.
Choose a region with non-lesional skin (e.g. the neck), outline this region with ‘Freehand 
selections’.
Analyse → Measure: record mean a* of non-lesional skin.
5. Transfer all recorded values to a digital database for data analysis.
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RESULTS
Clinical scores
Fig. 1 presents the clinical scores. At baseline, 71% of patients had an erythema score 
of 3 or 4, decreasing to 33% at week 6, 10% at week 16, and 0% at week 28. Only 10% of 
patients reached an erythema score of 0 at week 28, compared to 0% at baseline.
Figure 1. Clinical erythema scores of the rosacea patients at week 0, 6, 16 (during treatment), 
and 28 (follow-up).
R/G ratio and a*
Surprisingly, we found no significant changes in R/G ratios during the study (Fig. 2). A 
significant decrease in median lesional a* was measured from baseline (24.97, range 
19.94-32.95) to week 16 (20.98, range 18.12-34.92; P = 0.005) and week 28 (20.68, range 
15.17-29.46; P < 0.001). No significant differences in non-lesional a* values were seen 
during the study, see Fig. 3A. The a* was significantly higher in lesional skin compared 
to non-lesional skin at all time points (P < 0.001). ∆a* also significantly decreased from 
baseline (12.23, range 5.52-19.56) to week 16 (9.18, range 1.61-15.40; P = 0.001) and 
week 28 (7.97, range 3.17-16.13; P = 0.002), see Fig. 3B.
Figure 2. Red/green ratios of lesional skin in rosacea patients per visit. The green values were 
assessed using a green sticker attached to the cheek. The black lines indicate the median value; 
the white dots indicate individual values.
3
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Figure 3. A, a* values of lesional and non-lesional facial skin in rosacea patients per visit. B, ∆a* 
values (lesional skin minus non-lesional skin) per visit. The black lines indicate the median value. 
* 0.01 ≥ P <0.05, ** 0.001 ≥ P <0.01, *** P < 0.001.
Correlation of quantified vs. clinical erythema values
A weak correlation was found between clinical erythema scores and lesional a* 
(Rs = 0.37, P < 0.001; Fig. 4A), and between clinical erythema scores and ∆a* (Rs = 0.30, 
P = 0.007; Fig. 4B). Despite this, a clear trend towards higher a* and ∆a* for higher 
clinical scores was visible.
Figure 4. Spearman correlation analysis of clinical erythema scores vs. quantified erythema 
values. Data of all visits were merged. A, Clinical scores vs. lesional a* values. B, Clinical scores 
vs. ∆a* values (= lesional skin minus non-lesional skin).
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Interobserver concordance
Interobserver correlation was high. No significant differences in a* were found between 
the two researchers (Fig. 5A), and linear relationship was strong (R2 = 0.82, P < 0.001; 
Fig. 5B).
Figure 5. Interobserver variation of a* at week 0 and 28. A, Lesional and non-lesional a* values 
of both observers are displayed separately in a violin plot (median, interquartile range, upper 
and lower adjacent values; density plot width corresponds to frequency). B, a* of lesional and 
non-lesional skin of both observers are merged for the linear regression analysis.
DISCUSSION
In this study, we evaluated ImageJ, a simple image-based software tool, for the 
quantification and objective monitoring of facial erythema in rosacea during treatment, 
and we compared these values to clinical scores. Lesional a* and ∆a* decreased 
significantly during treatment, corresponding to a reduction in clinical erythema. The 
interobserver concordance of a* was high. R/G ratios did not change during the study 
and seem unsuitable to monitor redness. Our method is rapid, simple, objective and 
reproducible; the photographs allow retrospective analysis, evaluation of large and 
small lesions, and discrimination of subtle redness differences. We recommend using 
lesional a* to monitor erythema in daily clinical practice.
Visual erythema assessment, which is currently frequently applied in daily practice 
for redness monitoring in rosacea, has some important drawbacks. First, visual 
examination of skin colour is poor at quantifying subtle differences of erythema.11 
Namely, colour is a subjective and nonlinear sensory perception, because ocular 
sensitivity to visible light depends on wavelength and shows intraindividual variation.24 
Furthermore, skin colour is a mixture of “redness” from cutaneous blood flow, and 
“tanning” derived from epidermal melanin, imposing challenges in isolating these 
components by visual inspection only.8 So, visual erythema scoring is a subjective 
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and quite unreliable method in therapeutic monitoring, and its robustness, also by 
experienced dermatologists, can therefore be questioned.5
Various methods to objectify erythema have already been tested in dermatological 
research.25 These studies showed that quantified erythema values correlate well with 
clinical scores, both in rosacea,11-15,17,18 and in other inflammatory skin diseases.26,27 
Despite their promising value, none of these proposed methods have so far been 
implemented in daily clinical practice. We hypothesize that this is because they are 
too complex, expensive, or time-consuming to use. In this study, we evaluated a very 
simple method for erythema monitoring in rosacea using ImageJ, which is easy to use, 
freely available, and widely accepted for image analysis.28 Interobserver correlation is 
high, making our results reproducible; no extensive training is needed, so calculations 
can be easily performed by clinicians who are unexperienced with image software. 
Moreover, ImageJ allows temporal monitoring of exactly the same skin location due 
to ROI saving options. The ROI can be easily adjusted for analysis of both small as 
well as large skin areas to obtain distributions maps, only requiring sufficient image 
resolution.8 This is a great advantage over spectrophotometric measurements which 
are point measurements, also prohibiting use in small skin locations (e.g., the nose).22 
In this study, we chose a circular ROI with clearly visible facial erythema, serving as 
a representative piece of lesional skin. Moreover, this is a non-contact method, so it 
does not change skin colour due to capillary construction and consecutive blanching 
of the skin.8,9,22 In addition to avoiding pressure to the skin, there is no need to apply 
an instrument to the lesional skin, having hygienic disadvantages.9
In this study, both RGB and CIELAB colour space were used to calculate redness. 
RGB indicates how a colour of an object “appears”, corresponding to the three types 
of colour sensors (cones) in the human eye.9 Using RGB, no differences in R/G ratio 
were measured, corresponding to earlier work focussing on rosacea severity.12 An 
explanation for this could be that RGB values are not only influenced by colour but 
also by brightness, which probably varied slightly between photographs. With CIELAB 
colour space, one does not encounter this problem, as brightness is separated from 
the a* -axis of the colour space. CIELAB provides the perception of colour to a human 
observer, and closely approximates and linearly correlates with the response of the 
eye.6,9,20,22 Despite the relatively low Rs, a clear relationship between lesional a* values 
and clinical scores was seen. The weak correlation may be caused by the subjectivity 
of the determined clinical scores. As there is no noninvasive golden standard tool to 
provide the “real” erythema value, there was no other suitable noninvasive technique 
to compare all our results to.15
It is important to take into account that a* represents erythema of both physiologic 
and pathologic cause,12 as it correlates with haemoglobin, skin blood flow and 
vascularization.8,15,22,29-31 However, the correlation of a* with haemoglobin is almost 
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linear, and independent of the amount of melanin.10 Furthermore, erythema values can 
be influenced by various individual -and environmental related variables such as age, 
medication, caffeine intake, orthostatic effects, physical activity, regional and seasonal 
variation, ambient temperature and humidity rate, and lighting inconsistencies.9,10,20,30 
In this study, photographs were taken under standardized conditions, four time 
points were included per patient, and a non-lesional site was measured as an internal 
control. We deliberately chose not to correct for other possible influencing variables, 
because this limits clinical application immensely; still, the quantified a* and ∆a* 
values showed a clear correlating trend with clinical scores, and both parameters 
decreased significantly during treatment with ivermectin. This is probably caused by 
a reduction in inflammation, as topical ivermectin has moderate-to-high certainty 
evidence for reducing papules and pustules in rosacea.21 However, even after 16 weeks 
of treatment, lesional erythema values remained higher than non-lesional values, 
suggesting that persisting erythema is a partly non-inflammatory feature (e.g. due to 
telangiectasias).
Our method appears to be rapid, and can in our opinion compete with clinical 
assessment, which is highly recommended for application in clinical practice. Moreover, 
retrospective analysis of images is possible, preventing the use of extra time in the 
consultation room. It could possibly be expanded to quantify erythema in a wide range 
of inflammatory dermatoses, such as rosacea, atopic dermatitis and psoriasis. We 
suggest to use only a* values, and not ∆a*, because correlations of both parameters 
with clinical scores are comparable, but a* determination is faster than ∆a*. We 
recommend applying standardized, consistent, photography conditions in a studio 
setting.
CONCLUSION
The tested image-based software tool is a simple, free, rapid, and reproducible method 
to objectify and monitor erythema in rosacea patients during treatment. The only 
two requirements necessary for erythema analysis are: (a) ImageJ software, able to 
convert RGB images to CIELAB colour space and to quantify colour intensity (a*) of a 
selected ROI; (b) clinical photographs, taken under standardized conditions in a studio. 
The photographs allow retrospective analysis, evaluation of large and small lesions, 
and discrimination of subtle redness differences. We recommend using lesional a* in 
follow-up of erythema in inflammatory diseases in daily clinical practice (Table 3). We 
believe that this method is easily applicable for clinicians, and in the future, ideally 
would replace determination of subjective clinical scoring.
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Table 3. Step-by-step guideline for erythema quantification using ImageJ, recommended for daily 
clinical practice.
1. Drag original JPG photograph in ImageJ.
2. Split image into CIELAB colour space: Image → Color → RGB to CIELAB.
3. Scroll to second image (a*).
 - For first visit:
 Choose a region of interest (ROI) including lesional skin. Outline ROI with ‘Freehand selections’. 
Make sure
 to avoid any skin colour inconsistency due to pen lines, hair, tattoos, jewellery etc. inside ROI.
 Analyse → Measure: record mean a* of lesional skin.
 Save ROI: Analyse → Tools → ROI manager. Click Add [t] → More → Save.
 - For follow-up visits:
 Drag saved ROI into ImageJ; ROI is placed into the a* image.
 Analyse → Measure: record mean a* of lesional skin.
4. Transfer all recorded values to a digital database for data analysis.
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Rosacea is a chronic inflammatory skin disease of unknown etiology. We noticed 
a series of patients who were diagnosed with rosacea as well as obstructive sleep 
apnea syndrome (OSAS), for which they used a continuous positive airway pressure 
(CPAP) mask. This case series aims to give insight in the possible relationship between 
rosacea and the use of a CPAP mask for OSAS. We present five patients with OSAS who 
developed or worsened rosacea symptoms after use of a CPAP mask covering nose 
and mouth. Two patients showed centrofacial symptoms consistent with the shape of 
the CPAP mask; three patients had nasal cutaneous symptoms. It is postulated that 
the occlusive effect of the CPAP mask, increasing skin humidity and temperature, can 
induce primary symptoms in patients with an underlying sensibility for rosacea. This 
could have implications for choice of CPAP mask type and topical therapeutic options 
for rosacea.
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INTRODUCTION
Rosacea is a common chronic inflammatory skin disease presenting with erythema, 
papules, pustules and telangiectasias of predominantly the cheeks, forehead, chin 
and nose.1,2 Four rosacea subtypes are described; erythematotelangiectatic rosacea 
(ETR), papulopustular rosacea (PPR), phymatous rosacea, and ocular rosacea. The 
exact pathophysiology of rosacea remains unknown; many factors seem to play a role 
in disease development.3 In addition, it is associated with various chronic systemic 
diseases, like gastroesophageal reflux disease, and hypertension.4 We noticed multiple 
rosacea patients at our outpatient clinic with concurrent obstructive sleep apnea 
syndrome (OSAS) using a continuous positive airway pressure (CPAP) mask. In OSAS, 
the upper airways collapse repetitively during sleep, causing hypoxia, sleep disruption, 
and daily fatigue.5 A CPAP mask serves as a pneumatic stabilizer in moderate to severe 
OSAS. Here, we report five patients with rosacea and OSAS with use of a CPAP mask. 
We propose mechanisms to explain a possible causality between these two entities.
CASE REPORT
Case 1
A 60-year-old female with OSAS, obesity (body mass index, 36.8 kg/m2) and 
hypertension (for which she was prescribed a thiazide diuretic), experienced sunlight-
aggravated periodical facial sensations of burning, tightness, itching, pain, erythema, 
pustules and periorbital edema since 2010. She also started full-face CPAP ventilation 
(covering nose and mouth) every night in 2010. Clinical examination in 2016 revealed 
perioral erythematous papules consistent with the shape of her CPAP mask, and 
excoriated papules on the cheeks and forehead. Histology showed chronical focal 
active perivascular and perifollicular infiltrates without signs of contact dermatitis; 
consistent with rosacea and/or folliculitis. Based on the clinical picture, the diagnosis 
PPR was made. Previous treatments included topical metronidazole, azelaic acid and 
ivermectin, and oral tetracyclines, all giving short-term improvement of skin symptoms. 
She stated that her facial symptoms started after initial use of the mask, with symptom 
deterioration after prolonged usage. Topical metronidazole application in the evening 
was difficult because it caused displacement of the CPAP mask and consequently 
air leakage. After discontinuing CPAP ventilation in 2017 due to the disappearance 
of apnea complaints caused by substantial weight reduction, symptoms of rosacea 
improved drastically. Topical ivermectin monotherapy was provided since then.
Case 2
A 61-year-old female with mild OSAS suffered from mild heat-aggravated ETR and 
PPR since the age of 30. This patient was referred in 2015 because of development of 
an elevated spot on the right nasal ala. Also in 2015, this patient starting using a full-
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face CPAP mask every other night. Clinical examination revealed a mildly edematous 
right nasal ala, and mild erythema and telangiectasias on cheeks and forehead. No 
papules, pustules or signs of rhinophyma were present. The nasal edema was linked 
to active rosacea (morbus Morbihan) and expanded to both alae during follow-up in 
2016. Treatment with topical metronidazole and azelaic acid and oral tetracyclines were 
non-efficacious; manual lymphatic drainage is currently being considered. Nowadays, 
this patient is still using the full-face CPAP mask. (Intra)nasal devices were tried but 
not successful (less effective and painful).
Case 3
A 74-year-old-male with mild-severe OSAS, hypertension and coronary heart disease 
(for which he was prescribed a statin, angiotensin-converting enzyme (ACE)-inhibitor, 
thiazide diuretic and a beta-blocker), started using a full-face CPAP mask in 2012. This 
patient suffered from recurrent nasal inflammation since multiple years with periodical 
nasal thickening, erythema, pain, and outflow of pus. Symptoms aggravated in 2017. 
Physical examination in 2018 revealed prominent nasal follicle openings, sebum 
gland hypertrophy and open comedones, consistent with rhinophyma, together with 
multiple telangiectasias on the cheeks and forehead. Oral doxycyclin was prescribed, 
followed by surgical dermabrasion of the nasal skin one month later. This regimen 
resulted in decrease of nasal pustules and erythema. Metronidazole maintenance 
therapy was provided one month after surgery. In the same period, CPAP therapy was 
discontinued due to air leakage and replaced by a mandibular reposition device. The 
patient could not clearly indicate whether the change of device influenced rhinophyma 
symptoms.
Case 4
A 59-year-old male with OSAS and hypercholesterolemia (for which no therapy was 
used) experienced a sunlight-aggravated fatty skin of the nose for approximately 20 
years. He used a selective serotonin-reuptake inhibitor for depression. He started 
wearing a full-face CPAP mask every night in 2015. Since 2017, small bumps on the 
nose, roughening of nasal skin and periodical pustules were noticed. Previous topical 
therapies (corticosteroids, metronidazole) were ineffective. Clinical examination in 2018 
revealed diffuse nasal fatty erythema, telangiectasias, pustules and fibrosis, and mild 
diffuse erythema and yellowish desquamation at the nasolabial folds and eyebrows. 
Patient’s rhinophyma with concurrent seborrheic dermatitis were treated with topical 
ivermectin and ketoconazole and oral doxycyclin, resulting in improvement of skin 
symptoms.
Case 5
A 48-year-old male with OSAS, obesity, hypertension and diabetes mellitus type 2 
(for which he used blood glucose lowering drugs, and a statin, ACE-inhibitor, thiazide 
diuretic, calcium antagonist, beta-blocker, and low-dose acetylic acid) started using 
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a full-face CPAP mask in 2015. In the same period, symptoms of recurrent pustules, 
nasal thickening, and dermal inflammation of the perioral region and nose appeared. 
Clinical examination in 2017 revealed erythema, papules and pustules between the 
eyebrows, on the nose and in the nasolabial fold; moreover, nasal fibrosis was present. 
Aforementioned skin symptoms were consistent with the shape of the CPAP mask (Fig. 
1). The clinical diagnosis PPR with rhinophyma was made. Initial treatment with topical 
metronidazole was ineffective; oral tetracyclines reduced skin inflammation thereafter. 
As nasal fibrosis remained, surgical dermabrasion of nasal skin was performed. He 
suggested that his skin symptoms were caused by inadequate cleaning of his CPAP 
mask; nowadays, he cleans his mask more frequently. Moreover, he is actively trying 
to lose weight.
Figure 1. Patient with rhinophyma and papulopustular rosacea. Skin symptoms were consistent 
with the shape of the CPAP mask. Informed consent was obtained from the patient for publica-
tion of the photographic materials.
3
Voorbereid document - Jade.indd   159 01-05-2021   10:17
160
Chapter 3.4
A summary of the cases is presented in Table 1.
Table 1. Summary of reported cases of rosacea and CPAP mask for OSAS.
Case Age/sex Rosacea type (since) Mask type 
(since)
Comments
1 60/female PPR (2010) Full-face (2010)* Stopped using CPAP in 2017,
rosacea improved since then




Mild ETR and PPR since 90’s
3 74/male Rhinophyma, mild 
(2018)
Full-face (2012) Mild nasal symptoms for several 









Fatty nasal skin for 20 years
Skin symptoms consistent
with shape of CPAP mask
* Covering nose and mouth. CPAP, continuous positive airway pressure. OSAS, obstructive sleep apnea 
syndrome. PPR, papulopustular rosacea. ETR, erythematoteleangiectatic rosacea
DISCUSSION
We presented five patients with development or worsening of rosacea after use of full-
face CPAP masks covering nose and mouth for OSAS. Two patients were diagnosed with 
PPR, one with ETR with morbus Morbihan and three patients with rhinophyma. Three 
patients had nasal skin symptoms and two patients showed centrofacial symptoms 
consistent with the shape of the CPAP mask. Here, several hypotheses are proposed 
to explain the surprising similarities between our cases.
First, temperature may play a role; a significant higher rosacea frequency was found in 
females exposed to tandoor heat.6 Possibly, full-face CPAP masks cause a warm facial 
environment, inducing heat-specific transient receptor potential (TRP) receptors on 
keratinocytes, resulting in inflammation and vasodilatation.1,3 Also Demodex mites, part 
of normal facial skin flora, may be involved in this process, as they seem to play a role 
in the development of rosacea.3 Previous work showed increased immune-stimulatory 
protein production by Demodex-containing bacteria at higher temperatures.7
Secondly, occlusion could be a factor. A CPAP device is equipped with a humidifier 
pumping water into the mask to reduce dry mouth and nasal congestion. This water 
may cause a humid, occlusive layer onto facial skin. This effect can be enhanced 
by application of topical therapies or bad mask hygiene, resulting in sebum gland 
obstruction and inducing primary symptoms of an underlying sensibility for rosacea. 
We therefore advice to apply topical therapies as far as possible before putting on the 
mask. Furthermore, we recommend patients to follow the general cleaning guidelines 
for the CPAP apparatus.
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Lastly, comorbidities may play a role. OSAS is associated with metabolic syndrome, 
and diabetes and hypertension are frequent comorbitities.8,9 In OSAS patients with 
those comorbidities, changed cortisole levels and inflammatory mediators have 
been found that could declare an altered sensitivity for general inflammation.10,11 
Interestingly, rosacea is also associated with cardiovascular risk factors and metabolic 
syndrome.4,12,13 In our cases, four of five patients had cardiovascular and/or metabolic 
comorbidities. Possibly, those comorbidities are an important link between CPAP use 
for OSAS and rosacea.
It is important to note that other co-factors could influence rosacea symptoms. Due 
to the retrospective character and limited amount of subjects of this report, we did 
not study those factors in more detail. First, various food components like pepper, 
alcohol and hot beverages can aggravate rosacea by upregulating TRP channels.1,3,14 
Dietary factors did not seem to be of influence in our patients, as skin symptoms 
diminished after removal of the CPAP mask. Second, photosensitizing medication, 
e.g. chlorthalidone and metoprolol, could increase rosacea severity. Lastly, contact 
allergies coexist in rosacea,15 but no clinical/histological signs of contact dermatitis 
were present in our patients.
In conclusion, we reported five patients with development or worsening of rosacea 
symptoms after use of a full-face CPAP mask covering nose and mouth for OSAS. We 
propose an occlusive effect of the CPAP mask on the skin, increasing skin humidity and 
temperature, which induces primary symptoms of an underlying sensibility for rosacea. 
In addition, OSAS and its cardiovascular/metabolic comorbidities could play a role in 
the development of rosacea symptoms. In future, more attention should be paid to 
patients who develop rosacea when using CPAP masks. This could have implications 
for choice of CPAP mask type and topical therapeutic treatment for rosacea.
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Use of beta-blockers for rosacea associated 
facial erythema and flushing: a systematic
review and update on proposed
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Flushing and erythema are frequent skin symptoms in rosacea. Because their adequate 
treatment remains a clinical challenge, new treatment options are explored, such as 
oral β-blockers.
Objective
To evaluate the efficacy of oral β-blockers for rosacea-associated facial flushing and 
erythema.
Methods
PubMed, Embase, Web of Science, and Cochrane Library were systematically searched, 
including studies providing original data on the efficacy of oral β-blockers in rosacea 
patients with facial flushing and/or persistent erythema. Risk of bias was assessed 
using the Cochrane Risk of Bias tool, Newcastle-Ottawa scale, and Quality in Prognosis 
Studies tool.
Results
Nine studies evaluating the use of carvedilol, propranolol, nadolol, and β-blockers in 
general were included. Articles studying carvedilol and propranolol showed a large 
reduction of erythema and flushing during treatment with a rapid onset of symptom 
control. Bradycardia and hypotension were the most commonly described adverse 
events.
Limitations
Most studies had a retrospective design with a small sample size, and outcome 
measurement was often subjective.
Conclusion
Oral β-blockers could be an effective treatment option for rosacea patients with 
facial erythema and flushing that does not respond to conventional therapy. Larger 
prospective trials with objective outcome assessment are needed to validate the 
promising results of these studies.
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INTRODUCTION
Flushing and persistent erythema are common rosacea symptoms.1,2 In contrast to 
effective treatment options targeting inflammation in rosacea, diminishing erythema 
and flushing remains a clinical challenge.3,4 The etiology of increased blood flow in 
rosacea is complex and probably multifactorial; both vessel dilation and neuronal, 
inflammatory, and hormonal pathways, which can be enhanced by various external 
triggers, seem to be involved.5-7 The only approved treatments for facial erythema 
in rosacea are topical brimonidine and oxymetazoline, two selective α-adrenergic 
receptor agonists.8-10 Although effective in some cases, poor response and rebound 
erythema are common, especially for brimonidine.10-15 Their vasomotor target is, 
however, interesting, resulting in local vasoconstriction. Because skin appearance 
has a significant impact on quality of life, the importance of new approaches for facial 
erythema and flushing has become clear.16-18
A possible therapeutic option not yet approved for persistent erythema and flushing 
is treatment with oral β-blockers, which antagonize the effects of sympathetic nerve 
stimulation and circulating endogenous catecholamines at adrenoreceptors.19,20 Three 
types of adrenoreceptors exist; β1-receptors are mainly located in the heart,
21 β2-
receptors in the lungs, gastrointestinal tract, blood vessels, and skin (keratinocytes, 
fibroblasts),22-25 and α1-receptors are, among other locations, found in the smooth 
muscles of cutaneous blood vessels. In rosacea, β-blockers are believed to reduce 
erythema by blocking β2-adrenergic receptors on smooth muscles of cutaneous 
arterial blood vessels, causing vasoconstriction.26 Moreover, they may reduce anxiety 
and tachycardia, which can exacerbate flushing reactions.27-30
The aim of this systematic review was to elucidate the efficacy of oral β-blockers for 
flushing and persistent facial erythema in rosacea and to provide recommendations 
for clinical practice.
MATERIALS AND METHODS
The study protocol was registered in PROSPERO (identification 159025).31 A systematic 
literature search following the Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA) guidelines32 was conducted in PubMed, Embase, Cochrane 
Library, and Web of Science. Search terms were rosacea, flushing, facial erythema, and 
beta-blockers, along with all possible synonyms. Oral β-blocker types were extracted 
from a recent Cochrane review33 and by exploring their Medical Subject Heading 
terms. Search strategy details can be found in Table S1 (Supplementary Materials). 
We included studies conducted in adults with cutaneous facial rosacea that provided 
original data on use of oral β-blockers for rosacea-associated flushing and/or erythema 
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(Table S2, Supplementary Materials). Physical modalities such as laser therapy also act 
on the vascular component but were beyond the scope of this article.3,34
All databases were searched to include published studies from date of inception 
until November 20, 2019. Titles and abstracts were screened for relevance by two 
independent reviewers ( JGML and JIO). Next, full texts were critically assessed for 
eligibility by the same reviewers. Missing full texts were requested via the Radboud 
University Medical Library. In both phases, differences between the reviewers 
regarding inclusion were resolved by discussion. Excluded were articles involving 
patients younger than 16 years; ocular, extrafacial, or drug-induced rosacea; drug-
induced flushing; in vitro and animal studies; studies in languages other than English, 
German or Dutch; meta-analyses, (systematic) reviews, and abstracts of congresses, or 
those with unavailable full texts. The reference lists of included articles were checked 
for relevant articles not identified by the initial search.
Extracted study characteristics included study design; number of participants; 
rosacea symptoms; β-blocker type, dose, and treatment duration; erythema/flushing 
assessment method; study findings; and adverse events. A narrative synthesis was 
conducted for each β-blocker separately. Risk of bias was assessed by two reviewers 
( JGML and JIO), with disagreements resolved by discussion. The Cochrane Risk of Bias 
tool was used for assessment of risk of bias in randomized controlled trials (RCTs), 
with studies graded as having low, high, or unclear risk of bias.35 For case-control 
studies, the Newcastle-Ottawa Scale was used.36 For cohort studies without a control 
group (including case reports and case series), the Quality in Prognosis Studies tool 
was used.37 For the Quality in Prognosis Studies, the overall risk of bias for each of 
the studies was judged as (1) low, if there were a low risk of bias in all key domains; (2) 
unclear, if there was an unclear risk of bias for one or more key domains; and (3) high, 
if there was a high risk of bias for one or more key domains.
RESULTS
In total, 1941 articles were identified (Fig. 1). After duplicate removal, 1544 articles 
were screened, resulting in inclusion of 25 abstracts eligible for full-text screening. 
Finally, nine articles were included in this systematic review. Investigated β-blockers 
were carvedilol (n = 4),26,38-40 propranolol (n = 3),29,41,42 nadolol (n = 1),30 and β-blockers 
in general (n = 1).43 Among the included articles were 1 RCT, 1 cohort study, 1 case-
control study, 3 case reports, and 3 case series. In the following sections and in Tables 
1 and 2, the β-blockers included in this review are presented separately.
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Figure 1. Flow chart: article selection process.
Nadolol
Nadolol is a nonselective β-blocker, blocking both β1 and β2-adrenergic receptors. Its 
use was described in 1 RCT.30
Fifteen patients with rosacea with erythema and flushing received nadolol 40 mg once 
daily or twice daily, or placebo, for 53 days. During this period, flushing challenges 
using warm water, ethanol, and nicotinic acid were performed. The intensity of flushing 
reactions was measured as degree of skin perfusion using laser Doppler velocimetry. 
No statistically significant differences in skin perfusion index were seen between 
nadolol and placebo. A modest to significant subjective improvement in number of 
occurrences, duration, and intensity of flushing with nadolol was found in 60% of 
patients; however, slight to definite worsening of flushing with nadolol was seen in 
13% of patients as well.
Carvedilol
Carvedilol is a nonselective β-blocker with additional weak α1-blocking activity. Four 
publications describing use of carvedilol in rosacea were identified.26,38-40
3
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In a retrospective case study, five patients with moderate/severe rosacea-associated 
flushing or persistent erythema were treated with carvedilol titrated up to 12.5 mg 
twice daily for 6 months or longer.39 All patients observed a reduction in facial erythema 
after 2 to 7 days from the start of treatment, and clinical erythema scores decreased 
in all patients at 6 months of treatment or longer. Erythema and facial flushing were 
still provoked by known triggers but to a much lower degree.
In another case series, carvedilol (3.125-6.25 mg, 2 or 3 times daily) was added to the 
regular medication (doxycycline, oral antihistamines/corticosteroids) of 11 patients 
with persistent erythema and facial flushing, and the dose was gradually titrated up 
to 31.25 mg/day.26 This resulted in significant clinical erythema improvement within 
three weeks (range, 3-21 days) from the start of carvedilol, together with reduced 
cheek temperature and a large reduction in patient-assessed symptoms. Moreover, 
carvedilol allowed concurrent medications to be decreased in dosage or stopped.
Additionally, carvedilol usage was described in two case reports.38,40 Clinical and 
patient-assessed improvement in erythema and flushing were seen within two 
weeks carvedilol treatment of 6.25 mg 2 or 3 times daily, with increased improvement 
thereafter using maintenance therapy of 6.25 mg 1 to 3 times daily for 23 months. 
Moreover, only 6.25 mg daily was needed in the summer.38 Lee et al40 showed 
clinical reduction of erythema and flushing after the start of carvedilol (6.25-12.5 mg 
thrice daily) together with brimonidine gel. Dermatoscopy showed polygonal vessel 
disappearance and blood vessel vasoconstriction after several months. Carvedilol was 
only needed intermittently afterwards during summer.
Propranolol
Propranolol is a traditional nonselective β-blocker; three studies focused on its use 
in rosacea.29,41,42
In a retrospective cohort study, nine patients with facial erythema and flushing received 
propranolol 10 mg 3 times daily, with doses increased as tolerated until symptoms 
improved, which appeared to be 20 to 40 mg 2 or 3 times daily.29 Eight patients 
reported diminished symptoms and fewer flushing episodes while taking propranolol 
(duration of onset not described); one patient did not experience improvement but 
received only 100 mg thrice daily during one month without side effects and elected 
to discontinue propranolol thereafter.
Park et al42 studied treatment with propranolol 10 mg thrice daily during 12 weeks in 
22 patients with papulopustular and erythematotelangiectatic rosacea, and compared 
this with doxycycline (n = 15) and doxycycline and propranolol combination therapy 
(n = 26). The propranolol group showed a significant faster and larger reduction in 
clinical flushing scores compared to the other groups.
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Finally, erythema and flushing improvement was observed in one patient already after 
one week of treatment with propranolol 40 mg once daily combined with minocycline 
and tranexamic acid.41
β-blockers in general
One study evaluated the association of β-blockers and the risk of developing rosacea 
by performing a case-control study with 53.927 patients with rosacea and 53.927 
control individuals.43 The paper does not describe which β-blocker types were 
included. A marginal decreased risk (odds ratio [OR] 0.91; 95% confidence interval 
[CI], 0.86-0.95) for current and long-term users of all β-blockers (OR, 0.89; 95% CI, 
0.82-0.96) was found. Sensitivity analysis of the three most prescribed β-blockers in 
the United Kingdom (propranolol, atenolol, and bisoprolol) showed that the risk was 
slightly decreased for current users of atenolol (OR, 0.83; 95% CI, 0.74-0.94), and for 
current long-term users of bisoprolol (OR, 0.76; 95% CI, 0.60-0.96). Unexpectedly, no 
decreased risk for developing rosacea among propranolol users was found.
Adverse events
Seven included studies reported about adverse event occurrence (Table 2).26,29,30,38,39,41,42 
For nadolol, decreased heart rate and blood pressure was seen in 100% and 93% 
of patients, respectively.30 For carvedilol, treatment was discontinued in 9.1% of 
patients (1 in 11) due to hypotension,26 and dosage was adjusted in 20% of patients 
(1 in 5) because of vertigo and nausea.39 Additionally, feeling of weakness (1 in 5)39 
and decreased blood pressure (1 in 11)38 were noticed during carvedilol treatment. 
For propranolol, treatment was discontinued in 22% of patients (2 in 9) because of 
dizziness, bradycardia, and balance loss sensation.29 Other reported, acceptable, side 
effects were decreased migraine headache severity (2 in 9), weight gain (1 in 9), fatigue 
(1 in 9), dyspepsia (1 in 22), and headache (1 in 22).29,42 The case report from Kwon et 
al41 reported no adverse events during treatment with propranolol.
Risk of bias
The number of patients of most studies was small, including multiple case series/case 
reports. Although the RCT was double-blinded, no information about the allocation 
sequence and blinding procedure was given (Fig. S1, Supplementary Materials). In 
the case-control study, results could be biased by the copresence of papules and 
pustules and not solely erythema and flushing. For cohort studies, which were mostly 
retrospective, the domains outcome measurement and study confounding carried the 
highest risk of bias (Fig. S2, Supplementary Materials). It was often not stated how 
and by whom the outcome measurements were determined. Moreover, potential 
confounders such as co-medication, rosacea type, cutaneous comorbidity, and 
rosacea-aggravating triggers were often insufficiently described or not taken into 
account.
3
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Table 2. Reported adverse events in rosacea patients treated with oral β-blockers for flushing and 
persistent facial erythema.
Treatment Reported adverse events
Nadolol Decreased heart rate (n = 15)30; decreased blood pressure (n = 14)30
Carvedilol Hypotension (n = 1)26; decreased blood pressure (n = 1)38; vertigo and nausea 
(n = 1)39; feeling of weakness (n = 1)39
Propranolol Dizziness (n = 2)29; decreased migraine headache severity (n = 2)29; dyspepsia 
(n = 1)42; headache (n = 1)42; bradycardia (n = 1)29; sensation of balance loss (n = 1)29; 
weight gain (n = 1)29; fatigue (n = 1)29
CONCLUSIONS
Diminishing erythema and flushing in rosacea is challenging, because it hardly responds 
to conventional anti-inflammatory treatment. Patients in the included studies often 
had an extensive history of ineffective topical, oral, and/or physical treatments. Most 
studies showed improved erythema and flushing after initiation of oral β-blockers. 
The evidence was highest for carvedilol and propranolol, two nonselective β-blockers. 
Unfortunately, only a small selection of available β-blocker types was examined.
The most common adverse effects of nonselective β-blockers are bradycardia, 
hypotension, bronchospasm, dizziness, somnolence, and fatigue.20,44 One should be 
aware that β-blockers may exacerbate asthma and psoriasis.45-47 Contraindications 
to β-blockers are congestive heart failure, cardiogenic shock, sinus bradycardia of 
less than 50 beats/minute, atrioventricular block, hyperactive airway disease, and 
Raynaud disease.19 It is important to monitor patients for adverse events, especially 
blood pressure and heart rate.38
Compared to other nonselective β-blockers, carvedilol and propranolol possibly have 
additional antioxidant and anti-inflammatory actions.26,40,48,49 This may be beneficial 
in rosacea treatment, because reactive oxygen species released by inflammatory 
cells may play a role in disease development.50-52 Carvedilol is usually well tolerated, 
even in elderly patients with heart failure.53 Additionally, it results in fewer adverse 
effects, such as hypotension and bradycardia, than traditional β-blockers, which may 
be a limiting factor in normotensive patients.38,54 Propranolol can cause additional 
diarrhoea, nausea, and sexual dysfunction in males,55 and it is recommended that it be 
started at a lower dosage in geriatric patients and those with renal or hepatic disease.20 
Nadolol offers the advantage of a once-daily dosage because of its long plasma half-life 
(14-24 hours).30 β-blockers dosages for reducing facial erythema are generally lower 
compared to the maintenance dose needed in hypertension (nadolol: 40-80 mg vs 
80-320 mg daily;30 carvedilol: 6.25-37.5 mg vs 25 mg daily;26,38-40 propranolol: 30-120 
mg vs 160-320 mg daily29,41,42). The efficacy of topical β-blockers such as timolol, being 
effective in various vascular dermatoses,20 has not yet been investigated in rosacea.
3
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Several studies have investigated other systemic medications antagonizing erythema 
and flushing in rosacea. Clonidine, an α2-adrenergic agonist, did not suppress erythema 
and flushing.56,57 Also, rilmenidine, a central hypotensive drug, did not improve facial 
flushing compared to placebo.58 Ondansetron, a serotonin antagonist, improved 
persistent erythema and flushing in two patients.59 Naloxone, an opioid receptor 
antagonist, reduced alcohol-induced flushing, but has many side effects.60 Otherwise, 
phentolamine, an α-adrenergic antagonist, even increased blood flow during exercise 
in frequent blushers.28 The aforementioned medications, therefore, seem largely 
dissatisfying until today.
The quality of included studies was relatively low, and interstudy outcome variability 
was large. It was not possible to perform a meta-analysis, because erythema and 
flushing were assessed using a wide spectrum of mostly subjective clinical and patient-
based scores, and method standardization was often missing. The evaluation of facial 
erythema by visual assessment alone lacks objectivity and precision, and it is prone 
to inter- and intra-observer variability.61-63 This makes comparison of individual study 
outcomes challenging. Simple, standardized, and objective erythema and flushing 
assessment, such as spectrophotometry and computer-aided image analysis, are 
advisable.64
To conclude, oral nonselective β-blockers could be an effective treatment option 
for rosacea patients with persistent facial erythema and flushing. Currently, most 
evidence is available for carvedilol and propranolol. Large, prospective, clinical trials 
are warranted to validate the data of these small studies. Researchers should further 
focus on the determination of the optimal dosage, treatment duration, and long-term 
therapeutic effects for adequate treatment of erythema and flushing in rosacea.
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SUPPLEMENTARY MATERIALS
Table S1. Search strategy.
Pubmed EMBASE
No limitations No limitations
(“Rosacea”[Mesh] OR rosacea*[tiab] OR “Flushing”[Mesh] 
OR flush*[tiab] OR ((face[tiab] OR facial[tiab]) AND 
(erythem*[tiab] OR redness[tiab]))) AND (“Adrenergic 
beta-Antagonists”[Mesh] OR “Adrenergic beta-
Antagonists” [Pharmacological Action] OR Acebutolol[tiab] 
OR adaprolol[tiab] OR adimolol[tiab] OR afurolol[tiab] OR 
Alprenolol[tiab] OR amosulalol[tiab] OR arotinolol[tiab] OR 
Atenolol[tiab] OR befunolol[tiab] OR bornaprolol[tiab] OR 
brefonalol[tiab] OR bucumolol[tiab] OR bunitrolol[tiab] OR 
Betaxolol[tiab] OR bevantolol[tiab] OR Bisoprolol[tiab] OR 
bopindolol[tiab] OR bromoacetylalprenololmenthane[tiab] 
OR bucindolol[tiab] OR bufetolol[tiab] OR bufuralol[tiab] 
OR Bunolol[tiab] OR Bupranolol[tiab] OR butofilolol[tiab] 
OR Butoxamine[tiab] OR chlortalidone cloranolol[tiab] 
OR cyanoiodopindolol[tiab] OR carazolol[tiab] OR 
carpindolol OR Carteolol[tiab] OR Carvedilol[tiab] 
OR Celiprolol[tiab] OR cyanopindolol[tiab] OR 
deacetylmetipranolol[tiab] OR dexpropranolol OR 
diacetolol[tiab] OR dichlorisoprenaline OR dilevalol[tiab] 
OR Dihydroalprenolol[tiab] OR diprafenone OR 
epanolol[tiab] OR ersentilide OR esmolol[tiab] OR 
exaprolol[tiab] OR falintolol[tiab] OR flusoxolol[tiab] 
OR flestolol[tiab] OR hydroxybenzylpinodolol[tiab] OR 
hydroxycarteolol[tiab] OR hydroxymetoprolol[tiab] 
OR iodocyanopindolol[tiab] OR iodopindolol[tiab] OR 
iprocrolol[tiab] OR isamoltane OR isoxaprolol[tiab] 
OR indenolol[tiab] OR levomoprolol[tiab] OR 
Iodocyanopindolol[tiab] OR Labetalol[tiab] OR 
landiolol[tiab] OR Levobunolol[tiab] OR medroxalol[tiab] 
OR mepindolol[tiab] OR methylthiopropranolol[tiab] OR 
moprolol[tiab] OR mercuderamide OR Metipranolol[tiab] 
OR Metoprolol[tiab] OR Nadolol[tiab] OR nevibolol[tiab] 
OR nipradilol[tiab] OR nifenalol[tiab] OR oberadilol OR 
Oxprenolol[tiab] OR pafenolol[tiab] OR pamatolol[tiab] 
OR primidolol[tiab] OR procinolol[tiab] OR pronetalol[tiab] 
OR proxodolol[tiab] OR Penbutolol[tiab] OR Pindolol[tiab] 
OR Practolol[tiab] OR prizidilol[tiab] OR Propranolol[tiab] 
OR ridazolol[tiab] OR salcardolol[tiab]OR Sotalol[tiab] 
OR soquinolol[tiab] OR spirendolol[tiab] OR tazolol OR 
talinolol[tiab] OR tienoxolol[tiab] OR tolamolol[tiab] OR 
toliprolol[tiab] OR tribendilol[tiab] OR tertatolol[tiab] 
OR tilisolol[tiab] OR Timolol[tiab] OR trasitensin OR 
tobanum[tiab] OR xibenolol[tiab] OR zoleprodolol 
OR beta-Antagonist*[tiab] OR beta-Adrenoceptor 
Antagonist*[tiab] OR beta-Blocker*[tiab] OR beta-
Adrenergic Receptor Blockader*[tiab] OR beta-Adrenergic 
Blocking Agent*[tiab] OR beta Adrenergic Blocker*[tiab] 
OR beta-Adrenergic Antagonist*[tiab] OR Adrenergic 
beta-Receptor Blockader*[tiab])
(rosacea/ OR flushing/ OR face erythema/ or (rosacea* OR 
flush* OR ((face OR facial) AND (erythem* OR redness))).
ti,ab,kw.) AND (beta adrenergic receptor blocking 
agent/ OR Acebutolol.ti,ab,kw. OR adaprolol.ti,ab,kw. OR 
adimolol.ti,ab,kw. OR afurolol.ti,ab,kw. OR Alprenolol.
ti,ab,kw. OR amosulalol.ti,ab,kw. OR arotinolol.ti,ab,kw. OR 
Atenolol.ti,ab,kw. OR befunolol.ti,ab,kw. OR bornaprolol.
ti,ab,kw. OR brefonalol.ti,ab,kw. OR bucumolol.ti,ab,kw. OR 
bunitrolol.ti,ab,kw. OR Betaxolol.ti,ab,kw. OR bevantolol.
ti,ab,kw. OR Bisoprolol.ti,ab,kw. OR bopindolol.ti,ab,kw. OR 
bromoacetylalprenololmenthane.ti,ab,kw. OR bucindolol.
ti,ab,kw. OR bufetolol.ti,ab,kw. OR bufuralol.ti,ab,kw. OR 
Bunolol.ti,ab,kw. OR Bupranolol.ti,ab,kw. OR butofilolol.
ti,ab,kw. OR Butoxamine.ti,ab,kw. OR chlortalidone 
cloranolol.ti,ab,kw. OR cyanoiodopindolol.ti,ab,kw. 
OR carazolol.ti,ab,kw. OR carpindolol OR Carteolol.
ti,ab,kw. OR Carvedilol.ti,ab,kw. OR Celiprolol.ti,ab,kw. 
OR cyanopindolol.ti,ab,kw. OR deacetylmetipranolol.
ti,ab,kw. OR dexpropranolol OR diacetolol.ti,ab,kw. 
OR dichlorisoprenaline OR dilevalol.ti,ab,kw. OR 
Dihydroalprenolol.ti,ab,kw. OR diprafenone OR epanolol.
ti,ab,kw. OR ersentilide OR esmolol.ti,ab,kw. OR exaprolol.
ti,ab,kw. OR falintolol.ti,ab,kw. OR flusoxolol.ti,ab,kw. OR 
flestolol.ti,ab,kw. OR hydroxybenzylpinodolol.ti,ab,kw. OR 
hydroxycarteolol.ti,ab,kw. OR hydroxymetoprolol.ti,ab,kw. 
OR iodocyanopindolol.ti,ab,kw. OR iodopindolol.ti,ab,kw. 
OR iprocrolol.ti,ab,kw. OR isamoltane OR isoxaprolol.
ti,ab,kw. OR indenolol.ti,ab,kw. OR levomoprolol.
ti,ab,kw. OR Iodocyanopindolol.ti,ab,kw. OR Labetalol.
ti,ab,kw. OR landiolol.ti,ab,kw. OR Levobunolol.ti,ab,kw. 
OR medroxalol.ti,ab,kw. OR mepindolol.ti,ab,kw. OR 
methylthiopropranolol.ti,ab,kw. OR moprolol.ti,ab,kw. OR 
mercuderamide OR Metipranolol.ti,ab,kw. OR Metoprolol.
ti,ab,kw. OR Nadolol.ti,ab,kw. OR nevibolol.ti,ab,kw. OR 
nipradilol.ti,ab,kw. OR nifenalol.ti,ab,kw. OR oberadilol OR 
Oxprenolol.ti,ab,kw. OR pafenolol.ti,ab,kw. OR pamatolol.
ti,ab,kw. OR primidolol.ti,ab,kw. OR procinolol.ti,ab,kw. OR 
pronetalol.ti,ab,kw. OR proxodolol.ti,ab,kw. OR Penbutolol.
ti,ab,kw. OR Pindolol.ti,ab,kw. OR Practolol.ti,ab,kw. OR 
prizidilol.ti,ab,kw. OR Propranolol.ti,ab,kw. OR ridazolol.
ti,ab,kw. OR salcardolol.ti,ab,kw.OR Sotalol.ti,ab,kw. OR 
soquinolol.ti,ab,kw. OR spirendolol.ti,ab,kw. OR tazolol 
OR talinolol.ti,ab,kw. OR tienoxolol.ti,ab,kw. OR tolamolol.
ti,ab,kw. OR toliprolol.ti,ab,kw. OR tribendilol.ti,ab,kw. OR 
tertatolol.ti,ab,kw. OR tilisolol.ti,ab,kw. OR Timolol.ti,ab,kw. 
OR trasitensin OR tobanum.ti,ab,kw. OR xibenolol.ti,ab,kw. 
OR zoleprodolol OR beta-Antagonist*.ti,ab,kw. OR beta-
Adrenoceptor Antagonist*.ti,ab,kw. OR beta-Blocker*.
ti,ab,kw. OR beta-Adrenergic Receptor Blockader*.
ti,ab,kw. OR beta-Adrenergic Blocking Agent*.ti,ab,kw. OR 
beta Adrenergic Blocker*.ti,ab,kw. OR beta-Adrenergic 
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Table S1. Continued. 
Cochrane Library Web of Science
No limitations No limitations
1. MeSH Rosacea
2. MeSH Flushing
3. (rosacea* OR flush* OR ((face OR facial) AND (erythem* 
OR redness))):ti,ab,kw
4. MeSH Adrenergic beta-Antagonists
5. (Acebutolol OR adaprolol OR adimolol OR afurolol OR 
Alprenolol OR amosulalol OR arotinolol OR Atenolol OR 
befunolol OR bornaprolol OR brefonalol OR bucumolol 
OR bunitrolol OR Betaxolol OR bevantolol OR Bisoprolol 
OR bopindolol OR bromoacetylalprenololmenthane 
OR bucindolol OR bufetolol OR bufuralol OR Bunolol 
OR Bupranolol OR butofilolol OR Butoxamine OR 
chlortalidone cloranolol OR cyanoiodopindolol OR 
carazolol OR carpindolol OR Carteolol OR Carvedilol OR 
Celiprolol OR cyanopindolol OR deacetylmetipranolol OR 
dexpropranolol OR diacetolol OR dichlorisoprenaline OR 
dilevalol OR Dihydroalprenolol OR diprafenone OR epanolol 
OR ersentilide OR esmolol OR exaprolol OR falintolol 
OR flusoxolol OR flestolol OR hydroxybenzylpinodolol 
OR hydroxycarteolol OR hydroxymetoprolol OR 
iodocyanopindolol OR iodopindolol OR iprocrolol OR 
isamoltane OR isoxaprolol OR indenolol OR levomoprolol 
OR Iodocyanopindolol OR Labetalol OR landiolol 
OR Levobunolol OR medroxalol OR mepindolol OR 
methylthiopropranolol OR moprolol OR mercuderamide 
OR Metipranolol OR Metoprolol OR Nadolol OR nevibolol 
OR nipradilol OR nifenalol OR oberadilol OR Oxprenolol 
OR pafenolol OR pamatolol OR primidolol OR procinolol 
OR pronetalol OR proxodolol OR Penbutolol OR Pindolol 
OR Practolol OR prizidilol OR Propranolol OR ridazolol OR 
salcardololOR Sotalol OR soquinolol OR spirendolol OR 
tazolol OR talinolol OR tienoxolol OR tolamolol OR toliprolol 
OR tribendilol OR tertatolol OR tilisolol OR Timolol OR 
trasitensin OR tobanum OR xibenolol OR zoleprodolol OR 
beta-Antagonist* OR beta-Adrenoceptor Antagonist* OR 
beta-Blocker* OR beta-Adrenergic Receptor Blockader* 
OR beta-Adrenergic Blocking Agent* OR beta Adrenergic 
Blocker* OR beta-Adrenergic Antagonist* OR Adrenergic 
beta-Receptor Blockader*):ti,ab,kw
6. (#1 OR #2 #3) AND (#4 OR #5)
(rosacea OR flush* OR (face OR facial) AND (erythem* OR 
redness)) AND (“adrenergic beta-Antagonist” OR Acebutolol 
OR adaprolol OR adimolol OR afurolol OR Alprenolol OR 
amosulalol OR arotinolol OR Atenolol OR befunolol OR 
bornaprolol OR brefonalol OR bucumolol OR bunitrolol OR 
Betaxolol OR bevantolol OR Bisoprolol OR bopindolol OR 
bromoacetylalprenololmenthane OR bucindolol OR bufetolol 
OR bufuralol OR Bunolol OR Bupranolol OR butofilolol OR 
Butoxamine OR chlortalidone cloranolol OR cyanoiodopindolol 
OR carazolol OR carpindolol OR Carteolol OR Carvedilol OR 
Celiprolol OR cyanopindolol OR deacetylmetipranolol OR 
dexpropranolol OR diacetolol OR dichlorisoprenaline OR 
dilevalol OR Dihydroalprenolol OR diprafenone OR epanolol OR 
ersentilide OR esmolol OR exaprolol OR falintolol OR flusoxolol 
OR flestolol OR hydroxybenzylpinodolol OR hydroxycarteolol 
OR hydroxymetoprolol OR iodocyanopindolol OR iodopindolol 
OR iprocrolol OR isamoltane OR isoxaprolol OR indenolol 
OR levomoprolol OR Iodocyanopindolol OR Labetalol OR 
landiolol OR Levobunolol OR medroxalol OR mepindolol OR 
methylthiopropranolol OR moprolol OR mercuderamide OR 
Metipranolol OR Metoprolol OR Nadolol OR nevibolol OR 
nipradilol OR nifenalol OR oberadilol OR Oxprenolol OR pafenolol 
OR pamatolol OR primidolol OR procinolol OR pronetalol OR 
proxodolol OR Penbutolol OR Pindolol OR Practolol OR prizidilol 
OR Propranolol OR ridazolol OR salcardololOR Sotalol OR 
soquinolol OR spirendolol OR tazolol OR talinolol OR tienoxolol 
OR tolamolol OR toliprolol OR tribendilol OR tertatolol OR 
tilisolol OR Timolol OR trasitensin OR tobanum OR xibenolol 
OR zoleprodolol OR beta-Antagonist* OR “beta-Adrenoceptor 
Antagonist*” OR beta-Blocker* OR “beta-Adrenergic Receptor 
Blockader*” OR “beta-Adrenergic Blocking Agent*” OR “beta 






Table S2. In –and exclusion criteria.
Inclusion criteria Exclusion criteria
 • Cutaneous rosacea with flushing and/or 
persistent facial erythema
 • Oral β-blockers
 • Adolescents and adults (≥ 16 years)
 • Randomized controlled trials, non-randomized 
controlled trials, cohort studies, case-control 
studies, case series, case reports
 • Ocular, extrafacial and drug-induced rosacea
 • Drug-induced flushing
 • Topical β-blockers (brimonidine)
 • Children (< 16 years)
 • In vitro and animal studies
 • Languages other than English, German or Dutch
 • Meta-analysis systematic reviews and reviews 
(no primary source)
 • Full-text not available
 • Abstracts of congresses
 • Duplicates
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Figure S1. Review author’s judgement about each risk of bias item for the included RCT (n=1) 
with the Cochrane Risk of Bias tool.
Figure S2A. Review author’s judgement about each risk of bias item for each included cohort 
study and case report/series (n = 7) with the Quality in Prognosis Studies tool.
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Figure S2B. Review author’s judgement about each risk of bias item presented as percentages 
across all included cohort studies and case reports/series (n = 7) with the Quality in Prognosis 
Studies tool.
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The aim of this thesis was to evaluate the value of novel and conventional noninvasive 
imaging and biophysical tools in healthy and inflamed skin in daily clinical practice, 
with emphasis on rosacea. Rosacea was chosen because it is localized at a visible and 
cosmetically important region (the face), it has variable signs and symptoms which 
makes objective clinical evaluation extra challenging, and it responds well to anti-
inflammatory treatment. In this final chapter the main findings of the studies described 
will be summarized and discussed on the basis of the following two main objectives:
1. To investigate the value of imaging and biophysical tools in healthy and impaired 
skin barrier function.
2. To investigate the value of imaging and biophysical methods in inflamed skin, with 
emphasis on rosacea.
Table 1 provides a summary of research questions, study designs, and assessed 
parameters per study included in this thesis.
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Chapter 4
Aim 1. To investigate the value of imaging and biophysical tools in healthy and 
impaired skin barrier function.
The normal human skin barrier prevents excessive water loss and dehydration of our 
body. The main barrier function of the skin is formed by the stratum corneum (SC). In case 
of a disrupted skin barrier, inflammation can occur due to production of pro-inflammatory 
cytokines and proliferation of keratinocytes. An impaired skin barrier function is seen in 
several chronic inflammatory skin disorders, such as ichthyosis vulgaris, atopic dermatitis, 
plaque psoriasis, and possibly also rosacea. Skin barrier function can be assessed 
by objective determination of transepidermal water loss (TEWL) and water content.
In chapter 2 we evaluated the value of novel and combined biophysical tools to 
assess normal and impaired skin barrier function. First, we investigated the Epsilon® 
to determine its use in the measurement of anatomical site variation of water content 
in the healthy skin (chapter 2.1). The Epsilon® is a novel device which measures water 
content with multiple electronic sensors. Using the Epsilon®, we found significant 
differences in water content in various anatomical regions: the cheek had the highest 
water content, followed by the forearm, abdomen, lower back, and mid-calf. We 
discovered that the Epsilon® consistently measures lower water content values 
compared to single sensor corneometers. The Epsilon® may be more accurate in 
measuring water content values in the stratum corneum compared to single sensor 
devices for three reasons. First, due to its multisensory character and small sensors, 
measurements are restricted to the ‘dry’ SC only. Second, it corrects for time-
dependent skin occlusion differences. Third, multiple simultaneous measurements 
can be averaged or used to get a hydration overview image of the SC (skin mapping). 
By accurately measuring water content values, it is possible to precisely determine the 
degree of skin barrier disruption in inflammatory skin diseases, which enables easy 
monitoring of treatment effects. Disadvantages of the Epsilon® are its start-up time 
(approximately 10 minutes) and the requirement of a wired connection to a laptop, 
limiting its portability. Therefore, rapid use in clinical practice is difficult.
In chapter 2.2 we focused on the feasibility of four different biophysical/imaging devices 
to assess the healthy skin barrier function before and 30 minutes after application of 
Lanette or petrolatum cream. Erythema was determined by spectrophotometry (i.e. 
quantitative measurement of the reflection of visible light as a function of wavelength), 
water content by the Epsilon®, transepidermal water loss (TEWL) by the Aquaflux 
device (a device with a probe that calculates water vapor flux due to diffusion), and 
epidermal thickness by reflectance confocal microscopy (RCM, a noninvasive imaging 
technique for in vivo visualization of the superficial skin layers with a resolution 
comparable to conventional histology). We found that SC thickness was significantly 
increased after application of both creams. Erythema, TEWL, and water content 
did not significantly change after cream application. Our multiparametric approach 
demonstrates a feasible way to quickly obtain multifaceted information about the skin 
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barrier function, which could not have been obtained by a single device only. In an ideal 
world, for reasons of convenience this multiparametric outcome would be produced 
by one single, small, and wireless device. Our multiparametric approach provides very 
detailed information about the status of the skin barrier function in inflammatory 
diseases, both before and during treatment, allowing individualized treatment options. 
Furthermore, it may enable better understanding of the individual pathophysiological 
processes that are be responsible for cutaneous damage and subsequent restoration. 
Some disadvantages of our multiparametric approach are the need for a spacious 
room (especially the RCM is quite bulky), and the separate protocols for each device.
In chapter 2.3 we determined the value of the GPSkin® (a novel, portable handheld 
device that measures water content and TEWL simultaneously) to assess impaired skin 
barrier function after tapestripping, which is a procedure to mechanically remove the 
SC using tapestrips. Moreover, we also investigated its usability for monitoring skin 
barrier function at the cheeks of rosacea patients before and during treatment in 
daily practice. We found a strong and linear correlation between water content/TEWL 
values of the new device (the GPSkin®) and the other devices (the Aquaflux® and 
Epsilon®), both before and after tapestripping. Water content was significantly lower 
at the cheeks of rosacea patients compared to controls, with a trend towards recovery 
during successful anti-inflammatory treatment. TEWL was comparable between 
patients and controls, and did not change during treatment. Compared to the other 
skin barrier tools, the GPSkin® is much more usable in clinical practice due to the small 
size, wireless character, and rapid mode of action. Moreover, in contrast to the other 
devices, water content and TEWL are measured at exactly the same location and time, 
preventing probe replacements compared to using two separate devices. The latter 
is essential for accurate temporal measurements at the face, because of large water 
content and TEWL differences within very small distances on the face due to various 
environmental influences such as sebum gland activity and cutaneous vasculature.
Main conclusions for aim 1:
 • The Epsilon® is able to measure significant differences in water content in various 
anatomical locations. Compared to conventional water content devices, Epsilon® 
results are likely more accurate.
 • A multiparametric approach using the Epsilon®, Aquaflux®, spectrophotometer 
and RCM, to measure both water content, TEWL, erythema, as well as epidermal 
thickness, offers a practical way to obtain multifaceted information about skin 
barrier function.
 • The GPSkin® is a very practical tool to determine TEWL and water content in an 
accurate, simple, and rapid manner, both in normal skin as well as in skin with 
impaired barrier. We were able to measure improvement of skin barrier function 
in rosacea during successful treatment in daily practice.
4
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Aim 2. To investigate the value of imaging and biophysical tools in inflamed 
skin, with emphasis on rosacea.
Rosacea is a chronic inflammatory facial skin disease of uncertain etiology, 
characterized by among others papules, pustules, erythema, telangiectasia, and 
flushing. It is an interesting inflammatory skin disease for investigation of noninvasive 
techniques, due to its facial localization (making invasive techniques less attractive), 
chronic character with exacerbations and remissions (allowing temporal monitoring), 
multifactorial pathophysiology, wide range of clinical symptoms, and good response 
to successful anti-inflammatory treatment. Its current diagnosis is largely based on 
clinical evaluation, which is subjective and prone to interobserver variation. This makes 
treatment effect evaluation and comparison of study outcomes challenging.
The purpose of chapter 3 was to investigate the value of novel and conventional 
imaging and biophysical tools in rosacea for use in daily clinical practice. In summary, 
we tried to correlate objective imaging and biophysical parameters with clinical 
symptoms. This could result in obtaining a more objective measurement of the current 
status of the (inflamed) skin.
Biophysical and imaging tools have already extensively been used in rosacea, but 
a clear overview was lacking. In chapter 3.1, we conducted a systematic review of 
available noninvasive objective skin measurement techniques for diagnosis, assessing 
severity and therapy monitoring of rosacea. An extensive literature search revealed 
78 eligible studies. Imaging techniques used were RCM, dermatoscopy, capillaroscopy, 
optical coherence tomography, computer-aided image analysis, infrared photography, 
and sonography. Assessed biophysical parameters were SC hydration, TEWL, sebum 
excretion, pH, erythema, skin blood flow, and skin temperature. Most of the included 
studies were cohort studies, followed by case-control studies, randomized controlled 
trials, case reports, and case series. Quality of included studies was regularly low due 
to high risk of various forms of bias, small sample sizes, large interstudy outcome 
variability, and often a lack of method standardization. Despite these limitations, 
several tools showed additional value in monitoring rosacea. For treatment follow-
up, Demodex mites were easily counted by RCM, erythema was accurately monitored 
with spectrometry, and rosacea severity was quantified by skin hydration and TEWL 
measurements. We recommended developing adequate and validated protocols for 
further implementation of these tools in the research setting.
In chapter 3.2 we examined the value of RCM for the monitoring of rosacea during 
a 16-week treatment course with topical ivermectin. Treatment resulted in a clinically 
significant reduction of inflammatory lesions and erythema, but telangiectasias were 
not reduced. A clear decrease in number of Demodex mites inside the hair follicles 
was measured using RCM. However, Demodex was often difficult to distinguish from 
other cellular structures such as sebum or hairs. No clear changes in inflammatory 
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cells, epidermal thickness, vascular diameter, and vascular density were observed. 
The correlation between the number of inflammatory lesions and Demodex mites was 
low, and none of the RCM variables were significant predictors for clinical success. 
Therefore, the RCM in its current form seems of limited value for monitoring of rosacea 
patients in daily practice. Our results are most likely explained by various RCM device 
limitations, which will be described later on in this chapter.
In chapter 3.3 we developed and evaluated an image-based erythema quantification 
method using ImageJ® software to monitor facial erythema in rosacea patients during 
treatment with topical ivermectin. For this, we used standardized clinical photographs 
of the patient’s face, the RGB (red-green-blue) color model, and CIELAB colour space 
model (a*, indicating colour from green to red, corresponding well to the observation 
of the human eye). We found no significant changes in the RGB model values, but a* 
significantly decreased during successful treatment of rosacea. A weak correlation 
existed between clinical scores and lesional a*. Interobserver correlation was high. 
ImageJ® is a very simple, rapid, and open-source imaging software which can be easily 
used by clinicians. The photographs allow retrospective analysis, mapping of large and 
small anatomical locations, follow-up of exactly the same location, discrimination of 
subtle redness differences, and does not interfere with skin colour due to its non-
contact character. As erythema is an important feature of inflammation, standardized 
clinical images in combination with ImageJ® can improve objective measurement of 
inflammatory skin diseases (e.g. rosacea, psoriasis, and atopic dermatitis) compared 
to visual inspection.
In chapter 3.4, we reported five patients with development or worsening of rosacea 
symptoms after use of a full-face continuous positive airway pressure (CPAP) mask 
covering nose and mouth for obstructive sleep apnea syndrome (OSAS). These patients 
were diagnosed with papulopustular rosacea, erythematotelangiectatic rosacea, 
morbus Morbihan, and/or rhinophyma. Three patients had nasal skin symptoms and 
two patients showed centrofacial symptoms consistent with the shape of the CPAP 
mask. We propose an occlusive effect of the CPAP mask on the skin, increasing skin 
humidity, skin sebum, skin temperature, and in the gut of Demodex mites possibly also 
bacterial activity, inducing primary symptoms of an underlying sensibility for rosacea. It 
would be interesting to further examine our hypothesis by measuring these parameters 
objectively in OSAS patients before and during CPAP treatment. This could lead to 
profound insights into the mechanisms behind rosacea development in this population.
Lastly, in chapter 3.5, the efficacy of oral beta-blockers for rosacea-associated facial 
flushing and erythema was evaluated by performing a systematic review of the available 
literature. In total, nine studies were included. We discovered that it was difficult to 
compare individual study outcomes due to a large interstudy outcome variability. 
Erythema and flushing were assessed using a wide spectrum of subjective and 
4
Voorbereid document - Jade.indd   193 01-05-2021   10:17
194
Chapter 4
objective parameters such as clinical and patient scoring, clinical photographs, laser 
Doppler, skin temperature, and dermoscopy. Standardized and objective assessment 
of erythema and flushing would greatly facilitate the comparison of individual studies, 
which may lead to more solid conclusions about the effect of a particular treatment.
Main conclusions for aim 2:
 • Multiple imaging and biophysical tools have yet been tested for rosacea 
assessment. RCM, spectrophotometry, and determination of water content and 
TEWL seem promising to monitor rosacea. Our systematic review shows the need 
for larger, standardized studies.
 • RCM enables anti-inflammatory effect monitoring by determining mite presence, 
but quantifying exact mite number and inflammatory and vascular parameters 
is challenging due to device limitations. RCM seems of limited value for follow-up 
of rosacea in clinical practice.
 • ImageJ® software supports simple, rapid, objective, and reproducible 
quantification of facial erythema. The standard medical photographs allow 
retrospective analysis, evaluation of large and small lesions, and discrimination 
of subtle redness differences.
 • We hypothesize that CPAP masks for OSAS can induce rosacea symptoms due 
to skin occlusion, increased skin temperature and humidity, and activation of 
Demodex-related bacteria. Investigation of this hypothesis may lead to additional 
insights in the pathophysiology of rosacea.
 • It is difficult to compare outcomes of individual studies about facial erythema 
and flushing, due to a large heterogenicity in determination of these parameters. 
Objective evaluation of erythema and flushing would lead to easier comparison 
of these study results.
Rosacea as a model for skin inflammation
We consider rosacea to be a suitable model for monitoring inflammatory diseases, 
because it is localized at a visible and cosmetically important region, it has variable 
signs and symptoms which are making objective clinical evaluation challenging, and 
it responds well to effective anti-inflammatory treatment. However, our findings after 
extensive experience show that the rosacea model may have some restrictions. As 
outlined above, the facial region has many convex areas and sharp corners, which 
makes application of contact tools challenging. Additionally, skin lesions (i.e. erythema, 
inflammatory papules and pustules, telangiectasia) in rosacea often have a diffuse 
character, complicating the distinction with non-lesional facial skin. Furthermore, facial 
skin shows large skin barrier differences within very small distances due to internal and 
environmental influences such as variation in sebum gland density, skin pH, humidity, 
skin type, UV light, and air pollution.1-3 Before implementation, it is therefore important 
to investigate the tools examined in this thesis in other inflammatory diseases, both 
with facial and non-facial clinical symptoms, as well.
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Benefits of noninvasive tools
Until today, diagnosis and evaluation of inflammatory skin conditions is mainly based on 
visual inspection. However, recognizing subtle changes in skin symptoms is extremely 
challenging by visual assessment only. The image perceived by the human eye is a 
complex and nonlinear comprehension, being qualitative and individual. This makes 
visual evaluation subjective and prone to interobserver variation. From a patients’ 
point of view, visual scores are difficult to understand and interpret. Moreover, visual 
evaluation does not provide information about subsurface skin processes, while the 
most important early events in the pathogenesis of dermatoses are hidden beneath 
the skin surface. Visible symptoms occur at a later disease stage. Additionally, resolving 
of clinical symptoms is not equal to complete disease remission. For example, in atopic 
dermatitis, healthy-looking skin has a disrupted skin barrier function,4 and cytokine 
and T-cell activity is still upregulated in uninvolved skin in patients with psoriasis.5 
Noninvasive assessment of skin parameters provides qualitative and quantitative, 
objective, and reproducible information about the anatomy, function, and properties 
of the interior of the skin which cannot be collected by human visual observation 
alone. Imaging techniques such as RCM are suitable to gain additional information 
about subsurface skin morphology and inflammatory processes such as dynamics of 
inflammatory cells, vascularisation, and Demodex mites. This increases our knowledge 
about how dermatoses evolve and resolve at the subclinical level. Noninvasive 
techniques might reveal that apparently cleared skin sites are still inflamed, or may 
identify invisible early stage disease before the appearance of clinical symptoms, 
allowing to start effective treatment in a very early stage. This may prevent extended 
disease and irreversible skin damage.
Compared to histological evaluation of a skin biopsy, noninvasive techniques enable 
repeated monitoring of the same skin site over time without causing discomfort, pain, 
damage or scarring, which is especially important in cosmetically important regions 
such as the face. Additionally, biopsies provide a static picture at a specific point in 
time and interfere with the integral skin structure, while by using noninvasive tools 
the native skin structure is not altered, prohibiting challenges in result interpretations. 
Moreover, especially in resource limited settings, diagnostic devices could potentially 
reduce the delay in obtaining -expensive- histopathologic diagnosis.
For the research setting, objective assessment of cutaneous parameters would 
greatly improve comparison of individual study outcomes. Nowadays, for evaluation 
of many inflammatory dermatoses a golden standard is lacking, resulting in a mixture 
of parameters being assessed. Universal, objective assessment enables proper 
evaluation of treatment effects in systematic reviews and meta-analysis. In this way, 
firmer conclusions can be drawn about the actual effects of treatments. This would 
help in developing more robust, evidence-based treatment guidelines.
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While having many advantages, there are still hurdles to be overcome before 
noninvasive devices for evaluation of inflammatory dermatoses can be implemented 
in daily clinical practice. These obstacles are due to various technical and practical 
factors, which will be discussed in more detail in the next paragraph.
Many of the available noninvasive techniques are expensive, not commercially available, 
and highly specialized and only useful for investigators with a specific focus and training. 
Current tools can measure only one or a few parameters in the very complex environment 
of the skin.6 Contact devices may interfere with skin colour due to vessel compression. 
Biophysical tools provide point measurements (usually in the range of cm2), questioning 
representativeness of the results for an entire region. Repeated measuring on exactly 
the same location is challenging with a small probe. On the other side, larger probe heads 
will prevent measurements in recessed body parts such as the nose. Larger devices 
(e.g. the RCM, but also other noninvasive imaging methods which have been tested 
for skin imaging such as ultrasound, magnetic resonance imaging, nuclear magnetic 
resonance spectroscopy, near infrared imaging, optical coherence tomography, and 
Raman spectroscopy7-11) have some specific disadvantages. Due to their cost, size, weight, 
non-wireless character, and start-up time, their practical use is limited. Imaging of convex 
areas such as the eye region and nose fold is impossible, and extensive training about 
skin morphology may be needed to adequately interpret image results. Additionally, 
image depth and/or resolution may be limited. Images are often two-dimensional, 
horizontal to the skin surface (instead of vertical sections corresponding to histology) 
and in black and white only. Just recently, a low-cost, portable RCM connected to a 
smartphone was being developed;12 this could be a very promising upgrade compared 
to the current, bulky device. Three-dimensional imaging would be a very helpful 
improvement to retrieve optimal architectural and cellular information, and may also 
aid in quantifying elevated -inflammatory- lesions at the skin surface.9 3D imaging has 
already been used for evaluation of scars, such as atrophic acne scarring and keloids.13,14 
The VISIA® Skin Analysis System is a commercially available device with quantitative 
facial imaging analysis software, primary used for aesthetic and skin care consultations. 
It uses multi-spectral imaging (standard, UV, and polarized light) and analysis to capture 
visual information with respect to areas that affect the health and look of the skin 
from a cosmetic point of view: visible spots, UV spots, brown spots, wrinkles, texture, 
pores, red areas, and porphyrins (i.e. bacterial presence in pores).15-17 However, these 
outcome measures are not suitable as diagnostic features, because most of them are not 
directly related to inflammatory processes. Moreover, despite having fine image quality, 
this system is not very accurate for skin mapping due to software limitations, and the 
device is large, expensive, not easily portable, and designed for facial analysis only.17
Beside from techniques aspects, one must be aware of the occurrence of various 
internal and external human variations when using noninvasive devices. Determination 
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of TEWL, SC hydration and erythema may be influenced by skin blood flow, pH, sebum 
gland density, anatomical location, skin surface and environmental temperature, 
sweating, skin damage, air humidity, topical application of products, skin type, and 
sun exposure.1,18-20 It is therefore important to interpret the results in the light of these 
possible factors. Considering the possible intra-individual variation of skin parameters, 
we recommend to always register a baseline value or a reference untreated control 
site (i.e. non-lesional skin).6
Future perspectives: the ideal tool
In order to be suitable for use in daily clinical practice, a device for evaluating 
inflammatory skin diseases should be time saving, instead of time consuming. In daily 
practice, measurement according to extensive guidelines with standardization of 
environmental circumstances is therefore far from feasible.6 Based on the current 
knowledge and the results of this thesis, we assembled a core set of properties that the 
‘ideal tool’ for assessment of inflammatory skin diseases should comply with (Table 2). 
This ideal tool provides a core set of skin parameters, providing an overall view of 
current objective status of the (inflamed) skin.21
In this thesis, we showed that TEWL, water content, and erythema determination are 
promising objective parameters for the evaluation of inflamed skin. To determine 
which core set of parameters should be measured by the ‘ideal tool’, features other 
than the ones examined in this thesis must be explored. Sebum, skin pH, natural 
moisturizing factor (NMF),6,22-30 and biomarkers such as cutaneous cytokines may be 
interesting targets.30-39 Further research is needed to determine which parameters 
should be integrated in this core set of parameters, focussing on their intended 
purpose to monitor the severity of inflammation, sensitivity, specificity, and cost-
effectiveness.40-42
To facilitate result interpretation, automated analysis using machine learning 
and artificial intelligence is a promising perspective. This may overcome low 
reproducibility of some parameters, and reduce precious analysis time. Machine 
learning has already been applied in various medical specialties such as radiology,43 
pathology,44 orthopaedics,45 internal medicine,46 and, although still in its infancy, also 
in dermatology.47-49 We expect that increasingly sophisticated computer-assisted 
techniques will find its way into dermatological practice. However, an expert should 
oversee and double-check the process of (automatic) integrating of all available 
information to form a well-considered diagnosis and treatment regimen.
4
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Table 2. Characteristics of the ideal noninvasive tool for evaluation and follow-up of inflammatory 
skin diseases in daily practice.
 • Portable, wireless, light-weight, pocket-sized; or human-sized (like magnetic resonance imaging)
 • Non-contact
 • Affordable
 • Commercially available
 • Rapid measurement (< 5 min)
 • No need for repeated calibration
 • Easy to use, directly operational without start-up time
 • Provides distribution map for entire region of interest
 • Insensitive to external factor influences
 • Immediate reading and interpretation of results for direct feedback to the patient
 • Options for automatic retrospective analysis at the computer using a simple software package
 • Combination of core set of biophysical and imaging measurements, which are measured 
simultaneously
 • Surface and subsurface skin parameters
 • 3D images with sufficient penetration until subcutis
Final statements
Overall, in this thesis the value of novel and existing noninvasive imaging and biophysical 
tools in healthy and inflamed skin in daily practice was outlined. By means of this 
thesis, we tried to encourage clinicians as well as researchers to further investigate 
and improve the application of biophysical and imaging devices in the clinical and 
experimental dermatological setting. Once the most important hurdles have been 
overcome, a widespread application of these techniques in dermatological practice 
can be expected. We hypothesize in the future inflammatory skin diseases will be 
monitored with an ‘ideal tool’, replacing subjective scoring of severity of inflammation. 
This could greatly improve objective skin disease severity assessment in the clinical 
context, and promotes harmonization of outcomes in a research setting. Ideally, every 
patient with an inflammatory skin disease will possess the ‘ideal tool’ for home-based 
skin monitoring, enhancing patient involvement, personalized treatment, and therapy 
compliance.
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Onze huid vormt een belangrijke eerste barrière tegen potentieel schadelijke invloeden 
van buitenaf zoals bacteriën, chemicaliën, ultraviolet (UV) licht, en mechanische schade. 
Ook voorkomt de huidbarrière overmatig waterverlies via de huid. De huidbarrière 
wordt voornamelijk gevormd door de buitenste huidlaag, het stratum corneum (SC). 
De staat van de huidbarrière is objectief te meten met niet-invasieve apparatuur die 
de morfologie van de huid in kaart brengt (beeldvorming, Engels: ‘imaging ’), en die de 
functie van de barrière meet middels biofysische huidkenmerken (bijv. transepidermaal 
waterverlies [TEWL], waterinhoud, roodheid). Indien de huidbarrière verstoord is, kan 
de huid uitdrogen en kan er tevens ontsteking in de huid ontstaan. Een verstoorde 
barrière kan het gevolg zijn van mechanisch trauma, maar wordt ook gezien bij diverse 
ontstekingsziekten van de huid, zoals eczeem, psoriasis, en mogelijk ook rosacea. Het 
doel van dit proefschrift was het evalueren van nieuwe en bestaande niet-invasieve 
beeldvormende en biofysische methoden in gezonde en ontstoken huid in de 
dagelijkse klinische praktijk, met focus op rosacea. In het eerste deel (hoofdstuk 2) 
wordt de waarde van biofysische en beeldvormende meetmethoden in gezonde 
huid en huid met een verminderde huidbarrière onderzocht; in het tweede deel 
(hoofdstuk 3) wordt hun waarde in ontstoken huid bekeken, met focus op rosacea. 
Rosacea is een inflammatoire huidaandoening van het gelaat. Omdat juist in het gelaat 
niet-invasieve meetmethoden te prefereren zijn boven invasieve, werd de waarde van 
deze methodiek bij rosacea onderzocht.
Doelstelling 1. Het onderzoeken van de waarde van beeldvormende en biofy-
sische technieken bij gezonde en verstoorde huidbarrière.
In hoofdstuk 2.1 onderzochten we de waarde van de Epsilon®, een meetinstrument 
dat middels een array van sensoren de waterinhoud van de huid meet, gecombineerd 
met een morfologisch beeld van het stratum corneum (SC) op basis van de variatie in 
het gemeten watergehalte. We vonden significante verschillen tussen waterinhoud van 
het SC van verschillende anatomische regio’s; de wang had de hoogste waterinhoud, 
gevolgd door de onderarm, abdomen, rug, en kuit. Ook vonden we dat de Epsilon® 
consistent lagere waardes meet vergeleken met conventionele, vergelijkbare tools die 
maar één sensor hebben. Dit kan verklaard worden doordat de Epsilon® waterinhoud 
nauwkeuriger meet dan conventionele tools; de meting blijft beperkt tot het SC, het 
apparaat corrigeert voor tijdsafhankelijke occlusie-effecten, en er vinden meerdere 
metingen tegelijkertijd plaats die gebruikt kunnen worden voor een ‘hydratie-
map’. Hierdoor is het mogelijk om de mate van verstoring van de huidbarrière in 
ontstekingsziekten van de huid nog nauwkeuriger te bepalen. Dit vergemakkelijkt het 
monitoren van behandeleffecten. Enkele nadelen van de Epsilon® zijn de opstarttijd 
(ca. 10 minuten), en de noodzaak tot kabelverbinding met een laptop, waardoor de 
draagbaarheid beperkt is. Hierdoor lijkt het meetinstrument in de dagelijkse praktijk 
nog minder goed bruikbaar.
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In hoofdstuk 2.2 focusten we ons op het combineren van vier verschillende biofysische 
en beeldvormende apparaten om de huidbarrièrefunctie te meten zowel vooraf als 30 
minuten na applicatie van twee soorten emollientia (lanette crème en vaseline-lanette 
crème). Erytheem werd gemeten via spectrofotometrie (i.e. kwantitatieve bepaling van 
de reflectie van zichtbaar licht als een functie van de golflengte), waterinhoud met de 
Epsilon®, transepidermaal waterverlies (TEWL) met de Aquaflux® (een apparaat met 
een probe dat de waterdampstroom door diffusie vanuit de huid naar de omgeving 
meet) en dikte van het SC met de reflectie confocale microscoop (RCM; een niet-
invasieve imaging techniek voor het in vivo visualiseren van de bovenste huidlagen 
met een resolutie die vergelijkbaar is met conventionele histologie). Wij vonden een 
significant grotere dikte van het SC ná het smeren van beide crèmes vergeleken met 
daarvoor. Erytheem, TEWL, en waterinhoud veranderden niet na applicatie van crème. 
Met onze multi-parameter aanpak is het mogelijk om veelzijdige informatie over de 
staat van de huidbarrière in ontstekingsziekten van de huid te verzamelen, zowel 
voor als na een behandeling. Idealiter leidt dit tot een beter begrip van etiologische 
processen die betrokken zijn bij huidschade -en herstel, en gepersonaliseerde 
behandelopties. Om de praktische toepasbaarheid te vergroten zouden deze metingen 
bij voorkeur niet door vier losse tools, maar door één en hetzelfde apparaat uitgevoerd 
worden dat bovendien klein en draadloos is. Enkele nadelen van onze multiparameter-
aanpak zijn de noodzaak van een ruime onderzoekskamer en de separate protocollen 
behorende bij elke device.
Vervolgens bepaalden we in hoofdstuk 2.3 de waarde van de GPSkin®, een apparaat 
dat waterinhoud en TEWL tegelijk meet, om een defecte huidbarrière te meten. De 
huidbarrière werd middels tapestripping verstoord, een onderzoeksmodel waarbij 
het SC mechanisch verwijderd wordt middels herhaaldelijk aanbrengen van plakband. 
Ook onderzochten we de bruikbaarheid van de GPSkin® voor het monitoren van de 
barrièrefunctie bij patiënten met rosacea vóór en tijdens behandeling in de dagelijkse 
praktijk. We vonden een sterke lineaire correlatie tussen waterinhoud/TEWL-waardes 
van de GPSkin® en conventionele apparatuur (de Epsilon® en Aquaflux®), zowel vóór 
als na tapestrippen. De waterinhoud van de huid van rosaceapatiënten was significant 
lager dan die van proefpersonen met gezonde huid, waarbij er een trend was naar 
herstel gedurende succesvolle anti-inflammatoire behandeling middels topicaal 
ivermectine, een reeds effectief gebleken crème voor inflammatoire laesies bij rosacea 
(zie hoofdstuk 1 voor de behandelopties bij rosacea). TEWL was vergelijkbaar bij 
rosaceapatiënten en controles, en veranderde ook niet tijdens behandeling. Vergeleken 
met andere beschikbare instrumenten die de huidbarrière meten is de GPSkin® veel 
gebruiksvriendelijker in de dagelijkse praktijk door zijn handzame formaat, draadloze 
karakter, en snelheid. Bovendien worden waterinhoud en TEWL op exact dezelfde 
plek en tijd gemeten. Dit is extra belangrijk in het gelaat, waar grote verschillen in deze 
parameters bestaan binnen zeer kleine afstanden (centimeters).
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 • De Epsilon® is in staat om significante verschillen in waterinhoud te meten op 
verschillende anatomische locaties. Vergeleken met conventionele apparaten die 
waterinhoud meten, meet de Epsilon deze waarden nauwkeuriger.
 • Een multi-parameter aanpak waarbij de Epsilon®, Aquaflux®, spectrofotometer, 
en reflectie confocale microscoop worden gebruikt om respectievelijk 
waterinhoud, TEWL, erytheem, en epidermale dikte te meten, biedt een praktische 
en kwantitatieve manier om veelzijdige informatie te vergaren over de staat van 
de huidbarrière.
 • De GPSkin® is een zeer praktische tool om TEWL en waterinhoud op een 
nauwkeurige, simpele, en snelle manier te bepalen, zowel bij een normale 
als een verstoorde huidbarrière. We waren in staat om verbetering van 
de huidbarrièrefunctie te meten tijdens succesvolle behandeling van 
rosaceapatiënten in de dagelijkse praktijk.
Doelstelling 2. Het onderzoeken van de waarde van beeldvormende en biofy-
sische technieken in de ontstoken huid, met focus op rosacea.
Rosacea is een chronische ontstekingshuidziekte van het gelaat, met een scala aan 
symptomen, waaronder papels, pustels, erytheem, en teleangiëctasieën. De etiologie is 
tot op heden onopgehelderd, maar lijkt multifactorieel (immunologisch, neurovasculair, 
externe en genetische factoren, Demodex mijten, huidbarrière). De ernst van rosacea 
wordt momenteel vastgesteld door klinische symptomen te scoren. Dit is subjectief 
en gevoelig voor interobserver-variabiliteit. Hierdoor is het lastig om behandeleffecten 
te bepalen en om studie-uitkomsten onderling te vergelijken. Het afnemen van een 
huidbiopt is invasief en kan littekens achterlaten, wat zeker in het geval van een 
huidziekte in het gelaat niet wenselijk is. Derhalve is het ziektebeeld rosacea zeer 
bruikbaar voor onderzoek naar niet-invasieve meetmethoden van de huid.
Om rosacea te evalueren zijn er diverse biofysische en beeldvormende tools 
toegepast, maar een duidelijk overzicht van deze tools ontbrak tot op heden. In 
hoofdstuk 3.1 werden op systematische wijze de reeds onderzochte niet-invasieve 
meetmethoden voor de diagnostiek en follow-up van rosacea in kaart gebracht. In deze 
studie werden 78 studies geïncludeerd. Gebruikte beeldvormende technieken waren 
reflectie confocale microscopie, dermatoscopie, capillaroscopie, optische coherentie 
tomografie, computergestuurde beeldanalyse, infrarood fotografie, en echografie. 
Biofysische parameters die werden bepaald waren waterinhoud, TEWL, sebumexcretie, 
pH, erytheem, cutane doorbloeding, en huidtemperatuur. Helaas was de kwaliteit 
van de studies laag door kleine patiëntaantallen, een grote variabiliteit in studie-
uitkomsten, en een gebrek aan standaardisatie van de gebruikten meetmethoden. 
Desondanks lijken reflectie confocale microscopie, spectrofotometrie en bepaling van 
waterinhoud en TEWL veelbelovende technieken om de effecten van de behandeling 
van rosacea te monitoren.
Voorbereid document - Jade.indd   206 01-05-2021   10:17
207
Nederlandse samenvatting
Vervolgens werd in hoofdstuk 3.2 de waarde van reflectie confocale microscopie voor 
het monitoren van rosacea onderzocht tijdens een 16 weken durende behandeling 
met topicaal ivermectine. Behandeling resulteerde inderdaad in een afname in aantal 
klinische inflammatoire huidafwijkingen. Middels RCM werd vastgesteld dat het aantal 
Demodex mijten in de haarfollikels op de wangen van de patiënten met rosacea 
significant afnam. Echter, het bleek lastig om Demodex mijten op basis van RCM beeld 
te onderscheiden van bijv. talg of haren. Geen evidente veranderingen werden middels 
RCM geobserveerd in aantal ontstekingscellen, epidermale dikte, en vaatdiameter 
-en dichtheid. De correlatie tussen het aantal inflammatoire huidafwijkingen en het 
aantal Demodex mijten was laag, en geen enkele RCM-parameter bleek een significante 
voorspeller voor klinische verbetering. Derhalve werd geconcludeerd dat de RCM in zijn 
huidige vorm van beperkte waarde lijkt voor het monitoren van rosacea in de dagelijkse 
praktijk. Dit hangt met name samen met diverse beperkingen van het RCM apparaat, 
zoals de beperkte penetratiediepte in de huid, het zwart-wit en tweedimensionale 
karakter van de afbeeldingen, en de noodzaak tot uitgebreide training van de 
onderzoeker voor interpretatie van de afbeeldingen.
In hoofdstuk 3.3 werd een objectieve methode om klinisch erytheem (roodheid) 
te kwantificeren ontwikkeld en geëvalueerd. Erytheem is een belangrijke uiting van 
inflammatie. Wij monitorden het erytheem in het gelaat van rosaceapatiënten voor, 
tijdens, en na behandeling met topicaal ivermectine. Met behulp van ImageJ® software 
werden klinische, gestandaardiseerde foto’s van patiënten geanalyseerd en werd het 
erytheem beoordeeld binnen het CIELAB kleurenspectrum model. Hierbij weerspiegelt 
de waarde van a* de mate van roodheid, corresponderend met de observatie van het 
menselijk oog. Wij toonden aan dat de a*-waarde significant daalde tijdens succesvolle 
anti-inflammatoire behandeling van rosacea. Een zwakke relatie werd gevonden 
tussen klinische scores en a*. De interobserver-correlatie voor het berekenen 
van a* was hoog. ImageJ is een zeer eenvoudig, snel, en vrij verkrijgbaar imaging 
softwareprogramma dat gemakkelijk door clinici gebruikt kan worden. Het gebruik 
van foto’s maakt het mogelijk om retrospectieve analyses te verrichten, zeer kleine 
tot zeer grote anatomische locaties te onderzoeken, follow-up van exact dezelfde 
locatie te verrichten, en zelfs subtiele veranderingen in roodheid waar te nemen. Door 
het gebruik van de foto’s is huidcontact niet nodig, waardoor de mate van roodheid 
van de huid niet wordt beïnvloed door veneuze compressie zoals bij een device. Wij 
concludeerden dat het gebruik van klinische foto’s in combinatie met ImageJ® de 
objectieve meting van erytheem in inflammatoire ontstekingsziekten verbetert ten 
opzichte van observatie door het blote (klinische) oog.
In hoofdstuk 3.4 wordt een case series beschreven van vijf patiënten die een 
toename vertoonden van symptomen van rosacea na gebruik van een slaapapneu 
(CPAP, continuous positive airway pressure) masker. Onze hypothese is dat het masker de 
huid occludeert, waardoor luchtvochtigheid, temperatuur, talggehalte, en in de darm 
5
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van Demodex mijten mogelijk ook bacteriële activiteit toeneemt. Dit kan aanleiding 
geven tot het ontstaan van rosacea, of de klachten van een reeds bestaande rosacea 
verergeren. Het zou interessant zijn om onze hypothese verder te onderzoeken 
door huidbarrière parameters objectief te bepalen bij slaapapneu-patiënten. Dit kan 
mogelijk leiden tot aanvullende inzichten in de mechanismes die ten grondslag liggen 
aan het ontwikkelen van rosacea in deze populatie.
Ten slotte werd in hoofdstuk 3.5 systematisch de literatuur over de effectiviteit van 
orale bètablokkers voor rosacea-gerelateerde flushing en erytheem in het gelaat 
geëvalueerd. Er werden negen studies geïncludeerd. Door een grote variatie in 
individuele studie-uitkomsten was het lastig om deze separate resultaten met elkaar 
te vergelijken. Erytheem en flushing werden vastgesteld door diverse zowel subjectieve 
als objectieve parameters, namelijk klinische scores, laser Doppler, huidtemperatuur, 
en dermatoscopie. Het vergelijken van studieresultaten kan worden verbeterd door 
het gebruik van gestandaardiseerde en objectieve meetmethoden voor erytheem en 
flushing. Dit zal leiden tot meer robuuste conclusies over het effect van een specifieke 
behandeling.
Hoofdconclusies doelstelling 2:
 • Meerdere beeldvormende en biofysische tools zijn reeds onderzocht voor 
het evalueren van rosacea. RCM, spectrofotometrie en bepaling van TEWL en 
waterinhoud lijken veelbelovend voor rosacea monitoring. Echter, grotere en 
gestandaardiseerde studies zijn nodig.
 • Middels RCM is het mogelijk om het anti-inflammatoire effect van therapie te 
monitoren door Demodex aanwezigheid te meten, maar het tellen van exacte 
mijt-aantallen, inflammatoire cellen, en vasculaire parameters is uitdagend door 
diverse beperkingen van het RCM-apparaat. Daardoor lijkt RCM van gelimiteerde 
waarde voor rosacea follow-up in de dagelijkse praktijk.
 • ImageJ® software maakt het mogelijk om op simpele, snelle, objectieve, en 
reproduceerbare wijze faciaal erytheem te kwantificeren. Het gebruik van klinische 
foto’s maakt retrospectieve analyse, evaluatie van kleine en grote huidafwijkingen, 
en onderscheid van subtiele roodheidsveranderingen mogelijk.
 • Het vermoeden bestaat dat slaapapneumaskers rosacea symptomen induceren, 
mogelijk veroorzaakt door huidocclusie, verhoging van de huidtemperatuur -en 
vochtigheid, en bacteriële activiteit in Demodex mijten. Verder onderzoek van 
deze hypothese kan mogelijk leiden tot inzichten in de mechanismes die rosacea 
veroorzaken.
 • Het is lastig om individuele studie uitkomsten van behandeling van faciaal 
erytheem en flushing in rosacea met elkaar te vergelijken, door een grote 
heterogeniteit in gebruikte studie-parameters. Objectieve evaluatie van erytheem 
zou dit proces wel mogelijk kunnen maken.




Niet-invasieve evaluatie van huidparameters biedt ons de mogelijkheid om objectieve 
en kwantitatieve informatie over de anatomie, functie, en eigenschappen van onze 
huid te verkrijgen, die niet of minder adequaat door middel van menselijke observatie 
verzameld had kunnen worden. Hierdoor wordt het mogelijk aan te tonen dat een 
ogenschijnlijk ‘normale’ huid toch ontstoken is, en kan een huidziekte in een eerder 
stadium gedetecteerd worden, nog voordat de klinische symptomen zich voordoen. 
Dit maakt vroege behandeling mogelijk, waarbij ernstige symptomen en irreversibele 
huidschade idealiter voorkomen worden. Niet-invasieve technieken hebben daarnaast 
het belangrijke voordeel dat de huid intact blijft en niet verstoord wordt door een 
invasieve meting; dit is patiëntvriendelijker (geen pijn) en voorkomt huidherstelreacties 
(inflammatie, verlittekening) die longitudinale metingen verstoren. In de onderzoeks-
setting is vergelijking van individuele studieuitkomsten eenvoudiger indien uniforme, 
kwantitatieve, objectieve uitkomstmaten gebruikt worden.
Vóórdat niet-invasieve technieken op grote schaal ingezet kunnen worden in de 
dagelijkse klinische praktijk, zijn er nog diverse technische en praktische hindernissen die 
overbrugd dienen te worden. Deze hindernissen worden besproken in hoofdstuk 4. Op 
basis van de resultaten en ervaringen opgedaan in dit promotieonderzoek ontwikkelden 
wij een lijst met karakteristieken waaraan de ‘ideale tool’ voor het evalueren en monitoren 
van inflammatoire dermatosen in de dagelijkse praktijk zou moeten voldoen. Zo zou 
een dergelijke tool draagbaar, lichtgewicht, zonder huidcontact en draadloos moeten 
zijn, in de jaszak moeten passen, of juist heel groot moeten zijn (om erin plaats te 
kunnen nemen, zoals een MRI). Daarnaast dient deze tool betaalbaar en commercieel 
beschikbaar te zijn, en de beoogde parameter snel te meten (< 5 minuten) waarbij 
geen herhaaldelijke kalibratie nodig is. Andere gewenste kenmerken zijn: gemakkelijk en 
simpel in gebruik, directe aflezing van resultaten voor directe feedback aan de patiënt, 
opties voor automatische retrospectieve analyse, en generatie van een overzichtsplaatje 
van de hele regio van interesse. Als laatste dient de tool ongevoelig te zijn voor externe 
factoren zoals luchtvochtigheid en temperatuur, meet het driedimensionaal tot in de 
subcutis, en wordt met één apparaat een kernset aan beeldvormende en biofysische 
parameters gecombineerd die tegelijkertijd worden gemeten.
Samenvattend, hebben wij in dit proefschrift de waarde van nieuwe en bestaande niet-
invasieve technieken onderzocht in gezonde en ontstoken huid, met focus op rosacea. 
Wanneer de belangrijkste hindernissen overwonnen zijn, kan een wijdverspreide toepassing 
van deze technieken in de dermatologische praktijk verwacht worden. Wij hypothetiseren 
dat in de toekomst alle inflammatoire huidziekten objectief gemonitord zullen worden met 
de ‘ideale tool’, en dat dit de subjectieve scoring van de ernst van ontsteking vervangt. 
Idealiter leidt dit ook tot objectieve bepaling van de staat van de huid in de thuissituatie, 
waardoor de betrokkenheid van de patiënt bij zijn of haar ziekte, gepersonaliseerde 
behandeling, en therapietrouw hopelijk nog verder vergroot zullen worden.
5
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This thesis is based on the results of human clinical studies, which were conducted in 
accordance with the principles of the Declaration of Helsinki. The medical and ethical 
review board Committee on Research Involving Human Subjects Region Arnhem 
Nijmegen, Nijmegen, the Netherlands has given approval to conduct these studies.
All projects were stored on the local Radboudumc server. Patient-related data were 
additionally back-upped on university servers belonging to the department (chapter 
2.3, chapter 3.3: H:\Algemeen\Jade; chapter 2.2, chapter 3.2: R:\Vivascope\Backup; 
chapter 2.1, chapter 2.2: R:\Biophysica\Data). These data were not traceable to personal 
data; keys to personal data were stored separately.
All paperwork, including patient informed consent forms (chapter 2.1, chapter 2.2, 
chapter 2.3, chapter 3.2, chapter 3.3, chapter 3.4), patient diaries (chapter 3.2), and 
case report forms (chapter 2.1, chapter 2.2, chapter 2.3, chapter 3.2, chapter 3.3), were 
stored at the Dermatology department in a locked file cabinet (Radboudumc, room 
M351.00.012). Data management and monitoring was also performed digitally within 
Castor EDC (chapter 2.1, chapter 2.2, chapter 3.2) and by using password-secured Excel 
files (chapter 2.3, chapter 3.3, chapter 3.4). An audit trail was incorporated in Castor 
to provide evidence of the activities that altered the original data. Privacy of the 
participants in the studies was warranted by use of encrypted and unique individual 
subject numbers, not containing information regarding the identity of the patient. 
These numbers corresponded to the numbers on the informed consents, patient 
diaries, and case report forms. The keys of these numbers were stored separately from 
the study data at the local Radboudumc server (H:\SleutelsResearch\Sleutels\Jade). 
Keys were secured by a password and only accessible by the principle investigator 
and the study coordinator.
All data achieved will be saved for 15 years after termination of the studies. Using 
these patient data in future research is only possible after a renewed permission by 
the patient as recorded in the informed consent. Part of the results in this thesis have 
been published open access to make them available for everyone. The original datasets 
analysed during these studies are available from the associated corresponding author 
upon reasonable request.
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